

UNIVERSIDADE FEDERAL DE PERNAMBUCO
CENTRO DE BIOCÊNCIAS
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS BIOLÓGICAS

MARCOS DA SILVEIRA REGUEIRA NETO

**ANÁLISE COMPARATIVA DOS PERFIS FITOQUÍMICO E MICROBIOLÓGICO DA
PRÓPOLIS VERMELHA BRASILEIRA E DA RESINA DE *Dalbergia*
*ecastaphyllum***

Recife
2018

MARCOS DA SILVEIRA REGUEIRA NETO

**ANÁLISE COMPARATIVA DOS PERFIS FITOQUÍMICO E MICROBIOLÓGICO DA
PRÓPOLIS VERMELHA BRASILEIRA E DA RESINA DE *Dalbergia*
*ecastaphyllum***

Tese apresentada ao Programa de Pós-Graduação em Ciências Biológicas do Centro de Biociências, Universidade Federal de Pernambuco, como requisito parcial para obtenção do título de doutor em Ciências Biológicas.

Área de concentração: Biotecnologia

Orientador: Prof. Dr. Valdir de Queiroz Balbino

Coorientador: Prof. Dr. Henrique Douglas Melo Coutinho

Recife

2018

Catálogo na fonte:
Bibliotecário Bruno Márcio Gouveia - CRB-4/1788

Regueira Neto, Marcos da Silveira

Análise comparativa dos perfis fotoquímico e microbiológico da própolis vermelha brasileira e da resina de *Dalbergia ecastaphyllum* / Marcos da Silveira Regueira Neto. – 2018.

132 f. : il.

Orientador: Prof. Dr. Valdir de Queiroz Balbino.

Coorientador: Prof. Dr. Henrique Douglas Melo Coutinho.

Tese (doutorado) – Universidade Federal de Pernambuco. Centro de Biociências. Programa de Pós-graduação em Ciências Biológicas, Recife 2018.

Inclui referências e anexos.

1. Abelhas – produtos. 2. Própole. I. Balbino, Valdir Queiroz (Orientador). II. Coutinho, Henrique Douglas Melo (Coorientador). III. Título.

638.16

CDD (22.ed.)

UFPE/CB – 2018 - 379

MARCOS DA SILVEIRA REGUEIRA NETO

**ANÁLISE COMPARATIVA DOS PERFIS FITOQUÍMICO E MICROBIOLÓGICO DA
PRÓPOLIS VERMELHA BRASILEIRA E DA RESINA DE *Dalbergia*
*ecastaphyllum***

Tese apresentada ao Programa de Pós-Graduação em Ciências Biológicas do Centro de Biociências, Universidade Federal de Pernambuco, como requisito parcial para obtenção do título de doutor em Ciências Biológicas.

Aprovada em: 28/02/2018

BANCA EXAMINADORA

Prof. Dr. Valdir de Queiroz Balbino (Dep. de Genética/UFPE)

Prof. Dra. Cláudia Sampaio de Andrade Lima (Dep. de Biofísica/UFPE)

Prof. Dr. Antônio Fernando Moraes de Oliveira (Dep. de Botânica/UFPE)

Prof. Dra Neide Santos (Dep. de Genética/UFPE)

Prof. Dr. Marcos Antônio de Moraes Júnior (Dep. de Genética/UFPE)

*A minha mãe, Roseane,
fonte inesgotável de
carinho e ensinamentos,
com amor dedico.*

AGRADECIMENTOS

Primeiramente gostaria de agradecer àquela criança de há 24 anos atrás, que descia do prédio para revirar pedras e plantas atrás de bichinhos por não ter dado atenção aos pensamentos que poderiam ter me feito seguir um outro rumo profissional, que não continuar mexendo com bichinhos. Obrigado, estou muito feliz com o que faço hoje. Também quero agradecer ao alicerce mais perfeito que nenhum projeto de engenharia conseguiria fazer igual: meus pais, **Roseane e Marcos Regueira Jr**, e meus avós, **Elaine Regueira, Marcos Regueira e Dilma**. Obrigado por sempre estarem presente em minha vida e me apoiarem em todos os meus projetos. Quero agradecer também aos meus irmãos: **Márcio, Matheus e Bartô**. Meu amor por vocês todos não tem tamanho.

Agradeço aos meus orientadores, **Prof. Dr. Valdir de Queiroz Balbino e Prof. Dr. Henrique Douglas de Melo Coutinho** por me proporcionarem um ambiente estimulante de aprendizagem e por terem me apresentado um dos trabalhos mais apaixonantes que já fiz em minha vida.

Ao **CNPq** e a **CAPES** pelo apoio financeiro na realização deste trabalho.

Aos amigos e companheiros de trabalho do **Laboratório de Bioinformática e Biologia Evolutiva**: **Abigail, Carlos, Moisés, Raul, Wilson, Kláudia, Bruno, Manuela**, e em especial a **Lucas, Lidy e Heidi**, obrigado pela apoio, carinho, companheirismo e pelos videos, vivi com vocês um dos melhores quatro anos da minha vida.

As **Prof. Dra Neide Santos e Prof. Dra. Vilma Loreto**, pelo carinho, amizade e colaborações.

A **Rodrigo Oliveira**, meu amigo para todas as horas, bares e viagens. Obrigado pela sua amizade, carinho e apoio.

Agradeço ao **Dr. Iliano Gomes** e ao **Dr. Jesus Valenzuela** por abrirem as portas do **LMVR** e permitirem que eu tivesse umas das experiências profissionais e pessoais mais incríveis da minha vida.

Aos amigos que eu fiz para vida inteira no **National Institutes of Health**, **Anderson, Thiago Vieira, Tiago Donatelli, Thiago Luiz, Dionnê, Bia, Norine, Fabiano, Morgan e Sam**. Obrigado pela amizade, rizadas e companheirismo.

A minha DC family, **Lucas Belury** e **Troy**, obrigado pela amizade e por fazerem me sentir em casa e acolhido.

Aos meus amigos e familiares que fizeram esse periodo louco e maravilhoso da minha vida ser mais divertido, **Polly**, **Alex**, **Vanessa**, **Pérola**, **Luiz Henrique**, **Luana**, **Mari**, **Pablo**, **Clayton**, **André**, **Mitalle**, **Wheverton**, **Jouldes**, **Everton**, obrigado por tudo. Adoro vocês.

E a todos que de alguma forma contribuíram para a conclusão deste trabalho.
Obrigado.

RESUMO

No Brasil, a própolis é classificada em 13 tipos de acordo com a sua coloração e características fitoquímicas. A própolis vermelha pode ser encontrada em alguns estados do Nordeste. Em sua maioria é composta por flavonoides os quais são atribuídas muitas atividades biológicas. O objetivo deste estudo é comprovar a fonte botânica de resina para a produção de própolis vermelha e a analisar o perfil químico da resina e da própolis, comparar os resultados obtidos e realizar testes de atividade antibacteriana, antileishmania, antitripanossoma e citotóxica. A análise no HPLC da própolis vermelha e da resina permitiu identificar nove compostos: apigenina, ácido cafeico, ácido clorogênico, ácido elégico, luteolina, ácido p-coumárico, quercetina, rutina e vitexina. Uma variação sazonal foi observada no que diz respeito à concentração dos compostos para a própolis vermelha. Os extratos hidroetanólicos da própolis e da resina de *D. ecastaphyllum* apresentaram atividade contra as linhagens bacterianas de *Pseudomonas aeruginosa*, *Escherichia coli* e *Staphylococcus aureus*. Duas amostra de própolis vermelha e a amostra de resina apresentaram efeito sinérgico quando combinadas com as drogas antibacterianas. Os extratos de propolis vermelha de PE mostraram variação sazonal contra *E. coli* e *S. Aureus*, entretanto não foi observada variação contra *P. Aeruginosa*. Todas as amostras de propolis vermelha e resina apresentaram atividade contra as espécies de *Leishmania* e *T. cruzi* incluídas nesse estudo. De acordo com os nossos resultados, todas as amostras apresentaram atividade antibacteriana e a utilização da própolis vermelha coletada no período seco combinada com drogas antimicrobianas pode possivelmente trazer melhores resultados contra infecções multirresistentes. Quando comparada a atividade da própolis vermelha com a resina, observamos uma maior eficiência dos extratos de própolis em relação à resina.

Palavras-chave: Bactéria. *Dalbergia ecastaphyllum*. *Leishmania*. Própolis vermelha. Resina. *Trypanosoma*

ABSTRACT

In Brazil, the propolis is classified in 13 types according to its color and phytochemical characteristics. The 13th type, the red colored propolis, is found in some states of the Northeast of Brazil. It is composed in its majority by flavonoids and many biological activities have been reported. The aim of this study is to verify the botanical source for the production of red propolis and analyses the propolis and resin chemical profile, compare the obtained results and perform antibacterial, antileishmanial, antitrypanosomal and cytotoxic activity tests. The HPLC analysis of the Brazilian red propolis allowed us to identify nine compounds: apigenin, caffeic acid, chlorogenic acid, ellagic acid, luteolin, p-coumaric acid, quercetin, rutin and vitexin. Seasonal variation as observed according to concentrations of the compounds. The hydroethanolic extracts of propolis and the resin of *D. ecastaphyllum* showed bioactivity against the bacterial strains of *Pseudomonas aeruginosa*, *Escherichia coli* e *Staphylococcus aureus*. Two red propolis samples and the resin sample presented synergistic effect when combined with standard drugs. The red propolis extracts from Pernambuco showed seasonal variation against *E. coli* and *S. aureus*, however it was not observed any variation against *P. aeruginosa*. All red propolis and resin samples showed activity against the *Leishmania* species and *Trypanosoma cruzi* parasites. According to our results, all samples presented antibacterial activity and the use of red propolis collected in the dry season combined to antibacterial drugs might bring better results in the treatment of multiresistant infections. When the activity of red propolis was compared to the plant resin, we observed a higher efficiency of red propolis extracts over the resin.

Key-words: Bacteria. *Dalbergia ecastaphyllum*. *Leishmania*. Red propolis. Resina. *Trypanosoma*.

LISTA DE ILUSTRAÇÕES

Revisão Bibliográfica

Figura 1 –	Distribuição geográfica de nove subespécies de <i>A. mellifera</i>	21
Figura 2 –	Própolis vermelha.....	26
Figura 3 –	Núcleos fundamentais das famílias de flavonoides encontradas na própolis vermelha.....	30
Figura 4 –	Ciclo biológico da <i>Leishmania</i> spp.....	34
Figura 5 –	Ciclo biológico do parasita <i>Trypanosoma cruzi</i>	35
Figura 6 –	Foto de um exemplar de <i>Dalbergia ecastaphyllum</i>	37
Figura 7 –	Exudação da resina vegetal em galho da planta <i>Dalbergia ecastaphyllum</i>	39

Artigo 1

Figura 1 –	Chemical profile of the RP-PER hydroethanolic extract.....	43
Figura 2 –	Chemical profile of the RP-PED hydroethanolic extract.....	44
Figura 3 –	Combined effect of red propolis and antibacterial drug.....	45

Artigo 2

Figura 1 –	Perfil de de cromatografia líquida de alta performance representativa do extrato hidroetanólico da própolis vermelha....	60
Figura 2 –	Perfil de de cromatografia líquida de alta performance representativa do extrato hidroetanólico da resina.....	61

Figura 3 –	Associação da própolis vermelha e resina de <i>D. ecastaphyllum</i>	
	com antibióticos padrão	63

LISTA DE TABELAS

Revisão Bibliográfica

Tabela 1 –	Relação dos 13 tipos de própolis encontrados no Brasil.....	25
------------	---	----

Artigo 1

Tabela 1 –	Components of red <i>propolis</i> hydroethanolic extract.....	44
------------	---	----

Tabela 2 –	Values of MIC of the Brazilian red propolis from rainy and dry season against bacterial strains.....	44
------------	--	----

Artigo 2

Tabela 1 –	Origem das bactérias e perfis de resistência dos isolados clínicos	57
------------	--	----

Tabela 2 –	Componentes do extrato hidroetanólico da propolis vermelha e da resina <i>D. ecastaphyllum</i>	61
------------	--	----

Tabela 3 –	Valores de CIM da própolis vermelha e resina vegetal contra cepas bacterianas Gram-positivas e Gram-negativas.....	62
------------	--	----

Tabela 4 –	Valores de inibição do crescimento bacteriano alcançado com a associação da PV e RDE com drogas padrão.....	64
------------	---	----

Artigo 3

Tabela 1 –	Antileishmanial activities of the hydroethanolic extracts of red propolis and <i>Dalbergia ecastaphyllum</i> resin	79
------------	--	----

Tabela 2 –	Trypanocide and cytotoxic activities of the hydroethanolic extracts of red propolis and <i>Dalbergia ecastaphyllum</i> plant resin.....	80
------------	---	----

LISTA DE ABREVIATURAS E SIGLAS

A	Antibióticos
AE.	Antiepipimastigota
AP.	Antitripomastigota
BHI	<i>Brain-Heart Infusion</i>
C.	Indicador de citotoxicidade
CL.	<i>Cutaneous Leishmaniasis</i>
CLSI	<i>Clinical and Laboratory Standards Institute</i>
CPRG	Ensaio do Clorofenol vermelho- β -D-galactopiranosídeo
DER	<i>Dalbergia ecastaphyllum</i> resin
DMSO	Dimetilsulfóxido
DNA	Ácido Desoxiribonucleico
EC ATCC	<i>Escherichia coli</i> American Type Culture Collection
EC-06	<i>Escherichia coli</i> 06
FBS	<i>Fetal Bovine Serum</i>
HPLC DAD.	<i>High Performance Liquid Chromatography Diode-Array Detection</i>
IC ₅₀	<i>Half Maximal Inhibitory Concentration</i>
LacZ	Gene β -galactosidase de <i>E. coli</i>
LC	Leishmaniose Cutânea
LM	Leishmaniose Mucocutânea
LOD	<i>Limit of Detection</i>
LOQ	<i>Limit of Quantification</i>
LV	Leishmaniose Visceral
MIC	<i>Minimal Inhibitory Concentration</i>
ML	<i>Mucocutaneous Leishmaniasis</i>

MLC	<i>Minimal Lethal Concentration</i>
PA03	<i>Pseudomonas aeruginosa 03</i>
PA24	<i>Pseudomonas aeruginosa 24</i>
RP	<i>Red Propolis</i>
RP-AL	<i>Red Propolis collected in Alagoas</i>
RP-PED	<i>Red Propolis from Pernambuco Collected During the Dry Season</i>
RP-PER	<i>Red propolis from Pernambuco Collected During the Rainy Season</i>
SA ATCC	<i>Staphylococcus aureus American Type Culture Collection</i>
SA 10	<i>Staphylococcus aureus 10</i>
SD	<i>Standard Deviation</i>
SNP	<i>Single Nucleotide Polimorphism</i>
VL	<i>Visceral Leishmaniasis</i>

SUMÁRIO

1	INTRODUÇÃO.....	17
1.1	OBJETIVOS.....	19
1.1.1	Objetivo Geral.....	19
1.1.2	Objetivos Específicos.....	19
2	REVISÃO BIBLIOGRÁFICA.....	20
2.1	HISTÓRIA DEMOGRÁFICA DAS ABELHAS E SEUS PRODUTOS.....	20
2.1.1	Origem das abelhas.....	20
2.1.2	Introdução das abelhas no Brasil.....	21
2.1.3	As abelhas e seus produtos.....	22
2.2	PRÓPOLIS.....	23
2.2.1	O que é a própolis.....	23
2.2.2	Tipos de própolis.....	24
2.3	A PRÓPOLIS VERMELHA.....	26
2.3.1	Distribuição geográfica.....	26
2.3.2	Origem botânica.....	27
2.3.3	Componentes químicos da propolis vermelha.....	29
2.3.4	Atividade antibacteriana da própolis vermelha.....	31
2.3.5	Efeito modulador da atividade antibiótica pela própolis vermelha.....	31
2.3.6	Efeito da sazonalidade sobre a própolis.....	32
2.3.7	Atividade antileishmania e antitripanossoma da própolis.....	33
2.4	RESINA DE <i>Dalbergia ecastaphyllum</i>	37
2.4.1	<i>Dalbergia ecastaphyllum</i>	37
2.4.2	Produção de resina vegetal.....	38
2.4.3	Componentes químicos e atividades biológicas da resina de <i>Dalbergia ecastaphyllum</i>	38
3	RESULTADOS.....	40
3.1	ARTIGO 1 - SEASONAL VARIATION OF BRAZILIAN RED PROPOLIS: ANTIBACTERIAL ACTIVITY, SYNERGISTIC EFFECT AND PHYTOCHEMICAL SCREENING.....	40
3.2	ARTIGO 2 - ANÁLISE COMPARATIVA DA ATIVIDADE ANTIBACTERIANA E DO PERFIL FITOQUÍMICO DA PRÓPOLIS.....	

	VERMELHA BRASILEIRA E DA RESINA DE <i>Dalbergia ecastaphyllum</i> (L) TAUB.....	49
3.3	ARTIGO 3 - ANTIPROTOZOAL ACTIVITY OF BRAZILIAN RED PROPOLIS AND PLANT RESIN OF <i>Dalbergia ecastaphyllum</i>	76
4	CONCLUSÕES	83
	REFERÊNCIAS	84
	ANEXO A – NORMAS DA REVISTA FOOD AND CHEMICAL TOXICOLOGY	103
	ANEXO B – NORMAS DA REVISTA FOOD AND CHEMISTRY	119

1 INTRODUÇÃO

Própolis é um produto obtido de uma substância resinosa que é coletada de exsudatos de brotos e árvores, botões florais e pólen de diversas espécies de plantas pelas abelhas do mel (*Apis mellifera*). Essa resina é mastigada, enzimas salivares são adicionadas e o material parcialmente digerido é misturado à cera de abelha e usada na colmeia. As abelhas usam a própolis para reparar os favos de mel, para fechar pequenas frestas, suavizar as paredes internas, embalsamar as carcaças de invasores que as abelhas mataram dentro da colmeia, mas que elas não puderam transportar para fora, bem como proteger a colmeia da invasão de micro-organismos.

Os materiais disponíveis para as abelhas para a produção da própolis são substâncias ativamente secretadas pelas árvores assim como substâncias exsudadas pelas feridas das plantas: materiais lipofílicos nas folhas e brotos de folha, resinas, mucilagem ou goma. A partir da composição da fonte é possível determinar de qual planta (origem botânica) foi produzida a própolis. No Brasil existem ao menos quatro fontes distintas para a produção de própolis: *Baccharis dracunculifolia* (Asteraceae), mais conhecida como alecrim-do-campo, *Dalbergia ecastaphyllum*, popularmente conhecida como rabo-de-bugio (Fabaceae), *Hyptis divaricata* (Lamiaceae) e *Populus alba* (Salicaceae).

A própolis brasileira foi classificada quanto à composição química, origem geográfica e planta fonte em 12 grupos: seis no Sudeste (amarelo, marrom, marrom escuro, marrom esverdeado e verde) e seis no Nordeste (marrom avermelhado, marrom esverdeado, marrom escuro, amarelo, amarelo escuro). Recentemente foi descoberto a própolis vermelha em colmeias localizadas ao longo do litoral e margens de rio do Nordeste, mas precisamente em Alagoas. Na própolis vermelha já foram identificados: flavonoides (isoflavonoides, neoflavonoides, pterocarpanos, isoflavanonol, isoflavanonas, chalconas, isoflavanas, isoflavonas, flavanonas e favonol) além de componentes pertencentes a outros grupos químicos como, benzofenonas preniladas, terpenos e taninos. Porém, a maioria desses estudos estão concentrados na análise da própolis vermelha de Alagoas.

A própolis tem sido usada pela humanidade como produto medicinal desde antes de cristo. Usos como: antisséptico, antioxidante, anti-inflamatório, adesivo, protetor de madeira foram alguns dos usos reportados pelos homens na antiguidade.

Os egípcios faziam amplo uso da própolis nas múmias como produto antiputrefativo e na idade média era usado como antisséptico e cicatrizante, e os Incas ainda usavam própolis como antipirético. Diante de tantas possibilidades de uso, o interesse global nas pesquisas com própolis é grande e apresentam duas justificativas: a primeira delas é que a própolis apresenta diversas propriedades biológicas e alto valor agregado, onde no Brasil o valor de 30 mL do extrato de própolis vermelha está em torno de 50 reais.

Com os avanços tecnológicos foi possível aprimorar técnicas para análise do perfil químico dessas substâncias assim como das resinas das quais elas são oriundas. Já foram encontradas mais de 300 substâncias químicas com atividades biológicas, como por exemplo: atividades antitumorais, anti-HIV, antimicrobiana, antifúngica, hepatoprotetora, antiviral, anestésico local, antimofo, além de aplicações na dentística. Com a descoberta recente de um novo tipo de própolis, a vermelha, alguns estudos para saber qual a origem botânica, perfil químico e atividades biológicas dos seus componentes foram realizados. Porém, a maioria dos trabalhos focam apenas na própolis vermelha oriunda da resina de *Dalbergia ecastaphyllum*, originária de Alagoas. Porém, amostras de própolis de outras localidades do Nordeste brasileiro, assim como a avaliação das atividades da resina vegetal de *D. ecastaphyllum* estão subrepresentadas nos estudos científicos. Levando em conta o mencionado anteriormente e destacando a importância de se estudar própolis de diferentes regiões por conta da influência dos fatores edafoclimáticos, no presente trabalho realizamos uma avaliação da atividade antiactérica, antileishmania, antitrypanosoma e cytotoxicidade de amostras de própolis vermelha de Pernambuco, coletadas em duas estações diferentes (chuvosa e seca), da própolis vermelha de Alagoas e da resina vegetal de *Dalbergia ecastaphyllum*. Além disso, também realizamos uma análise fitoquímica das amostras previamente citadas.

1.1 OBJETIVOS

1.1.1 Objetivo geral

Analisar o perfil químico da própolis vermelha e da resina, comparar os resultados obtidos e realizar testes de atividade antimicrobiana, antileishmania, antitripanossoma e citotóxica.

1.1.2 Objetivos específicos

- a) Realizar uma análise comparativa do perfil químico dos extratos de amostras coletadas periodicamente de própolis vermelha de diferentes colônias de abelhas do mel em períodos de chuva e estiagem no estado de Pernambuco;
- b) Analisar o perfil químico dos extratos das amostras de resinas coletadas das plantas visitadas pelas abelhas;
- c) Confrontar os dados gerados dos perfis químicos das resinas e das amostras de própolis;
- d) Comparar os resultados das atividades antimicrobianas, antileishmania e antitripanossoma das amostras de própolis vermelha coletadas no período chuvoso e seco com a da resina de *D. ecastaphyllum*;
- e) Comparar os resultados obtidos com as amostras da própolis vermelha de Pernambuco e da resina de *D. ecastaphyllum* com os obtidos da análise da própolis vermelha de Alagoas.

2 REVISÃO BIBLIOGRÁFICA

2.1 HISTÓRIA DEMOGRÁFICA DAS ABELHAS E SEUS PRODUTOS

2.1.1 Origem das abelhas

Abelhas são essencialmente vespas que em um certo momento de sua história evolutiva, abandonaram a predação em favor de cuidar de um ninho, provendo-o com néctar e pólen. Supõe-se que as abelhas tenham evoluído de uma vespa ancestral, provavelmente da família Sphecidae, com partes bucais capazes de ingerir néctar, onde começaram coletando pólen para alimentar suas crias ao invés de se alimentar de presas (WINSTON, 1987).

Análises filogenéticas realizadas com as 10 espécies de abelhas do gênero *Apis* reconhecidas até então dividem este gênero em três grupos distintos: abelhas que nidificam em cavidades (*A. mellifera*, *A. cerana*, *A. koschevnikovi* e *A. nuluensis*); abelhas gigantes (*A. dorsata*, *A. laboriosa*, *A. binghami* e *A. nigrocincta*); e as abelhas anãs (*A. florea* e *A. adreniformis*). Com exceção de *A. mellifera*, todas as outras espécies estão restritas ao continente asiático (ARIAS e SHEPPARD, 2005).

As primeiras abelhas podem ter surgido no interior do paleocontinente Gondwana, que também foi o provável ponto de origem das angiospermas (WINSTON, 1987). Porém, a região geográfica de origem das abelhas *A. mellifera* é um tema que ainda hoje é muito discutido entre os cientistas. A distribuição nativa destas abelhas compreende África, Europa e Oeste da Ásia (WALLBERG et al., 2014). Os primeiros trabalhos, baseados em análises morfológicas, sugeriam um centro de origem de *A. mellifera* no Meio Leste ou Nordeste da África. Essa hipótese foi corroborada por análises de DNA mitocondrial e de polimorfismos de nucleotídeo único (SNPs, acrônimo de *Single Nucleotide Polymorphism*). Entretanto, outros trabalhos não dão suporte a esta hipótese, afirmando que os dados obtidos não colocam as linhagens africanas como ancestrais. Sendo assim, levantou-se uma hipótese alternativa de um centro de origem asiático e justificam isso com o fato de que todas as outras espécies do gênero *Apis* são encontradas no continente asiático (HAN et al., 2012; WALLBERG et al., 2014).

Foram descritas, até então, ao menos 29 subespécies de *A. mellifera* que hoje estão divididas em quatro grandes grupos com base em morfometria e análises genéticas: grupo A, que inclui as subespécies africanas; grupo M, inclui subespécies do Oeste e Norte europeus; grupo C, inclui subespécies do Leste europeu; e o grupo O, que inclui as subespécies da Turquia e do Oriente Médio (Figura 1) (RUTTNER, 1988; ENGEL, 1999; SHEPPARD et al., 2003).

Figura 1 – Distribuição geográfica das duas subespécies de *A. mellifera*, *A. mellifera ligustica* e *A. mellifera scutellata*, que foram introduzidas no Brasil, mais tarde gerando as abelhas Africanizadas. Quatro principais grupos geográficos identificados pelas letras: A, C, M e O.



Fonte: O Autor (2018). Adaptado de WALLBERG et al. (2014).

2.1.2 Introdução das abelhas no Brasil

As primeiras abelhas introduzidas no Brasil foram trazidas do continente europeu pelos imigrantes que trouxeram consigo alguns enxames. Isso aconteceu na primeira metade do século XIX, quando o Imperador D. Pedro II autorizou a importação de abelhas *Apis mellifera mellifera* para o Estado do Rio de Janeiro. Uma outra subespécie de abelha, a *A. mellifera ligustica* (mais conhecida como abelha italiana) foi trazida da Alemanha para o Rio Grande do Sul no final do século XIX (WIESE, 2005).

Mais uma subespécie de abelha do mel, *A. mellifera scutellata*, foi introduzida em 1956 pelo pesquisador Dr. Warwick Estevan Kerr. Essa subespécie foi coletada na região de Pretória na África do Sul e foram levadas para o Estado de São Paulo. Por conta de uma manipulação descuidada 26 enxames fugiram das colmeias e este episódio deu início a um processo de cruzamentos naturais com as abelhas europeias existentes, resultando na formação de um híbrido denominado de abelha africanizada. Os enxames híbridos rapidamente se dispersaram em direção ao norte, atingindo a América do Norte em menos de 40 anos. Supõe-se que a vantagem das abelhas africanizadas sobre as abelhas europeias deva-se a três fatores primordiais: fatores genéticos, comportamentais e ambientais (WINSTON, 1992; RUBINK et al., 1996; WIESE, 2005).

2.1.3 As abelhas e seus produtos

Além do papel ecológico e econômico que as abelhas desempenham, elas são conhecidas pela sua importância na produção de produtos naturais. Dentre eles, os mais conhecidos são: o mel e a própolis; outros produtos também são muito explorados em pesquisa e pela indústria farmacêutica e de suplementos alimentares, tais como: geleia real, cera e pólen (PYRZYNSKA e BIESAGA, 2009; PREMRATANACHAI e CHANCHAO, 2014; BILIKOVA et al., 2015; VUJIC E POLAK, 2015).

O mel é uma mistura de componentes de plantas e da abelha, sendo um produto alimentício produzido pelas abelhas melíferas a partir do néctar das plantas ou de excreções de insetos sugadores de plantas (BILIKOVA et al., 2015). A geleia real é uma substância secretada por abelhas jovens (nutrizes) com 4 a 12 dias de vida, através de glândulas secretoras [(hipofaringeanas)] (KATAYAMA et al., 2008). A cera de abelha é uma substância secretada pelas abelhas operárias entre 14 e 18 dias de vida. A cera é produzida por quatro pares de glândulas cerígenas localizadas na parte inferior do abdômen. A principal função da cera de abelha é a construção de favos (WIESE, 2005). O pólen de abelha é uma mistura de pólenes de diferentes espécies de plantas. As abelhas transportam o pólen na pata traseira, numa dobra chamada corbícula, sendo aglutinado com a ajuda de néctar e de enzimas secretadas pelas glândulas salivares das abelhas. Este componente é usado pelas abelhas

principalmente para o preparo do alimento e da geleia real (DENISOW e DENISOW-PIETRZYK, 2016). E por fim, a própolis, que é uma substância resinosa que é obtida pelas abelhas da partir de exsudatos de plantas e é usada para reparos da colmeia e proteção contra agentes externos (GHISALBERTI, 1979; MARCUCCI, 1995).

2.2 PRÓPOLIS

2.2.1 O que é a própolis

Própolis é o nome genérico dado a um produto obtido de uma substância resinosa que é coletada de exsudatos (resinas, mucilagem, goma ou materiais lipofílicos) de brotos e árvores, botões florais, folhas, feridas de plantas e pólen de diversas espécies pelas abelhas do mel (*Apis mellifera*) (CRANE et al., 1988). As abelhas fazem uso das mandíbulas, com as quais raspam o produto secretado pelas plantas e o tornam maleável, manipulando-o com ajuda das patas, até fixar o material nas corbículas, transportando-o até a colmeia. Essa resina é mastigada, enzimas salivares são adicionadas e o material parcialmente digerido é misturado à cera de abelha e usado na colmeia (GHISALBERTI, 1979; MARCUCCI, 1995).

A própolis é um produto que contém uma mistura complexa composta aproximadamente por 50% de resina e bálsamo, 30% de cera, 10% de óleos essenciais e aromáticos, 5% de pólen e 5% de impurezas (THOMSON, 1990). Além dos fatores já citados que modificam a composição química da própolis, a composição também pode variar em decorrência de fatores como sazonalidade, iluminação, altitude, tipo de coletor, disponibilidade de comida e atividade desenvolvida durante a exploração da própolis (BANKOVA et al., 1998; TORETI et al., 2013).

As abelhas usam a própolis ou “cola de abelha”, como também é comumente conhecida, para reparar os favos de mel, para fechar pequenas frestas, suavizar as paredes internas, embalsamar as carcaças de invasores que as abelhas mataram dentro da colmeia, mas que elas não puderam transportar para fora, bem como proteger a colmeia da invasão de microrganismos (GHISALBERTI, 1979; BURDOCK, 1998).

Pelo homem, a própolis tem sido usada como remédio popular desde 300 a.C. para vários propósitos, a saber: antisséptico; antioxidante; anti-inflamatório; ou como

adesivo para selar quebras, revestir madeira e outras superfícies. Há registros bíblicos no livro de Gênesis do seu uso; os egípcios usavam a própolis como substância antiputrefativa em suas múmias; na Idade Média foi amplamente usado como antisséptico e cicatrizante; e os Incas o utilizavam como antipirético (TORETI et al., 2013). Inúmeras atividades biológicas foram atribuídas às substâncias presentes nesta mistura, como atividades: antioxidante, anti-inflamatória, melhorias do coração e função circulatória, antilipídica, antihiperglicêmica, citotóxica, anticâncer (BANKOVA, 2005).

2.2.2 Tipos de própolis

Os diferentes tipos de própolis estão particularmente ligados à flora existente em cada região do planeta. Os principais fatores analisados para diferenciar os tipos de própolis são: características organolépticas; composição química; e fonte botânica. Na Europa, América do Norte, oeste da Ásia e Nova Zelândia, as principais fontes de resina para a produção da própolis são os brotos de choupo (*Populus* spp.). Na Rússia foi observado que a principal fonte vegetal utilizada pelas abelhas é a *Betula verrucosa*, mais conhecida como bétula ou vidoeiro (BURDOCK et al., 1998; BANKOVA et al., 1992). Na América do Sul, mais precisamente na Venezuela e em Cuba, a fonte mais utilizada pelas abelhas do mel para a produção de própolis são espécies do gênero *Clusia* (TOMÁS-BARBERÁN et al., 1993; CUESTA-RUBIO et al., 2002).

No Brasil são conhecidos pelo menos 13 tipos de própolis (Tabela 1) e ao menos quatro espécies vegetais que participam na produção da própolis: *Baccharis dracunculifolia* (Asteraceae), mais conhecida como alecrim-do-campo; *Dalbergia ecastaphyllum* (Fabaceae), conhecida no Nordeste do Brasil como rabo de bugio; *Hyptis divaricata* (Lamiaceae); e *Populus alba* (Salicaceae) (PARK et al., 2002a; PARK et al., 2002b; DAUGSCH et al., 2008). Fatores como localização geográfica, origem botânica, composição química e cor foram importantes para encaixar as própolis brasileiras nesses grupos.

Tabela 1 – Relação dos 13 tipos de própolis encontrados no Brasil.

Extratos Etanólicos da Própolis		
Grupos	Cor	Origem da própolis
Grupo 1 (RS)	Amarelo	Sul
Grupo 2 (RS)	Marrom	Sul
Grupo 3 (PR)	Marrom escuro	Sul
Grupo 4 (PR)	Marrom	Sul
Grupo 5 (PR)	Marrom esverdeado	Sul
Grupo 6 (BA)	Marrom avermelhado	Nordeste
Grupo 7 (BA)	Marrom esverdeado	Nordeste
Grupo 8 (PE)	Marrom escuro	Nordeste
Grupo 9 (PE)	Amarelo	Nordeste
Grupo 10 (CE)	Amarelo escuro	Nordeste
Grupo 11 (PI)	Amarelo	Nordeste
Grupo 12 (SP)	Verde ou marrom esverdeado	Sudeste
Grupo 13 (AL)	Vermelho	Nordeste

Fonte: O Autor (2018). Adaptado de TORETI et al. (2013)

O perfil químico das amostras de própolis oriundas de regiões tropicais tem sido bastante estudado, especialmente as brasileiras. Os flavonoides, em muitos casos, estão presentes em grande quantidade, embora sejam de origens botânicas diferentes (PARK et al., 2002b; BANKOVA, 2005). Em amostras brasileiras foram encontrados kaempferida, 5,6,7-trihidroxi-3,4'-dihidroxi-flavona, aromadendreno-4' metil éter, 3,5,7 – trihidroxi-6,4'-dimetoxiflavona (BANKOVA et al., 2000). Outra nova classe de fenólicos achados em amostras de própolis brasileira são os ácidos p-cumáricos prenilados e seus resíduos com prenil cíclico e acetofenonas (ambos são metabólitos secundários típicos de *B. dracunculifolia*). Artepilina C, um diprenil derivado do ácido p-cumárico, é um componente marcante da própolis verde brasileira (BANSKOTA et al., 1998; TAZAWA et al., 1998; FERNANDES-SILVA et al., 2013). Outros compostos fenólicos foram isolados da própolis brasileira: derivados do ácido cafeoilquinico (típico da própolis Brasileira); c-guaiacilglicerol; e o radical livre limpador, ácido 3-[4-

hidroxi-3-(3-oxobut-1-enil)-fenilacrílico (TATEFUJI et al., 1996; FERNANDES-SILVA et al., 2013). Di e triterpenos também são importantes classes constituintes da própolis brasileira. Alguns triterpenos alcoólicos estão presentes em própolis do Brasil e Egito como: beta-amirina, triterpenos alcoólicos do tipo amirina e cicloartenol (MARCUCCI et al., 1998). Em baixas concentrações encontra-se componentes voláteis, açúcares e minerais (BANKOVA et al., 2000).

2.3 A PRÓPOLIS VERMELHA

2.3.1 Distribuição geográfica

A própolis vermelha (Figura 2) produzida pela *Apis mellifera* pode ser encontrada atualmente em seis países espalhados em três continentes. No continente africano, a própolis vermelha é produzida na Nigéria. Na Ásia, é encontrada na Arábia Saudita e na China. No continente americano, a própolis vermelha pode ser encontrada no México, em Cuba, na Venezuela e no Brasil (THRUSHEVA et al., 2004; IZUTA et al., 2009; LOTTI et al., 2010; PICCINELLI et al., 2011; OMAR et al., 2016; SADDIQ et al., 2016).

Figura 2 – Própolis vermelha. Quadro retirado de colmeia em apiário localizado em Tamandaré – PE.



Fonte: O Autor (2014).

No Brasil, a própolis vermelha é encontrada no litoral do Nordeste em colmeias localizadas em regiões de mangue, nos estados da Bahia, Sergipe, Alagoas, Pernambuco e Paraíba. A descoberta da própolis vermelha no Brasil ainda é recente, em torno de uma década desde o seu primeiro relato em publicação científica. THRUSHEVA et al. (2006) publicaram o primeiro trabalho que analisou os constituintes bioativos da própolis vermelha de Alagoas. Nos anos seguintes foram feitos outros estudos com a própolis vermelha proveniente de outros estados (DAUGSCH et al., 2008; FROZZA et al., 2013; REGUEIRA et al., 2017). Porém, apesar de ser encontrada em vários estados da região Nordeste, a própolis vermelha de Alagoas ainda permanece sendo a bem mais estudada. Mais recentemente, ISHIDA et al. (2011) e LÓPEZ et al. (2014) relataram a existência da própolis de cor avermelhada também no Norte do Brasil, nos estados de Roraima e da Amazônia; através da comparação da composição química da própolis vermelha destes estados com a encontrada em outras localidades, os autores afirmam ser um tipo novo de própolis por não ser idêntica a própolis vermelha cubana e nem idêntica à própolis vermelha brasileira.

2.3.2 Origem botânica

A origem botânica da própolis vermelha pode variar nos diferentes países onde ela é encontrada, em decorrência da diversidade florística de cada região (LÓPEZ et al., 2014). Para se investigar de qual fonte botânica as abelhas do mel retiram as substâncias para produção da própolis, três metodologias podem ser empregadas: i. análise comparativa da composição química através dos perfis cromatográficos da própolis e das possíveis plantas fontes; ii. análise palinológica; iii. identificação da fonte botânica da própolis vermelha a metodologia do *DNA barcoding*, que consiste basicamente da extração de DNA da própolis, realização de uma PCR utilizando *primers* para sequências da possível planta fonte e sequenciamento (DAUGSCH et al., 2008; BARTH E LUZ, 2009; JAIN et al., 2014).

As plantas do gênero *Clusia* e *Dalbergia* estão entre as principais espécies procuradas pelas abelhas para a produção da própolis vermelha em diferentes países (TOMÁS-BÁRBERAN et al., 1993; PICCINELLI et al., 2011; LOPEZ et al., 2014). No continente americano, as plantas do gênero *Clusia*, i.e. *C. scrobiculata*, *C. minor* e *C.*

major, são as fontes botânicas preferenciais para produção da própolis vermelha pelas abelhas na Venezuela, que visitam a flor e coletam a resina secretada na base dos estames (TOMÁS-BÁRBERAN et al., 1993; TRUSHEVA et al., 2006). CUESTA-RUBIO et al. (2004), através de análise cromatográfica, identificaram componentes químicos da resina floral de *Clusia rosea* na própolis vermelha de Cuba. Entretanto, foi relatado a presença, também, de componentes químicos oriundos da resina secretada pela planta *Dalbergia ecastaphyllum* em amostras de própolis vermelha cubana (PICCINELLI et al., 2011; LOPEZ et al., 2014). Plantas do gênero *Dalbergia* foram relatadas, também, como fontes botânicas da própolis vermelha da Nigéria através da análise comparativa com os compostos químicos encontrados em *D. ecastaphyllum*, o que se sustenta por conta do número de espécies de *Dalbergia* que são encontradas no Oeste da África (SAHA et al., 2013; OMAR et al., 2016).


No Nordeste brasileiro, a própolis vermelha ocorre ao longo do litoral e está presente nos estados de Alagoas, Bahia, Paraíba, Pernambuco e Sergipe (ALENCAR et al., 2007; DAUGSCH et al., 2008; FROZA et al. 2013; LÓPEZ et al., 2014). DAUGSCH et al. (2008) através da observação do comportamento das abelhas e da análise comparativa entre a própolis vermelha e a resina da planta a qual elas estavam visitando, concluíram que *D. ecastaphyllum* é a principal fonte botânica da própolis vermelha nos estados do nordeste do Brasil. LÓPEZ et al. (2014) através de análises cromatográficas dividiu a própolis vermelha em dois grupos: um grupo formado por amostras dos estados de Alagoas e Paraíba, o qual eles identificaram traços químicos fortes de plantas da família Clusiaceae; e um outro grupo formado por amostras de própolis de Cuba e do estado da Paraíba, que apresentaram componentes químicos majoritários de *D. ecastaphyllum*. A hipótese de que componentes químicos da própolis vermelha do Nordeste do Brasil podem ser oriundos de duas fontes botânicas também foi levantada previamente por PICCINELLI et al. (2011). As própolis de cor avermelhada encontradas nos estados de Roraima e da Amazônia, tem como possíveis fontes botânicas plantas da família Clusiaceae, por conta disso, se parecendo mais com a própolis venezuelana e cubana do que com a própolis vermelha encontrada no Nordeste do Brasil (ISHIDA et al., 2011; LÓPEZ et al., 2014).

2.3.3 Componentes químicos da própolis vermelha


Em geral, a composição química da própolis depende de alguns fatores: altitude, flora ao redor da colmeia, iluminação, sazonalidade e tipo de abelha coletora (SILICI E KUTLUCA et al., 2005; THRUSHEVA et al., 2006; TEIXEIRA et al., 2008; ISLA et al., 2012). A própolis vermelha brasileira tem como componentes químicos majoritários flavonoides (isoflavanonol, chalconas, flavanonas e flavonol) e isoflavonoides (pterocarpanos, isoflavanonas, isoflavanos e isoflavonas) (Figura 3), além de componentes pertencentes a outros grupos químicos [e.g. benzofenonas preniladas, terpenos e taninos] (SILVA et al., 2007; DAUGSCH et al., 2008; AWALE et al., 2008; RIGHI et al., 2010; PICCINELLI et al., 2011; LÓPEZ et al., 2014; MAYWORM et al., 2014). Os isoflavonoides são compostos marcadores para a própolis vermelha brasileira e quatro deles se destacam: biochanina A, formonetina, pinocembrina (LÓPEZ et al., 2014) e medicarpina (THRUSHEVA et al., 2006).

Inúmeros trabalhos foram realizados para testar várias atividades biológicas (e.g. antioxidante, antimicrobiana, antitumoral, anti-inflamatória, citotóxica), da própolis vermelha brasileira e os compostos químicos encontrados nas amostras testadas têm participação essencial na bioatividade apresentada pela própolis vermelha (ALENCAR et al., 2007; LI et al., 2008; RIGHI et al., 2010; BUENO-SILVA et al., 2013). As isoflavonas encontradas nas amostras de própolis vermelha do Nordeste do Brasil estão associadas às atividades antibacteriana, antifúngica, anti-inflamatória e citotóxica (SILVA et al., 2007; BUENO-SILVA et al., 2013; LÓPEZ et al., 2015). Isoflavonóides têm uma distribuição muito restrita no reino vegetal e ocorre quase que exclusivamente em leguminosas (PICCINELLI et al., 2005). Outros grupos químicos como flavanonas, chalconas e pterocarpanos, encontradas na própolis vermelha, possuem atividade citotóxica (LI et al., 2008).


Figura 3 – Núcleos fundamentais das famílias de flavonóides e isoflavonóides encontrados na própolis vermelha.




Chalcona




Flavanona




Flavonol




Isoflavona




Isoflavanona



Isoflavana



Pterocarpano



Isoflavanonol

Fonte: O Autor (2018).

2.3.4 Atividade antibacteriana da própolis vermelha

A atividade antibacteriana da própolis vermelha brasileira já foi avaliada contra bactérias Gram-negativas – *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Escherichia coli*, *Proteus mirabilis*, *P. morganii*, *Neisseria meningitidis*, *Haemophilus influenzae* e *Enterobacter aerogenes* (RIGHI et al., 2010; LÓPEZ et al., 2015) e bactérias Gram-positivas – *Bacillus subtilis*, *Enterococcus faecalis*, *Streptococcus pyogenes*, *Staphylococcus aureus* e *S. epidermidis* (ALENCAR et al., 2007; CABRAL et al., 2009; RIGHI et al., 2010; LOPEZ et al., 2015). Entretanto, a maioria dos estudos foi conduzida com amostras de própolis vermelha provenientes dos estados de Alagoas, Paraíba e Sergipe.

A própolis vermelha possui atividade antibacteriana por conta da presença de flavonoides em grandes quantidades (DAUGSCH et al., 2008). A atividade antibacteriana dos flavonoides ainda continua sendo bastante estudada e esses compostos podem exercer essa atividade de três modos: matando diretamente a bactéria; através da ativação sinérgica de antibióticos; e através da atenuação da patogenicidade da bactéria (CUSHNIE et al., 2011).

2.3.5 Efeito modulador da atividade antibiótica pela própolis vermelha

Uma questão sempre preocupante com relação ao tratamento de infecções bacterianas e fúngicas é o aparecimento de cepas e linhagens resistentes aos antibióticos comerciais (WOJTYCZKA et al., 2013; PIPPI et al., 2015). Microrganismos resistentes aos antibióticos são uma importante questão de saúde pública, uma vez que eles podem facilmente se disseminar no ambiente. Por conta disto, vem-se tentando encontrar uma forma alternativa de tratar infecções microbianas resistentes em seres humanos. A associação de agentes antimicrobianos sintéticos e produtos naturais tem sido estudada e algumas combinações tiveram efeito sinérgico inibindo o crescimento bacteriano (MATIAS et al 2010; HASSAN et al 2016).

A própolis têm sido combinada com alguns tipos de drogas: anticâncer (MARKIEWWICZ-ZUKOWSKA et al., 2013; ORSOLIC et al., 2013); antibacteriana (WOJTYCZKA et al., 2013); antifúngica (PIPPI et al., 2015) e em alguns estudos foi observado efeito sinérgico (ORSI et al., 2012; MARKIEWWICZ-ZUKOWSKA et al.,

2013; ORSOLIC et al., 2013; HASSAN et al., 2016). A associação da própolis vermelha brasileira com agentes antifúngicos apresentou efeito sinérgico contra *Candida* sp. (PIPPI et al., 2015), entretanto estudos combinando a própolis vermelha e agentes antibacterianos permanecem escassos.

Alguns mecanismos de ação têm sido propostos para a atuação sinérgica de classes de flavonoides presentes na própolis com antibióticos comerciais. Danos causados à membrana citoplasmática (por conta da redução da fluidez da membrana), inibição da síntese de ácidos nucleicos (causada pela inibição da topoisomerase), inibição da energia de metabolismo (causada pela inibição da NADH-citocromo c redutase), inativação da bomba de efluxo e a inibição da formação de biofilme são alguns dos mecanismos de atividade antimicrobiana associados aos flavonoides (CUSHINIE et al., 2011).

2.3.6 Efeito da sazonalidade sobre a própolis


Os fatores ambientais (e.g. temperatura, luz e umidade) podem influenciar na biossíntese dos metabólitos nas plantas (TEIXEIRA et al., 2008). No Brasil, diferentemente do que é observado em países com clima temperado, as abelhas coletam material vegetal durante todo o ano, então algumas variações sazonais são possíveis (BANKOVA et al., 1998). Dessa forma, a sazonalidade é um importante fator que pode, também, determinar variações na composição química da própolis. Essas variações são importantes para a aplicação prática dos usos da própolis, por exemplo saber em que época coletar a própolis com maior concentração de compostos bioativos (BANKOVA et al., 1998). BANKOVA et al. (1998) também observaram a presença de ácidos diterpênicos em amostras de própolis coletadas no verão, entretanto observou uma diminuição destes mesmos compostos no outono. Porém, não foi observada uma significativa variação da atividade antibacteriana da própolis coletada em diferentes estações (SFORCIN et al., 2000; JORGE et al., 2008; TEIXEIRA et al., 2008).

2.3.7 Atividade anti-leishmania e antitripanossoma da própolis

Leishmaniose é um grupo de doenças tropicais negligenciadas que podem ser causadas por mais de 20 espécies de protozoários do gênero *Leishmania* (WHO, 2017a). A doença pode se apresentar através de diferentes formas clínicas, como a cutânea (LC), mucocutânea (LM) e visceral (LV) (WHO, 2017a). A LC é a forma mais comum da doença e é caracterizada por úlceras geralmente localizadas na face, nos braços e pernas, e o número de úlceras pode chegar a 200. Na LM as lesões podem levar à destruição parcial ou total das membranas mucosas do nariz, da boca e das cavidades da garganta. A LV, também conhecida como Calazar, é caracterizada por ataques irregulares de febre, perda de peso, hepato e splenomegalia (WHO, 2017a). A LC pode ser causada primariamente pelas *Leishmania* (*Leishmania*) *major*, *L. (Leishmania) amazonensis*, *L. (Leishmania) mexicana*, *L. (Viannia) braziliensis* e outras espécies do subgênero *Viannia*. A maioria dos casos de LM são ocasionados por *L. (Viannia) braziliensis* e acontece em aproximadamente 5% dos indivíduos que já estão com LC. Por fim, a LV pode ser causada pelas *L. (Leishmania) infantum* e *L. (Leishmania) donovani* (AYRES et al., 2007; VALDIVIA et al 2015).

Em ambos os subgêneros *Leishmania* e *Viannia*, os parasitas estão presentes como amastigotas intracelulares no interior de fagolisossomos de fagócitos em hospedeiros invertebrados e nas formas promastigotas nos vetores insetos. A leishmaniose pode ser transmitida pela picada de fêmeas infectadas de flebotomíneos que injetam as formas promastigotas no hospedeiro vertebrado durante sua alimentação. Quando as promastigotas atingem a ferida causada pela alimentação, elas são fagocitadas por macrófagos e outros tipos de células fagocíticas. Uma vez dentro das células, os parasitas passam para a forma amastigota, onde se multiplicam por bipartição e infectam outras células. Nos mosquitos, as formas amastigotas se transformam em promastigotas, se desenvolvem no intestino e migram para a probóscide (Figura 4) (CONCEIÇÃO-SILVA E ALVES, 2014).

Figura 4 – Ciclo biológico da *Leishmania* spp.




Fonte: CDC, Atlanta, USA (2018).

A doença de Chagas, também conhecida como Tripanossomíase Americana, é uma importante questão de saúde pública na América Latina, sendo causada pelo parasita *Trypanosoma cruzi*. Na América Latina, *T. cruzi* é transmitido na maioria dos casos pelo contato com as fezes ou urina de insetos triatomíneos mais conhecidos como barbeiros. A infecção ocorre no momento em que o barbeiro pica uma área de pele exposta e o inseto em seguida defeca próximo à picada (CHATELEIN, 2017; WHO, 2017b).

A Doença de Chagas se apresenta em duas fases: a primeira, fase aguda, pode durar cerca de até dois meses após a infecção. Durante esta fase, há um grande número de parasitas na forma tripomastigota. Nessa fase os sintomas são ausentes ou são fracos. As vezes pode aparecer lesão no local da picada e inchaço das pálpebras. Durante a segunda fase, crônica, o parasita se aloca principalmente nas células – sobe a forma amastigota - do coração e de músculos do sistema digestivo (Figura 5). Anos depois da infecção, pode acontecer morte súbita falha do coração causada pela destruição das células e do sistema nervoso (WHO, 2017b).

Figura 5 – Ciclo biológico do parasita *Trypanosoma cruzi*.



Ciclo de transmissão do *Trypanosoma cruzi* (simplificado). Infográfico: Venício Ribeiro, ICICT/Fiocruz.

Fonte: <http://portaldoprofessor.mec.gov.br/fichaTecnicaAula.html?aula=58597> (2017)

Para o tratamento de pacientes infectados com *Leishmania* spp. ou *Trypanosoma cruzi*, é feito o uso de fármacos de primeira linha. Em pacientes com leishmaniose, antimoníato de meglumina (Glucantime®, Sanofi aventis) é uma droga de primeira linha usada no combate ao protozoário, enquanto que anfotericina B e pentamidina são usadas as vezes como fármacos de segunda ou terceira linha. As drogas previamente citadas são usadas no tratamento de LC e LM (AYRES et al, 2007; HASHIGUCHI et al., 2017). A Miltefosina (Paladin, Canadá) é um fármaco de uso oral usado no tratamento de LV (HASHIGUCHI et al. 2017). Atualmente, o tratamento da Doença de Chagas é feito com a utilização de duas drogas nitro-heterocíclicas: benzonidazol (Abarax/ELEA) e nifurtimox (LAMPIT/Bayer). Porém, essas drogas apenas são efetivas na fase aguda da infecção (CHATELEIN, 2017).

Os tratamentos disponíveis atualmente para essas doenças têm se mostrado complicados e dolorosos. Os pacientes com LC geralmente abandonam o tratamento

com Glucantime® por causa das múltiplas injeções dolorosas da droga, por morarem longe dos centros e dos efeitos colaterais à droga (HASHIGUCHI et al., 2017). No caso dos fármacos utilizados para o tratamento da Doença de Chagas, o uso deles é limitado devido à baixa disponibilidade e efeitos colaterais, tais como: dermatite alérgica; coceiras; e manifestações gastrointestinais (CHATELEIN et al., 2017). Esses problemas são agravados pelo aparecimento de resistência a essas drogas em áreas endêmicas.

Muitos estudos estão tentando provar a eficácia e incorporar o uso de produtos naturais no tratamento da leishmaniose e da doença de chagas. Com o passar do tempo vários trabalhos têm mostrado que os produtos naturais podem ser uma boa estratégia na busca de compostos bioativos que podem otimizar a atividade biológica dos fármacos e minimizar efeitos colaterais. Uma grande variedade de alcalóides, esteróides, terpenos, cumarinas e flavonoides, tanto de origem vegetal e animal, vêm sendo testados contra diferentes espécies de *Leishmania* e *Trypanosoma*. (CHEUKA et al., 2017)

Nos últimos 20 anos inúmeros estudos sobre as atividades in vitro da própolis contra espécies de *Leishmania spp.* e *Trypanosoma spp.* tem sido realizados. Própolis de diversas origens (e.g. América do Sul, Europa e África) e tipos (e.g. verde e vermelha) já demonstraram possuir atividades contra espécies de *Leishmania* (*L. amazonensis*, *L. braziliensis*, *L. infantum* e *L. major*) e *Trypanosoma* (*T. cruzi*, *T. brucei* e *T. evansi*) (HIGASHI E CASTRO, 1994; AYRES et al., 2007; MACHADO et al., 2007; OMAR et al., 2016). Em um estudo comparando os efeitos das própolis verde e vermelha contra as formas amastigotas e promastigotas de *Leishmania*, AYRES et al. (2007) puderam observar que a própolis vermelha foi a mais ativa contra *Leishmania* e menos citotóxica contra os macrófagos e ainda estimulou sua produção. Da própolis vermelha nigeriana foram isolados 10 compostos e foi observada, dentre eles, de moderada a alta atividade contra *Trypanosoma brucei* (OMAR et al., 2016). Os efeitos causados pelo tratamento de formas tripomastigotas de *Trypanosoma* vão desde alterações mitocondriais até danos a membrana plasmática (MENNA-BARRETO et al., 2009).

2.4 RESINA DE *Dalbergia ecastaphyllum*

2.4.1 *Dalbergia ecastaphyllum*

O gênero pantropical *Dalbergia* L.f. (Fabaceae: Papilionoideae) consiste de arbustos, trepadeiras, e árvores com cerca de 250 espécies no total, e a Indochina representa um dos seus centros de diversificação com aproximadamente 30 a 45 espécies (HARTVIG et al., 2015). Esse gênero está distribuído nas Américas do Norte, Central e do Sul e oeste da África (TROPICOS, 2018). O gênero é caracterizado por folhas alternas, imparipinada; estípulas geralmente pequenas e caducas. A inflorescência pode ser racemosa ou paniculada. As flores são pequenas e geralmente numerosas. Os frutos são oblongos ou oblongo-elípticos, samaróide, reniforme, orbicular ou suborbicular, membranoso, subcoriáceo ou coriáceo (CARVALHO, 1997).

Dalbergia ecastaphyllum (L.) Taub. (Figura 6) é conhecida popularmente como rabo-de-bugio, bugi, marmelo e marmeleiro-da-praia. Essa espécie ocorre nas Américas, desde a costa sul da Flórida até o sul do Brasil, além da costa oeste africana. *D. ecastaphyllum* está principalmente associada a estuários, beira de rios, ou manguezais. Menos frequentemente a espécie cresce em vegetação de restinga em solos arenosos como arbustos robustos ou árvores pequenas. *D. ecastaphyllum* está presente atualmente em 18 estados brasileiros (CARVALHO, 1997; SILVA E SANTOS, 2009). Essa espécie vem se tornando popular por ser a principal fonte botânica de resina para a produção da própolis vermelha (ALENCAR et al., 2007).

Figura 6 – Foto de um exemplar de *Dalbergia ecastaphyllum*.



Fonte: Anita Estival (2010), Flora Digital, UFRGS.

2.4.2 Produção da resina vegetal

Resina vegetal é definida como uma mistura composta por terpenoides e/ou compostos fenólicos secundários solúveis em lipídios que são (i) geralmente secretados em estruturas especializadas localizadas internamente ou na superfície das plantas e (ii) de potencial significância em interações ecológicas. Há dois tipos de secreção resinosa extracelular: endógena, o material se acumula em estruturas internas (glandulas ou ductos) e normalmente esse material é exudado quando planta sofre injúria; exógena, vários tipos de células secretórias epidérmicas descarregam o material para fora do órgão (LANGENHEIM, 2003).

Diferentes organelas estão envolvidas na produção de resinas, como os plastídeos (leucoplastos) e o retículo endoplasmático liso (REL). Em geral, a síntese de monoterpenos e diterpenos começa nos plastídeos e terminam no REL. Flavonóides e fenilpropanóides são sintetizados no REL e acumulados em células secretórias colunares. O transporte dos componentes da resina pode ser feito por vesículas que são envelopadas pela membrana plasmática antes de serem despejadas no espaço intercelular (LANGENHEIM, 2003).

Em alguns casos, a resina é exudada após algum tipo de injúria. No caso de *D. ecastaphyllum*, insetos são responsáveis pela exudação da resina através da produção de furos na casca dos galhos. Essa resina que é um mecanismo de defesa da planta contra invasão de micro-organismos é usada pelas abelhas melíferas para a produção de própolis (NAIR, 2007).

2.4.3 Componentes químicos e atividades biológicas da resina de *Dalbergia ecastaphyllum*

No que se trata do estudo da composição da própolis vermelha brasileira, a resina vegetal a qual as abelhas usam para a produção da própolis (Figura 7) tem sido tratada desde a descoberta da própolis vermelha como coadjuvante. Com o objetivo de identificar a origem botânica da própolis vermelha foi possível identificar na resina de *D. ecastaphyllum* a presença de flavonóides, e.g. quercetina, crisina, rutina, daidzeína, formonetina, biochanina A, pinocembrina, luteolina, e ácidos fenólicos, como ácido ferúlico (ALENCAR et al., 2007; DAUGSCH et al., 2008; SILVA et al.,

2007; LÓPEZ et al., 2014). BUENO-SILVA et al. (2017) analisaram a atividade antibacteriana da resina de *D. ecastaphyllum* e observaram que a mesma possui atividade antibacteriana contra bactérias Gram-positivas.

Figura 7 – Exudação da resina vegetal em galho da planta *Dalbergia ecastaphyllum*.



Fonte: O Autor (2015).

3 RESULTADOS

Os resultados estão apresentados em três artigos.

3.1 ARTIGO 1 - SEASONAL VARIATION OF BRAZILIAN RED PROPOLIS: ANTIBACTERIAL ACTIVITY, SYNERGISTIC EFFECT AND PHYTOCHEMICAL SCREENING

Food and Chemical Toxicology 107 (2017) 572–580



Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox



Seasonal variation of Brazilian red propolis: Antibacterial activity, synergistic effect and phytochemical screening



M.S. Regueira Neto ^{a,*}, Saulo Relison Tintino ^b, Ana Raquel Pereira da Silva ^b,
Maria do Socorro Costa ^b, Aline Augusti Boligon ^c, Edinardo F.F. Matias ^d,
Valdir de Queiroz Balbino ^a, Irwin R.A. Menezes ^b, Henrique Douglas Melo Coutinho ^b

^a Departamento de Genética, Centro de Ciências Biológicas, UFPE, Brazil

^b Departamento de Química Biológica, Centro de Ciências Biológicas e Saúde, Universidade Regional do Cariri, Brazil

^c Department of Industrial Pharmacy, Federal University of Santa Maria, Santa Maria, Brazil

^d Departamento de Biomedicina, Centro Universitário Leão Sampaio, Brazil

ARTICLE INFO

Article history:

Received 18 February 2017

Received in revised form

24 March 2017

Accepted 25 March 2017

Available online 27 March 2017

Keywords:

Red propolis

Antibacterial activity

Phenolic compounds

Seasonal variation

Synergistic effect

ABSTRACT

The aim of this study was to investigate the effect of the dry and rainy season on the antibacterial activity and chemical composition of the Brazilian red propolis. The samples were collected in rainy (RP-PER) and dry (RP-PED) seasons and analyzed by HPLC-DAD. The extracts were tested alone and in association with antibiotics against *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*. The HPLC analysis identified luteolin and quercetin as the main compounds. Seasonal variation was observed according to concentrations of the compounds. The MIC values against *E. coli* ranged from 128 µg/mL to 512 µg/mL (EC 06 and EC ATCC). The red propolis showed MIC values of 512 µg/mL against both strains of *P. aeruginosa* used in our study (PA03 and PA24) and against strains of Gram-positive bacteria *S. aureus* the MICs ranged from 64 µg/mL to ≥1024 µg/mL (SA10). A synergistic effect was observed when we combined the RP-PED with gentamicin against all the strains tested. When we combined the RP-PED with Imipenem, we only observed synergistic effect against *P. aeruginosa*. According to our synergistic activity results, the utilization of red propolis collected in the drier periods can be used as an adjuvant against multiresistant bacterial infections.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Propolis is a resinous mixture produced by honeybees for various purposes. It is used to avoid intruders by protecting the entrance of the hive and sealing the holes; to prevent contamination inside the hive by bacteria, viruses or parasites because of its antiseptic effect; as well as to cover intruders who died inside the hive in order to avoid their decomposition (Salatino et al., 2005; Righi et al., 2010). Many plant constituents are found in propolis composition e.g. plant resins, pollen and bud excretions. Additionally, it is also found bee products as beeswax and bees secretion, so it has been considered an organotherapy product (Daugusch et al., 2007; Mendonça et al., 2015; Anvisa, 2005). After collecting the plant parts, the resin is chewed, then salivary enzymes are added

and the partially digested material is mixed with beeswax (Burdock, 1998).

In Brazil, we have 13 groups of propolis based on physicochemical characteristics (Park et al., 2000; Daugsch et al., 2007). The characteristic of each different type of propolis is dependent of some factors as e.g. plant source and edaphoclimatic conditions (Silva et al., 2015). The most recent type of propolis discovered in northeast Brazil has a reddish color and is located in beehives along the river shores (Daugusch et al., 2007). The Brazilian red propolis is found in the states of Alagoas, Paraíba, Pernambuco, Sergipe, Bahia and Roraima (Daugusch et al., 2007; López et al., 2014). However, red propolis can also be found in other countries as Cuba, China, Mexico and Venezuela (Trusheva et al., 2004; Daugsch et al., 2007; Izuta et al., 2009; Lotti et al., 2010; Piccinelli et al., 2011). One species has been suggested to be the botanical source for the Brazilian red propolis: *Dalbergia ecastophyllum*. However, in other countries, other botanical sources are associated to red propolis as *Clusia major*, *C. minor* and *C. scrobiculata* in Venezuela and *C. rosea* in Cuba

* Corresponding author.
E-mail address: mareg1988@gmail.com (M.S. Regueira).

(Tomas-Barberan et al., 1993; Cuesta-Rubio et al., 2002; Trusheva et al., 2004, 2006).

Previous studies have reported many biological activities for the Brazilian red propolis like antioxidant (Alencar et al., 2007; Righi et al., 2010; Frozza et al., 2013), antimicrobial (Bispo-Junior et al., 2012; Cabral et al., 2009; Righi et al., 2010), anticancer (Awale et al., 2008; Li et al., 2008), anti-inflammatory (Bueno-Silva et al., 2013; Cavendish et al., 2015), cytotoxicity (Alencar et al., 2007), repair of wounds (Batista et al., 2012) and antinociceptive (Cavendish et al., 2015). These properties are attributed to the phenolic compounds, which are present in high amount in Brazilian red propolis, but the substances involved in those biological activities are still being researched. Some studies showed that isoflavones found in red propolis have a participation in many activities as e.g. antimicrobial, antifungal, anticancer and antioxidant (Alencar et al., 2007; Freires et al., 2016). Flavanones, isoflavones, chalcones and pterocarpanes have displayed important activity against cancer cell lines (Li et al., 2008). Neovestitol and vestitol isolated from Brazilian red propolis inhibited neutrophil migration in mouse thus showing an anti-inflammatory activity (Bueno-Silva et al., 2013).

In the last decade, many researchers focused their efforts on the discovery of chemicals that participates in the composition of the Brazilian Red Propolis. Among the red propolis samples from the states of Alagoas, Paraíba and Sergipe, it has been found flavones, isoflavones, flavonols, chalcones, auronos, pterocarpanes and xanthones (Awale et al., 2008; Li et al., 2008; López et al., 2014; Mendonça et al., 2015). However, some chemical compounds are more frequently found in those samples and between them, there are formonetin, biochanin A, quercetin, pinocembrin, daidzein, medicarpin, homopterocarpan and liquiritigenin (Alencar et al., 2007; Cabral et al., 2009; Zulueta et al., 2009; Righi et al., 2010; Piccinelli et al., 2011; Oldoni et al., 2011; Frozza et al., 2013; Cavendish et al., 2015; Lopez et al., 2015). These major compounds are also present in the exudate of *Dalbergia ecastophyllum*, the main source for the production of red propolis in the Northeast of Brazil. On the other hand, López et al. (2014) showed that probably a second plant species participates as one of the main source of resins for the red propolis in Brazil.

The red propolis of some Northeastern Brazilian states (e.g. Alagoas, Paraíba and Sergipe) have been tested for antibacterial activity against Gram-negative bacteria – *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Escherichia coli*, *Proteus mirabilis*, *P. morganii*, *Neisseria meningitidis*, *Haemophilus influenzae* and *Enterobacter aerogenes* – (Righi et al., 2010; Lopez et al., 2015) and Gram-positive bacteria – *Bacillus subtilis*, *Enterococcus faecalis*, *Streptococcus pyogenes*, *Staphylococcus aureus* and *S. epidermidis* (Alencar et al., 2007; Cabral et al., 2009; Righi et al., 2010; Lopez et al., 2015). Trusheva et al. (2006) attributed the antibacterial activity found in the Brazilian red propolis to the flavonoids, especially isoflavonoids and prenylated benzophenones. However, studies about the antimicrobial activity of the red propolis from other Brazilian states remains very scarce.

Resistance of microorganism to commercial antimicrobials drugs has been reported in the literature, so scientists all over the world are gathering efforts to find an alternative way to treat resistant microbial infections in humans diseases (Mandal et al., 2010; Eumkeb et al., 2012). The association between synthetic antimicrobial agents and natural substances have been studied and some combinations have had synergistic effect to inhibit bacterial growing (Matias et al., 2010; Hassan et al., 2016). Propolis has been combined with some kind of drugs, e.g. anticancer (Guo et al., 2015), antibacterial (Wojtyczka et al., 2013), antifungal (Pippi et al., 2015) and in some studies, it was observed a synergistic effect (Fernandes et al., 2005; Wojtyczka et al., 2013). The association

of Brazilian red propolis with antifungals showed synergistic effect against *Candida* sp, however studies with red propolis and antimicrobials agents remains scarce (Pippi et al., 2015).

The major effect that can affect the chemical composition of propolis is the geographical location. Every place on earth has its own particularities concerning to the diversity of plants, climate, soil, and these factors together strongly influences the chemical composition of propolis (Teixeira et al., 2008; Sampaio et al., 2016). However, seasonality is also an important factor that can determine the propolis composition due to the influence of phenological factors in biosynthesis of plant metabolites (Teixeira et al., 2008). Seasonal variation of chemical compounds from propolis were previously described for Brazilian propolis, but was not observed a significant variation for antibacterial activity (Sforzin et al., 2000; Jorge et al., 2008; Teixeira et al., 2008).

The Northeast of Brazil has two seasons (drier and rainy) that are very distinct between them and one of these differences comprises the amount of rain during the year (APAC, 2016). Accordingly, these seasonal variations, as mentioned above, can influence the biosynthesis of plant metabolites and consequently affect the resin that is secreted by plants, which is used by the honeybees to produce propolis (Teixeira et al., 2008). Therefore, we aimed to investigate the effect of the dry and rainy season on the antibacterial activity and chemical composition of the Brazilian red propolis to bring the possibility whether a better antibacterial activity could be assessed for the red propolis alone or in association with standard drugs.

2. Material and methods

2.1. Propolis sampling and processing

Red propolis produced by Africanized *Apis mellifera* was collected in apiaries located in Tamandaré, state of Pernambuco. Those samples were collected in two moments: rainy season (between April and august of 2014) and dry season (between December/2015 and March/2016). Those periods are historically known by have the higher and the lowest precipitation in the state of Pernambuco (APAC, 2016), respectively. Raw red propolis from Pernambuco Rainy (RP-PER) and Dry (RP-PED) season were stored at -20°C and then the propolis samples were dissolved in hydroethanolic solution (ethanol 54%) for 72 h. Afterward, the extract was filtered and concentrated using a rotary vacuum evaporator (model Q-344B-Quimis, Brazil). The concentrated solution was frozen and then lyophilized to obtain a fine powder of the red propolis hydroethanolic extract. For the microbiological assays, the dry extract of red propolis was solubilized in dimethyl sulfoxide (DMSO) and afterward, the DMSO-red propolis solution was diluted in sterile water to reach the concentration of 1024 $\mu\text{g}/\text{mL}$.

2.2. Chemical, apparatus and general procedures for HPLC-DAD

All chemical were of analytical grade. Acetonitrile, methanol, phosphoric acid, chlorogenic acid, caffeic acid, *p*-coumaric acid and ellagic acid were purchased from Merck (Darmstadt, Germany). Quercetin, apigenin, vitexin, rutin and luteolin were acquired from Sigma Chemical Co. (St. Louis, MO, USA). The standards vitexin and rutin were used only for RP-PER samples and the *p*-coumaric acid for the RP-PED samples. High performance liquid chromatography (HPLC-DAD) was performed with a Shimadzu Prominence Auto Sampler (SIL-20A) HPLC system (Shimadzu, Kyoto, Japan), equipped with Shimadzu LC-20AT reciprocating pumps connected to a DGU 20A5 degasser with a CBM 20A integrator, SPD-M20A diode array detector and LC solution 1.22 SP1 software.

2.3. HPLC-DAD analysis

2.3.1. Red propolis rainy season

Chromatographic analyses were carried out under gradient conditions using Phenomenex C₁₈ column (4.6 mm × 250 mm) packed with 5 µm diameter particles; the mobile phase was water containing 2% formic acid and methanol. Methanol concentration was gradually increased as follows: 0–5 min, 10%; 5–7 min, 20%; 7–31 min, 31%; 32–44 min, 40%; 44–50 min, 100%; and 55–60 min, 3%; following the method described by Boligon et al. (2015) with slight modifications. Red propolis hydroethanolic extract and mobile phase were filtered through 0.45 µm membrane filter (Millipore) and then degassed by ultrasonic bath prior to use, the extract was analyzed at a concentration of 25 mg/mL. The flow rate was 0.6 mL/min and the injection volume was 40 µL. The sample and mobile phase were filtered through 0.45 µm membrane filter (Millipore) and then degassed by ultrasonic bath prior to use. Stock solutions of standards references were prepared in the HPLC mobile phase at a concentration range of 0.030–0.200 mg/mL. Quantifications were carried out by integration of the peaks using the external standard method, at 325 nm for chlorogenic acid, caffeic acid and ellagic acid; and 367 nm for rutin, vitexin, quercetin, apigenin and luteolin. Chromatography peaks were confirmed by comparing its retention time with those of reference standards and by DAD spectra (200–500 nm). All chromatography operations were carried out at ambient temperature and in triplicate. Calibration curve for chlorogenic acid: $Y = 13519x + 1267.4$ ($r = 0.9999$); caffeic acid: $Y = 11964x + 1173.5$ ($r = 0.9998$); ellagic acid: $Y = 11845x + 1309.6$ ($r = 0.9995$); rutin: $Y = 12573x + 1258.9$ ($r = 0.9999$); quercetin: $Y = 13508x + 1267.2$ ($r = 0.9997$); vitexin: $Y = 12549x + 1182.3$ ($r = 0.9994$); luteolin: $Y = 12651x + 1376.4$ ($r = 0.9998$) and apigenin: $Y = 11987x + 1293.6$ ($r = 0.9999$).

2.3.2. Red propolis dry season

RP-PED hydroethanolic extract at a concentration of 15 mg/mL was injected by means of a model SIL-20A Shimadzu Auto sampler. Separations were carried out using Phenomenex C₁₈ column (4.6 mm × 250 mm × 5 µm particle size). The mobile phase was water with 1% phosphoric acid (v/v) (solvent A) and HPLC grade acetonitrile (solvent B) at a flow rate of 0.6 mL/min and injection volume 40 µL. The composition gradient was: 5% solvent B reaching 15% at 10 min; 30% solvent B at 25 min, 65% solvent B at 40 min and 98% solvent B at 45 min, followed by 50 min at isocratic elution until 60 min. At 80 min the gradient reached the initial conditions again, following the method described by Carvalho et al. (2016) with slight modifications. The sample and mobile phase were filtered through 0.45 µm membrane filter (Millipore) and then degassed by ultrasonic bath prior to use. Stock solutions of standards references were prepared in the acetonitrile: water (1:1, v/v) at a concentration range of 0.030–0.500 mg/mL. Quantifications were carried out by integration of the peaks using the external standard method, at 254 nm for ellagic acid; 327 nm for caffeic acid, *p*-coumaric acid and chlorogenic acids; and 366 nm for quercetin, apigenin and luteolin. The chromatography peaks were confirmed by comparing its retention time with those of reference standards and by DAD spectra (200–600 nm). Calibration curve for chlorogenic acid: $Y = 12457x + 1045.9$ ($r = 0.9996$); caffeic acid: $Y = 13509x + 1173.2$ ($r = 0.9998$); apigenin: $Y = 10865x + 1473.7$ ($r = 0.9999$); ellagic acid: $Y = 12758x + 1064.8$ ($r = 0.9993$); quercetin: $Y = 11470x + 1357.8$ ($r = 0.9997$); *p*-coumaric acid: $Y = 13541x + 1269.5$ ($r = 0.9999$) and luteolin: $Y = 10582x + 1346.9$ ($r = 0.9997$). All chromatography operations were carried out at ambient temperature and in triplicate.

2.4. Limit of detection (LOD) and limit of quantification (LOQ)

LOD and LOQ were calculated based on the standard deviation of the responses and the slope using three independent analytical curves, as defined by Boligon et al. (2015). LOD and LOQ were calculated as 3.3 and 10 σ/S , respectively, where σ is the standard deviation of the response and S is the slope of the calibration curve.

2.5. Bacterial strains

The strains used were the clinical isolates of *Escherichia coli* 06 (EC06), *Pseudomonas aeruginosa* 03 (PA03), *P. aeruginosa* 24 (PA24) and *Staphylococcus aureus* 10 (SA10) and standard strains of *E. coli* ATCC 25922 (ECATCC) and *S. aureus* ATCC 6538 (SAATCC). The bacterial strains were maintained and activated, prior to the assay, overnight at 37 °C on Nutrient Agar (Difco Laboratories).

2.6. Drugs

Gentamicin and Imipenem were obtained from Sigma Chemical Co. All drugs were dissolved in sterile water.

2.7. Minimal inhibitory concentration

The minimal inhibitory concentration (MIC) of Red Propolis from Pernambuco Rainy and Dry season were determined in a microdilution assay using 100 µL of each suspended bacterial strain inoculum in saline solution which corresponds to 0.5 of McFarland scale, followed by the addition of 900 µL brain heart infusion (BHI) in 1.5 mL microtubes. The BHI-inoculum solutions were transferred to a 96-well microtiter plates and serial dilutions of each red propolis extract was performed with concentrations ranging from 512 to 8 µg/mL (1:1). The plates were incubated for 24 h at 37 °C and the bacterial growth was assessed by the use of resazurin. The MIC was defined according to CLSI (2008) in which is the lowest concentration where no growth can be observed. The antibacterial assays were performed in triplicates and results were expressed as an average of replicates.

2.8. Combined effect of red propolis with standard antibiotics

We combined the RE-PER and the RE-PED with Imipenem and Gentamicin to assess whether the red propolis can decrease the MIC of standard antibiotics. The increase of the antibiotic activity of the standard antibiotics was tested using a sub-inhibitory concentration of the extracts of red propolis (MIC/8). For the control, 150 µL of each bacterial strain in saline solution (0.5 in McFarland scale), were added to a 1.5 mL micro tubes together with 1350 µL of BHI broth. For the tests, 150 µL of each bacterial strain in saline solution (0.5 in McFarland scale), were added together with the red propolis extract from the rainy and dry season (MIC/8) and completed with BHI until reach 1.5 mL. The previous solutions were then transferred to a 96-well microtiter plate and serial dilutions (1:1) were performed with 100 µL of the antimicrobial drugs. The plates were incubated at 37 °C for 24 h and the bacterial growth was assessed with resazurin. The plates were incubated at 37 °C for 24 h, and bacterial growth was assessed by the use of resazurin. MIC was defined with the concentrations of antibiotics between 2500 and 1,22 µg/mL. The MIC of controls were assessed using the antibiotics alone.

2.9. Statistical analysis

2.9.1. Microbiological results

The assays were performed in triplicates and results were

expressed as average of replicates. The results are expressed as the geometric mean. Two-Way ANOVA was applied as Statistical hypothesis analysis followed by Bonferroni post hoc using GraphPad Prism 6.0 software (2008).

2.9.2. HPLC-DAD

Differences between groups of HPLC were assessed by an analysis of variance model and Tukey's test. The level of significance for the analyses was set to $p < 0.05$. These analyses were performed by using the free software R version 3.1.1. (R Core Team, 2014).

3. Results

3.1. Chemical characterization of red propolis

3.1.1. Rainy season

HPLC fingerprinting of RP-PER hydroethanolic extract revealed the presence of two major peaks (4 and 7) identified as vitexin and luteolin and the others were identified as chlorogenic acid, caffeic acid, ellagic acid, rutin, quercetin and apigenin (Fig. 1 and Table 1).

3.1.2. Dry season

The HPLC profile of RP-PED is shown in Fig. 2. Two major peaks (5 and 6) stands out and they were identified as quercetin and luteolin. The sample contains other minor compounds in addition to the other two: chlorogenic acid, caffeic acid, ellagic acid, *p*-coumaric acid and apigenin (Fig. 2 and Table 1).

4. Microbiological assays

4.1. Minimal inhibitory concentration

The red propolis showed MIC values (Table 2) ranging from 128 $\mu\text{g/mL}$ to 512 $\mu\text{g/mL}$ against *E. coli* strains and from 64 $\mu\text{g/mL}$ to ≥ 1024 $\mu\text{g/mL}$ against *S. aureus* strains. However, for the *P. aeruginosa* strains the MIC values were all the same, 512 $\mu\text{g/mL}$.

4.2. Combined effect of red propolis with standard antibiotics

The Brazilian red propolis, which was collected in the dry season, has demonstrated to improve the imipenem and gentamicin activity against strains of *P. aeruginosa* and *S. aureus*. However, there was no synergistic effect between the red propolis collected in the rainy season and the imipenem and gentamicin against the same strains (Fig. 3). The RP-PER did not influenced the effect of gentamicin against the PA03, SA10 and SAATCC, except against the PA24 strain, which there was an antagonist effect. When the RP-PER was combined with imipenem we also observed no effect against all of

the strains used in this study. On the other hand, the RP-PED improved the gentamicin activity against all bacterial strains. A synergistic effect was also observed against *P. aeruginosa* (PA03 and PA24) when we combined the RP-PED with imipenem. The RP-PED did not improve the imipenem activity against *S. aureus* strains (SA10 and SAATCC).

5. Discussion

5.1. Chemical characterization of red propolis

Honey Bees that produces red propolis has been already reported in three continents: Africa (Nigeria), Asia (Saudi Arabia) and America (Brazil, Cuba, Mexico and Venezuela) (Trusheva et al., 2004; Piccinelli et al., 2005, 2011; Lotti et al., 2010; Lopez et al., 2015; Omar et al., 2016; Saddiq and Mohamed, 2016). The red propolis found at those locations has its own particularities regarding to chemical composition. Those specific characteristics are associated with the geographical location where the red propolis is produced. The edaphoclimatic conditions and the botanical source are important factors, which can affect the chemical composition of propolis (Silva et al., 2015).

The HPLC analysis of the Brazilian red propolis sampled from the state of Pernambuco allowed us to identify nine compounds: apigenin, caffeic acid, chlorogenic acid, ellagic acid, luteolin, *p*-coumaric acid, quercetin, rutin and vitexin. The compounds apigenin, chlorogenic acid, ellagic acid and vitexin were never described before for red propolis. Among them we have flavonoids, acid hydroxycinnamic and derivatives of acid hydroxycinnamic. Those bioactive compounds are most known by have some biological activities, e.g. neuroprotective, anti-cancer, anti-inflammatory, antioxidante, antimicrobial and anti-leishmania (Ural et al., 2015; Bak et al., 2016; Fonseca-Silva et al., 2015; Kasala et al., 2016; Tsang et al., 2016; Pei et al., 2016). Flavonoids represents more than 60% of the composition of the Brazilian red propolis and many chemical classes have been found, e.g. flavones, flavanones, isoflavones, isoflavonoids, chalcones, aurones, flavonols and neo-flavonoids (Silva et al., 2007; Dausch et al., 2007; Alencar et al., 2007; Li et al., 2008; Cabral et al., 2009; Zulueta et al., 2009; Righi et al., 2010; Piccinelli et al., 2011; Oldoni et al., 2011; Frozza et al., 2013; Mendonça et al., 2015; Cavendish et al., 2015; Lopez et al., 2015).

The compounds *p*-coumaric acid, rutin, quercetin, Luteolin and caffeic acid were previously reported only in Brazilian red propolis samples from Alagoas, Brazil (Silva et al., 2007; Dausch et al., 2007; Cabral et al., 2009; Mendonça et al., 2015). However, a variety of chemical compounds have been found in red propolis samples from the Northeast of Brazil (Freires et al., 2016). Most of the compounds identified in red propolis were from the State of Alagoas (Alencar et al., 2007; Cabral et al., 2009; Mendonça et al., 2015), followed by the states of Segipe (Pinheiro et al., 2014) and Paraíba (Lopez et al., 2015). The red propolis from the states of Pernambuco and Bahia are placed as less studied in number of publications.

5.2. Seasonal effect on chemical compounds of Brazilian red propolis

This is the first report of seasonal variation of the concentrations of chemicals compounds in red propolis. When we compared the concentration of the compounds found in both propolis used in this study, we observed that the concentrations of quercetin, caffeic acid and ellagic acid were almost two times higher in RP-PED than in RP-PER. However, we observed an increase of luteolin and apigenin in the RP-PER compared to RP-PED. The concentration of




Fig. 1. Chemical profile of the RP-PER hydroethanolic extract. Chlorogenic acid (peak 1), caffeic acid (peak 2), ellagic acid (peak 3), vitexin (peak 4), rutin (peak 5), quercetin (peak 6), luteolin (peak 7) and apigenin (peak 8).

Table 1
Components of red propolis hydroethanolic extract.

Compounds	RP-PER	LOD	LOQ	RP-PED	LOD	LOQ
	mg/g	µg/mL	µg/mL	mg/g	µg/mL	µg/mL
Chlorogenic acid	0.73 ± 0.01 a	0.011	0.037	0.97 ± 0.03 a	0.015	0.049
Caffeic acid	1.32 ± 0.03 b	0.009	0.029	2.15 ± 0.01 b	0.008	0.026
Ellagic acid	1.28 ± 0.01 b	0.013	0.042	2.09 ± 0.03 b	0.026	0.085
Vitexin	3.69 ± 0.01 c	0.028	0.093			
Rutin	0.45 ± 0.02 d	0.031	0.102			
p-Coumaric acid				0.18 ± 0.04 c	0.013	0.043
Quercetin	3.19 ± 0.03 e	0.015	0.051	6.34 ± 0.01 d	0.024	0.079
Luteolin	7.51 ± 0.01 f	0.026	0.085	4.11 ± 0.02 e	0.016	0.052
Apigenin	2.97 ± 0.04 e	0.017	0.058	1.95 ± 0.05 b	0.011	0.034

Results are expressed as mean ± standard deviations (SD) of three determinations. Averages followed by different letters differ by Tukey test at $p < 0.05$.




Fig. 2. Chemical profile of RP-PED hydroethanolic extract. Chlorogenic acid (peak 1), caffeic acid (peak 2), ellagic acid (peak 3), p-coumaric acid (peak 4), quercetin (peak 5), luteolin (peak 6) and apigenin (peak 7).

Table 2
Values of MIC of the Brazilian red propolis from rainy and dry season against bacterial strains.

Bacterial strains	MIC (µg/mL)	
	RP-PER	RP-PED
EC06	128	512
ECATCC	512	161.3
PA03	512	512
PA24	512	512
SA10	64	101.6
SAATCC	≥1024	512

chlorogenic acid were slightly higher in the RP-PED. A previous study with Argentinian propolis showed that the extracts of propolis collected in the summer and spring had a higher content of phenolic and flavonoid contents than the samples collected in winter and autumn (Isla et al., 2012). It was also observed that concentrations of phenolic compounds from Brazilian propolis showed seasonal variations. Other studies reported that in samples of alecrim propolis an inversely proportional amount of triterpenoids and phenolic was observed (Teixeira et al., 2008). Similar phenomenon was observed by Bankova et al. (1998), where diterpenes started appearing in summer and reached a maximum in autumn.

That variation found in chemical compounds of red propolis is probably due to a seasonal pressure suffered by the botanical font. We believe that because the mean element in the production of red propolis is a resin secreted by *Dalbergia ecastophyllum* trees and the production and accumulation of secondary metabolites of plants are influenced by seasonal variations. In a study about the effect of the environment on the secondary metabolic profile of *Tithonia diversifolia*, Sampaio et al. (2016) observed that samples collected during the rainiest period were rich in primary metabolites,

meanwhile the leaf and stem samples collected during the drier periods were rich in secondary metabolites. The mentioned study could also explain why the red propolis samples collected in the drier periods had a higher concentration in four of the six compounds compared with the rainiest period.

5.3. Antimicrobial activity

Previous studies have shown that Brazilian red propolis has a large content of phenolic compounds, mostly flavonoids and these phenolic compounds found in red propolis are associated to antibacterial activity (Cabral et al., 2009; Freires et al., 2016). The antibacterial activity of the hydroethanolic extract of Brazilian red propolis from the state of Pernambuco were tested against strains of *E. coli*, *P. aeruginosa* and *S. aureus*. The MIC values of *E. coli* ranged from 128 µg/mL to 512 µg/mL (EC 06) and from 161 µg/mL to 512 µg/mL (EC ATCC). These results are similar to those found by Righi et al. (2010), Bispo-Junior et al. (2012) and Lopez et al. (2015) when they evaluated the MIC of red propolis from the states of Alagoas, Sergipe and Paraíba. The red propolis samples showed MIC values of 512 µg/mL against both strains of *P. aeruginosa* used in our study (PA03 and PA24). Red propolis samples from the states of Alagoas, Paraíba and Sergipe showed MIC values above 200 µg/mL (Lopez et al., 2015). Red propolis samples from Alagoas analyzed by Righi et al. (2010) presented MIC 256 µg/mL. Red propolis MIC values against strains of Gram-positive bacteria *S. aureus* ranged from 64 µg/mL to 101.6 µg/mL (SA10) and from 512 µg/mL to ≥1024 µg/mL (SAATCC). Similar results against *S. aureus* were reported for red propolis from Alagoas, Paraíba and Sergipe (Alencar et al., 2007; Cabral et al., 2009; Oldoni et al., 2011; Bispo-Junior et al., 2012; Bueno-Silva et al., 2013; Lopez et al., 2015). In a study with plant extract, Kuete (2010) showed that an extract has significant antibacterial activity if MIC is 100 µg/mL, moderate if its MIC is between 100 and 625 µg/mL and low when MIC is above 625 µg/mL. Based on this, we can deduce that both red propolis hydroethanolic extract has antibacterial effect against the bacterial strains used in this study. As we observed in our results, the red propolis extract was more effective against Gram-positive bacteria than the Gram-negative bacteria. This was also observed in previous studies when the ethanolic extract of red propolis was tested against *S. aureus* (Alencar et al., 2007; Cabral et al., 2009; Oldoni et al., 2011; Bispo-Junior et al., 2012; Bueno-Silva et al., 2013; Lopez et al., 2015). The mechanisms of antibacterial activity, as mentioned above, involves the flavonoids present in the propolis. In the literature, some reviews summarized these mechanisms, they are: (1) inhibition of nucleic acids synthesis (DNA and RNA); (2) inhibitory mechanism on DNA gyrase; (3) inhibition of cytoplasmic membrane function (damage to the cytoplasmic membrane caused by a reduction in the fluidity); (4) Inhibition of energy metabolism (due to the damage to




Fig. 3. Combined effect of red propolis and antibacterial drugs. The histograms show the results of the antibiotic activity of the extract of red propolis from rainy and dry season combined with standard drugs, against strains of *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

the cytoplasmic membrane the exchange of nutrients and metabolites is disturbed, inhibiting the energy supply); (5) Inhibition of attachment and biofilm formation (Xie et al., 2015; Freires et al., 2016).

5.4. Seasonal variation of minimal inhibitory concentration

In our study, we compared the antibacterial activity of samples of red propolis from rainy and dry seasons, then we could observe different MIC values between them. Then we observed that the hydroethanolic extract of RP-PER had the lowest MIC against the multiresistant strain of *Staphylococcus aureus* (SA10) that inhibited the bacterial growing with 64 µg/mL. However, the MIC of RP-PED against same strain had an increase (101,6 µg/mL). The same happened when we tested the red propolis samples against the a multiresistant strain of *Escherichia coli*. The RP-PER showed the lowest MIC (128 µg/mL) when compared to the MIC of RP-PED (512 µg/mL). The hydroethanolic extract of RP-PED showed a lower MIC in comparison to the RP-PER extract against the ECATCC and SAATCC strains. The red propolis samples from rainy and drying seasons had the same MIC for both *Pseudomonas aeruginosa* strains (512 µg/mL). In other studies, seasonal variation of the antibacterial activity of propolis against *S. aureus* and *E. coli* were observed, but no significant differences was observed along the year (Sforin

et al., 2000; Jorge et al., 2008). However, the Argentinian propolis sample collected in the summer and autumn showed higher antibacterial activity than the other samples (Isla et al., 2012).

5.5. Seasonal variation of combined effect of red propolis with standard antibiotics

Gentamicin and Imipenem are effective antibiotics against Gram-positive and Gram-negative bacteria, e.g. *Escherichia coli*, *Klebsiella* spp., *Pseudomonas aeruginosa* and *Staphylococcus aureus* (Selim et al., 2012; Zhang et al., 2014; Saha et al., 2016; Vázquez et al., 2016). However, multidrug resistance it is a major concern all over the world, especially in the hospital environment, and it has significantly increased in recent years (Özçelik et al., 2008; Biedenbach et al., 2016). Previous studies have shown that association of standard drugs with phenolic compounds can enhance the activity of these drugs against a range of diseases (Mun et al., 2013; Amin et al., 2015; Guo et al., 2015). Taking in to account what was mentioned above, we decided to test both of our red propolis samples combined with standard antibiotics against strains of *S. aureus* and *P. aeruginosa*. Our results showed that RP-PER combined with imipenem and gentamicin had no synergistic effect against the strains of *S. aureus* and *P. aeruginosa*. On the other hand, a synergistic effect was observed when we combined the RP-PED

with gentamicin against all the strains tested. When we combined the RP-PED with Imipenem, we only observed synergistic effect against *P. aeruginosa* strains. However, The RP-PED-imipenem association was not effective against *S. aureus* strains. A synergistic effect of red propolis was also observed against *Candida* spp. when the propolis was combined with fluconazole (Pippi et al., 2015).

Other types of propolis also showed synergistic activity against microorganisms. Synergistic effect between propolis and gentamicin against *S. aureus* was also observed by the Kirby and Bauer and E-test methods (Fernandes-Júnior et al., 2005). Wojtyczka et al. (2013) tested the ethanolic extract of propolis associated with 10 different antimicrobial drugs against clinical isolates of *S. aureus*. The study revealed synergism between the ethanolic extract of propolis and eight antimicrobial drugs against all tested strains of *S. aureus* (Wojtyczka et al., 2013). In a study with Bulgarian and Brazilian propolis the authors also observed a synergism with antimicrobial drugs against *Salmonella Typhi* (Orsi et al., 2006, 2012). The application of the association of chemical compounds isolated from natural products with standard drugs against bacterial infections could open a new horizon for the application of bee products, as propolis, in the treatment of bacterial infections, which became resistant to standard drugs.

Bacteria cell wall or membrane damage is probably the main mechanism in which propolis chemical compounds participates. That mechanism makes the entrance inside the cell easier for antibiotics and, consequently, enhance its activity (Orsi et al., 2006, 2012). Some studies have shown that flavonoids, eg. apigenin, quercetin, galangin, pinocembrin, and caffeic acid, benzoic acid, cinnamic acid act synergistically with antibiotics causing functional and structural damages to the outer cytoplasmic membrane (Scazzocchio et al., 2006; Xie et al., 2015). Also, other mechanisms could be involved in the synergism between the flavonoids found in propolis and other drugs, as peptidoglycan synthesis inhibition and inhibition of the activity of β -lactamase enzymes (Eumkeb and Chukrathok, 2013). In addition, it was observed that pinocembrin, a common flavonoid found in the Brazilian red propolis, inhibited the efflux activity, decreasing the MIC of ethidium bromide (EtBr) and rifampicin against mycobacteria (Gröblacher et al., 2012).

Here, we have the first report of synergistic effect of Brazilian red propolis combined with imipenem and gentamicin against *P. aeruginosa* and *S. aureus*. As mentioned above, many studies have been performed with Gram-positive bacteria, however studies with Gram-negative bacteria remains scarce. A previous report made by Taher (2015) showed that a resistant strain of the Gram-negative *Klebsiella pneumoniae* became susceptible when the antibiotic drugs were combined to propolis. In our study, we observed that only propolis collected in the drier period showed synergistic effect with imipenem and gentamicin. What could explain this variation is the fact that the concentrations of compounds are higher in RP-PED than in RP-PER due to the influence of seasonality on resin plants what directly affects the chemical profile of red propolis.

6. Conclusions

The HPLC analysis allowed us to identify four compounds that have never been reported before for the Brazilian red propolis. We could also observe a seasonal variation according to concentrations of the compounds that were identified. We compared the concentration of six compounds in the rainiest and driest periods and we observed that four of them had the highest concentration in the dry season.

The antibacterial tests showed that the red propolis collected in the state of Pernambuco is effective against strains of *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*. We observed seasonal variations on MICs against *E. coli* and *S. aureus*,

but no seasonal variation was observed against *P. aeruginosa*.

The results obtained with the synergistic analysis showed that the RP-PED had a better performance than the RP-PER when combined with the antibacterial drugs imipenem and gentamicin. The RP-PER had no synergistic effect against all the used in this study. However, when we combined the RP-ED with gentamicin we obtained synergistic effect against all bacterial strains. On the other hand, when we combined the RP-PED with imipenem, we only observed a synergistic effect against the *P. aeruginosa* strains. These results encourage us to explore the seasonal variants of natural products and look for to that one who has the best results against pathogenic bacteria.

Acknowledgements

The authors are grateful to the Laboratório de Microbiologia e Biologia Molecular from Universidade Federal do Cariri for the technical support in microbiological analysis. The authors also acknowledge to the Phytochemical Research Laboratory from Universidade Federal de Santa Maria for the logistic and technical assistance. This work was sponsored by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (141397/2014-4).

Transparency document

Transparency document related to this article can be found online at <http://dx.doi.org/10.1016/j.fct.2017.03.052>.

References

- Agência Pernambucana de Águas e Clima, 2016. Climatologia da Precipitação Mensal. <http://www.apac.pe.gov.br/meteorologia/>. Accessed 18 December 2016.
- Alencar, S.M., Oldoni, T.L.C., Castro, M.L., Cabral, I.S.R., Costa-Neto, C.M., Cury, J.A., et al., 2007. Chemical composition and biological activity of a new type of Brazilian propolis: red propolis. *J. Ethnopharmacol.* 113 (2), 278–283.
- Amin, M.U., Khurram, M., Khattak, B., Khan, J., 2015. Antibiotic additive and synergistic action of rutin, morin and quercetin against methicillin resistant *Staphylococcus aureus*. *BMC Complement. Altern. Med.* 15, 59. <http://doi.org/10.1186/s12906-015-0580-0>.
- Awale, S., Li, F., Onozuka, H., Esumi, H., Tezuka, Y., Kadota, S., 2008. Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. *Bioorg. Med. Chem.* 16, 181–189.
- Bak, J., Kim, H.J., Kim, S.Y., Choi, Y.-S., 2016. Neuroprotective effect of caffeic acid phenethyl ester in 3-nitropropionic acid-induced striatal neurotoxicity. *Korean. J. Physiol. Pharmacol.* 20 (3), 279–286. <http://doi.org/10.4196/kjpp.2016.20.3.279>.
- Bankova, V., Baoudourova-Krasteva, G., Paopov, S., Sforzin, J.M., Funari, S.R.C., 1998. Seasonal variations of the chemical composition of Brazilian propolis. *Apidologi* 29, 361–367.
- Batista, L.L.V., Campesatto, E.A., Assis, M.L.B., Barbosa, A.P.F., Grillo, L.A.M., Dornelas, C.B., 2012. Comparative study of topical green and red propolis in the repair of wounds induced in rats. *Rev. Col. Bras. Cir.* 39 (6), 515–520.
- Biedenbach, D.J., Gao, P.T., Hung Van, P., Su Minh Tuyet, N., Thi Thanh Nga, T., Phuong, D.M., et al., 2016. Antimicrobial-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* from patients with hospital-acquired or ventilator-associated pneumonia in Vietnam. *Clin. Ther.* 38 (9), 2098–2105. <http://doi.org/10.1016/j.clinthera.2016.07.172>.
- Bispo-Junior, W., Miranda, E.O., Alvino, V., Araujo, B., Silva, D.W., Porfirio, Z., 2012. Antimicrobial activity of fractions of red propolis from Alagoas, Brazil. *Semina Ciências Biológicas e da Saúde* 33 (1), 03–10.
- Boligon, A.A., Piana, M., Kubiça, T.F., Mario, D.N., Dalmolin, T.V., Bonez, P.C., et al., 2015. HPLC analysis and antimicrobial, antimycobacterial and antiviral activities of *Tabernaemontana catharinensis* A. DC. *J. Appl. Biomed.* 13, 7–18.
- Brazilian Health Surveillance Agency (ANVISA), 2005. Technical Chamber of Phytotherapy Medicines. CATEF, BRAZIL. <http://www.anvisa.gov.br/medicamentos/catef/propolis.htm>. Accessed 19 November 2016.
- Bueno-Silva, B., Alencar, S.M., Koo, H., Ikegaki, M., Silva, G.V.J., Napimoga, M.H., et al., 2013. Anti-inflammatory and antimicrobial evaluation of Neovestitol and vestitol isolated from Brazilian red propolis. *J. Agric. Food Chem.* 61, 4546–4550.
- Burdock, G.A., 1998. Review of the Biological properties and toxicity of bee propolis (propolis). *Food Chem. Toxicol.* 36, 347–363.
- Cabral, I.S.R., Oldoni, T.L.C., Prado, A., Bezerra, R.M.N., Alencar, S.M., 2009. Phenolic composition, antibacterial and antioxidant activities of Brazilian red propolis. *Quim. Nova* 32 (6), 1523–1527.

- Carvalho, F.B., Boligon, A.A., Athayde, M.L., Rubin, M.A., Ferreira, J., Trevisan, G., 2016. Inhibitory effect of *Scutia buxifolia* extracts, fractions, and ursolic acid on Na⁺, K⁺-ATPase activity in vitro in membranes purified from rat hearts. *J. Ethnopharmacol.* 179, 45–54.
- Cavendish, R.L., Santos, J.S., Belo-Neto, R., Paixão, A.O., Oliveira, J.V., Araújo, E.D., 2015. Antinociceptive and anti-inflammatory effects of Brazilian red propolis extract and formononetin in rodents. *J. Ethnopharmacol.* 173, 127–133. <http://dx.doi.org/10.1016/j.jep.2015.07.022>.
- Clinical and Laboratory Standards Institute, 2008. Performance Standards for Antimicrobial Susceptibility Testing. Eighteenth Informational Supplement. CLSI document M100–18. Clinical and Laboratory Standards Institute, Wayne, PA.
- Cuesta-Rubio, O., Frontana-Urbe, B.A., Ramírez-Apan, T., Cardenas, J., 2002. Polyisoprenylated Benzophenones in Cuban propolis: biological activity of nemorosone. *Z. Naturforsch.* 57c, 372–378.
- Daugusch, A., Moraes, C.S., Fort, P., Park, Y.K., 2007. Brazilian red propolis—chemical composition and botanical origin. *eCAM* 5 (4), 435–441.
- Eumkeb, G., Chukrathok, S., 2013. Synergistic activity and mechanism of action of ceftazidime and apigenin combination against ceftazidime-resistant *Enterobacter cloacae*. *Phytomedicine* 20 (3), 262–269. <http://doi.org/10.1016/j.phymed.2012.10.008>.
- Eumkeb, G., Siriwan, S., Thumanu, K., 2012. Synergistic activity of luteolin and amoxicillin combination against amoxicillin-resistant *Escherichia coli* and mode of action. *J. Photochem. Photobiol. B* 117, 247–253.
- Fernandes-Júnior, A., Balestrin, E.C., Betoni, J.E.C., Orsi, R.O., Cunha, M.L.R.S., Montelli, A.C., 2005. Propolis: anti-*Staphylococcus aureus* activity and synergism with antimicrobial drugs. *Mem. Inst. Oswaldo Cruz* 100 (5), 563–566.
- Fonseca-Silva, F., Canto-Cavaleiro, M.M., Menna-Barreto, R.F.S., Almeida-Amaral, E.E., 2015. Effect of apigenin on *Leishmania amazonensis* is associated with reactive oxygen species production followed by mitochondrial dysfunction. *J. Nat. Prod.* 78 (4), 880–884. <http://doi.org/10.1021/acs.jnatprod.5b00011>.
- Freires, I.A., Alencar, S.M., Rosalen, P.L., 2016. A pharmacological perspective on the use of Brazilian red propolis and its isolated compounds against human diseases. *Eur. J. Med. Chem.* 110, 267–279.
- Froza, C.O.S., Garcia, C.S., Gambato, G., Souza, M.D.O., Salvador, M., Moura, S., et al., 2013. Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis. *Food. Chem. Toxicol.* 52, 137–142.
- GraphPad Software, Inc., 2008. Accessed 5 November 2008. <http://www.graphpad.com/faq/viewfaq.cfm?faq=1362>.
- Gröblacher, B., Kunert, O., Bucar, F., 2012. Compounds of *Alpinia katsumadai* as potential efflux inhibitors in *Mycobacterium smegmatis*. *Bioorg. Med. Chem.* 20 (8), 2701–2706. <http://doi.org/10.1016/j.bmc.2012.02.039>.
- Guo, X., Yang, Z., Wang, J., Lei, X., Lv, X., Dong, W., 2015. Synergistic antitumor effect of puerarin combined with 5 fluorouracil on gastric carcinoma. *Mol. Med. Rep.* 11, 2562–2568. <http://dx.doi.org/10.3892/mmr.2014.3016>.
- Hassan, S.T.S., Berchová, K., Majerová, M., Pokorná, M., Švajdlenka, E., 2016. In vitro synergistic effect of *Hibiscus sabdariffa* aqueous extract in combination with standard antibiotics against *Helicobacter pylori* clinical isolates. *Pharm. Biol.* 1–5. <http://dx.doi.org/10.3109/13880209.2015.1126618>.
- Isla, M.I., Dantur, Y., Salas, A., Danert, C., Zampini, C., Arias, M., et al., 2012. Effect of seasonality on chemical composition and antibacterial and Anticandida activities of Argentine propolis. Design of a topical formulation. *Nat. Prod. Commun.* 7 (10), 1315–1318.
- Izuta, H., Narahara, Y., Shimazawa, M., Mishima, S., Kondo, S., Hara, H., 2009. 1,1-Diphenyl-2-picrylhydrazyl radical scavenging activity of bee products and their constituents determined by ESR. *Biol. Pharm. Bull.* 32 (12), 1947–1951.
- Jorge, R., Furtado, N.A.J.C., Sousa, J.P.B., Silva Filho, A.A., Gregório Junior, L.E., Martins, C.H.G., 2008. Brazilian propolis: seasonal variation of the prenylated p-coumaric acids and antimicrobial activity. *Pharm. Biol.* 46 (12), 889–893.
- Kasala, E.R., Bodduluru, L.N., Barua, C.C., Gogoi, R., 2016. Antioxidant and antitumor efficacy of Luteolin, a dietary flavone on benzo(a)pyrene-induced experimental lung carcinogenesis. *Biomed. Pharmacother.* 82, 568–577. <http://doi.org/10.1016/j.biopha.2016.05.042>.
- Kuete, V., 2010. Potential of cameroonian plants and derived products against microbial infections: a review. *Planta Med.* 76, 1479–1491. <http://dx.doi.org/10.1055/s-0030-1250027>.
- Li, F., Awale, S., Tezuka, Y., Kadota, S., 2008. Cytotoxic constituents from Brazilian red propolis and their structure–activity relationship. *Bioorg. Med. Chem.* 16, 5434–5440.
- López, B.G.C., Schmidt, E.M., Eberlin, M.N., Sawaya, A.C.H.F., 2014. Phytochemical markers of different types of red propolis. *Food Chem.* 146, 174–180.
- Lopez, B.G.C., Lourenço, C.C., Alves, D.A., Machado, D., Lancellotti, M., Sawaya, A.C.H.F., 2015. Antimicrobial and cytotoxic activity of red propolis: an alert for its safe use. *J. Appl. Microbiol.* 119, 677–687.
- Lotti, C., Fernandez, M.C., Piccinelli, A.L., Cuesta-Rubio, O., Hernandez, I.M., Rastrelli, L., 2010. Chemical constituents of red mexican propolis. *J. Agric. Food Chem.* 58, 2209–2213.
- Mandal, S., DebMandal, M., Pal, N.K., Saha, K., 2010. Synergistic anti-*Staphylococcus aureus* activity of amoxicillin in combination with *Emblica officinalis* and *Nymphaea odorata* extracts. *Asian Pac. J. Trop. Med.* 711–714.
- Matias, E.F.F., Santos, F.A.V., Silva, J.M.F.L., Souza, C.E.S., Tintino, S.R., Guedes, G.M.M., et al., 2010. Screening the *in vitro* modulation of antibiotic activity of the extracts and fractions of *Ocimum gratissimum* L. *Afr. J. Microbiol. Res.* 6 (9), 1902–1907. <http://dx.doi.org/10.5897/AJMR11.652>.
- Mendonça, I.C.G., Porto, I.C.C.M., Nascimento, T.G., Souza, N.S., Oliveira, J.M.S., Arruda, R.E.S., et al., 2015. Brazilian red propolis: phytochemical screening, antioxidant activity and effect against cancer cells. *BMC Complement. Altern. Med.* 15, 357. <http://doi.org/10.1186/s12906-015-0888-9>.
- Mun, S.H., Jung, D.K., Kim, Y.S., Kang, O.H., Kim, S.B., Seo, Y.S., et al., 2013. Synergistic antibacterial effect of curcumin against methicillin-resistant *Staphylococcus aureus*. *Phytomedicine* 20 (8), 714–718. <http://doi.org/10.1016/j.phymed.2013.02.006>.
- Oldoni, T.L.C., Cabral, I.S.R., d'Arce, M.A.B.R., Rosalen, P.L., Ikegaki, M., Nascimento, A.M., et al., 2011. Isolation and analysis of bioactive isoflavonoids and chalcone from a new type of Brazilian propolis. *Sep. Purif. Technol.* 77, 208–213.
- Omar, R.M.K., Igoli, J., Gray, A.I., Ebioma, G.U., Clements, C., Fearnley, J., et al., 2016. Chemical characterisation of Nigerian red propolis and its biological activity against *Trypanosoma Brucei*. *Phytochem. Anal.* 27, 107–115. <http://dx.doi.org/10.1002/pca.2605>.
- Orsi, R., de, O., Sforcin, J.M., Funari, S.R.C., Fernandes Junior, A., Bankova, V., 2006. Synergistic effect of propolis and antibiotics on the *Salmonella* Typhi. *Braz. J. Microbiol.* 37 (2), 108–112. <http://doi.org/10.1590/S1517-83822006000200002>.
- Orsi, R.O., Fernandes, A., Bankova, V., Sforcin, J.M., 2012. The effects of Brazilian and Bulgarian propolis in vitro against *Salmonella* Typhi and their synergism with antibiotics acting on the ribosome. *Nat. Prod. Res.* 26 (5), 430–437. <http://doi.org/10.1080/14786419.2010.498776>.
- Özçelik, B., Orhan, D.D., Özgen, S., Ergun, F., 2008. Antimicrobial activity of flavonoids against extended-spectrum β -Lactamase (ES-L)-Producing *Klebsiella pneumoniae*. *Trop. J. Pharm. Res.* 7 (4), 1151–1157.
- Park, Y.K., Ikegaki, M., Alencar, S.M., Moura, F., 2000. Evaluation of Brazilian propolis by both physicochemical methods and biological activity. *Honeybee Sci.* 21, 85–90.
- Pei, K., Ou, J., Huang, J., Ou, S., 2016. p-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities. *J. Sci. Food Agric.* 96 (9), 2952–2962. <http://doi.org/10.1002/jsfa.7578>.
- Piccinelli, A.L., Fernandez, M.C., Cuesta-Rubio, O., Hernández, I.M., Simone, F., Rastrelli, L., 2005. Isoflavonoids isolated from Cuban propolis. *J. Agric. Food Chem.* 53, 9010–9016.
- Piccinelli, A.L., Lotti, C., Campone, L., Cuesta-Rubio, O., Fernandez, M.C., Rastrelli, L., 2011. Cuban and Brazilian red propolis: Botanical origin and comparative analysis by high-performance liquid chromatography-Photodiode Array Detection/Electrospray Ionization Tandem Mass Spectrometry. *J. Agric. Food Chem.* 59, 6484–6491. <http://doi.org/10.1021/jf201280z>.
- Pinheiro, K.S., Ribeiro, D.R., Alves, A.V.F., Pereira-Filho, R.N., Oliveira, C.R., Lima, S.O., et al., 2014. Modulatory activity of Brazilian red propolis on chemically induced dermal carcinogenesis. *Acta Cir. Bras.* 29 (2), 111.
- Pippi, B., Lana, A.J.D., Moraes, R.C., Güez, C.M., Machado, M., Oliveira, L.F.S., 2015. In vitro evaluation of the acquisition of resistance, antifungal activity and synergism of Brazilian red propolis with antifungal drugs on *Candida* spp. *J. Appl. Microbiol.* 118, 839–850. <http://dx.doi.org/10.1111/jam.12746>.
- R Core Team, 2014. R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <http://www.R-project.org/>.
- Righi, A.A., Alves, T.R., Negri, G., Marques, L.M., Breyer, H., Salatino, A., 2010. Brazilian red propolis: unreported substances, antioxidant and antimicrobial activities. *J. Sci. Food. Agri* 91, 2363–2370.
- Saddiq, A.A., Mohamed, A.M., 2016. Potential role of Saudi red propolis in alleviating lung damage induced by methicillin resistant *Staphylococcus aureus* virulence in rats. *Pak. J. Pharm. Sci.* 9 (4), 1197–1207.
- Saha, S.K., Saha, S., Akhter, S.M., Khatun, S., Islam, M.M., Roy, P., 2016. In vitro determination of minimum inhibitory concentration of aqueous garlic extract and imipenem against *Staphylococcus aureus* and *Escherichia coli*. *Mymensingh Med. J.* 25 (3), 477–484.
- Salatino, R., Teixeira, E.W., Negri, G., Message, D., 2005. Origin and chemical variation of Brazilian propolis. *eCAM* 2 (1), 33–38.
- Sampaio, B.L., Edrada-Ebel, R., Costa, F.B., 2016. Effect of the environment on the secondary metabolic profile of *Tithonia diversifolia*: a model for environmental metabolomics of plants. *Nature* 6, 29265. <http://dx.doi.org/10.1038/srep29265>.
- Scazzocchio, F., D'Auria, F.D., Alessandrini, D., Pantanella, F., 2006. Multifactorial aspects of antimicrobial activity of propolis. *Microbiol. Res.* 161 (4), 327–333. <http://doi.org/10.1016/j.micres.2005.12.003>.
- Selim, S., Alfay, S.E., Al-Ruwaili, M., Abdo, A., Al Jaouni, S., 2012. Susceptibility of imipenem-resistant *Pseudomonas aeruginosa* to flavonoid glycosides of date palm (*Phoenix dactylifera* L.) tamar growing in Al Madinah, Saudi Arabia. *Afr. J. Biotechnol.* 11 (2), 416–422. <http://dx.doi.org/10.5897/AJB11.1412>.
- Sforcin, J.M., Fernandes Jr., A., Lopes, C.A.M., Bankova, V., Funari, S.R.C., 2000. Seasonal effect on Brazilian propolis antibacterial activity. *J. Ethnopharmacol.* 73, 243–249.
- Silva, B.B., Rosalen, P.L., Cury, J.A., Ikegaki, M., Souza, V.C., Esteves, A., et al., 2007. Chemical composition and Botanical origin of red propolis, a new type of Brazilian propolis. *eCAM* 1–4. <http://dx.doi.org/10.1093/ecam/nem059>.
- Silva, R.O., Andrade, V.M., Bullé Rêgo, E.S., Azevedo Dória, G.A., Santos Lima, B., Silva, F.A., Araújo, A.A.S., et al., 2015. Acute and sub-acute oral toxicity of Brazilian red propolis in rats. *J. Ethnopharmacol.* 170, 66–71. <http://doi.org/10.1016/j.jep.2015.05.009>.
- Taher, N.M., 2015. Synergistic effect of propolis extract and antibiotics on multi-resistant *Klebsiella pneumoniae* strain isolated from wound. *J. Nat. Sci. Res.* 5 (17), 98–103.
- Teixeira, E.W., Message, D., Negri, G., Salatino, A., Stringheta, P.C., 2008. Seasonal

- variation, chemical composition and antioxidant activity of Brazilian propolis samples. *eCAM* 7 (3), 307–315. <http://dx.doi.org/10.1093/ecam/nem177>.
- Tomas-Barberan, F., García-Viguera, C., V It-Olivier, P., Ferreres, F., Tomas-Lorente, F., 1993. Phytochemical evidence for the botanical origin of tropical propolis from Venezuela. *Phytochemistry* 34 (1), 191–196.
- Trusheva, B., Popova, M., Bankova, V., Simova, S., Marcucci, M.C., Miorin, P.L., et al., 2006. Bioactive constituents of Brazilian red propolis. *eCAM* 3 (2), 249–254.
- Trusheva, B., Popova, M., Naydenski, H., Tsvetkova, Iva, Rodriguez, J.G., Bankova, V., 2004. New polyisoprenylated benzophenones from Venezuelan propolis. *Fito-terapia* 75, 683–689.
- Tsang, M.S.M., Jiao, D., Chan, B.C.L., Hon, K.-L., Leung, P.C., Lau, C.B.S., et al., 2016. Anti-inflammatory activities of pentaherbs formula, berberine, gallic acid and chlorogenic acid in atopic dermatitis-like skin inflammation. *Molecules* 21 (4), 519. <http://doi.org/10.3390/molecules21040519>.
- Ural, M.Ş., Yonar, M.E., Mişe Yonar, S., 2015. Protective effect of ellagic acid on oxidative stress and antioxidant status in *Cyprinus carpio* during malathion exposure. *Cell. Mol. Biol. (Noisy-le-grand)* 61 (5), 58–63.
- Vázquez, N.M., Fiorilli, G., Guido, P.A.C., Moreno, S., 2016. Carnosic acid acts synergistically with gentamicin in killing methicillin-resistant *Staphylococcus aureus* clinical isolates. *Phytomedicine*. <http://dx.doi.org/10.1016/j.phymed.2016.07.010>.
- Wojtyczka, R.D., Dziedzic, A., Idzik, D., Kępa, M., Kubina, R., Kabała-Dzik, A., et al., 2013. Susceptibility of *Staphylococcus aureus* clinical isolates to propolis extract alone or in combination with antimicrobial drugs. *Molecules* 18, 9623–9640. <http://dx.doi.org/10.3390/molecules18089623>.
- Xie, Y., Yang, W., Tang, F., Chen, X., Ren, L., 2015. Antibacterial activities of flavonoids: structure-activity relationship and mechanism. *Curr. Med. Chem.* 22 (1), 132–149. <http://dx.doi.org/10.2174/0929867321666140916113443>.
- Zhang, R., Wang, X., Lü, J., 2014. Isolation of a carbapenem-resistant K1 serotype *Klebsiella pneumoniae* strain and the study of resistance mechanism. *Zhonghua Yi Xue Za Zhi* 94 (46), 3666–3670.
- Zulueta, A., Esteve, M.J., Frigola, A., 2009. ORAC and TEAC assays comparison to measure the antioxidant capacity of food products. *Food Chem.* 114, 310–316.

3.2 ARTIGO 2 - ANÁLISE COMPARATIVA DA ATIVIDADE ANTIBACTERIANA E
DO PERFIL FITOQUÍMICO DA PRÓPOLIS VERMELHA BRASILEIRA E DA
RESINA DE *Dalbergia ecastaphyllum* (L) TAUB

Marcos da Silveira Regueira-Neto^a, Saulo Relison Tintino^b, Ana Raquel Pereira da
Silva^b, Maria do Socorro Costa^b, Aline Augusti Boligon^c, Irwin R.A. Menezes^b, Valdir
de Queiroz Balbino^a, Henrique Douglas de Melo Coutinho^b.

^aLaboratório de Bioinformática e Biologia Evolutiva, Departamento de Genética,
Centro de Biociências, UFPE, Recife, PE, Brazil

^bLaboratório de Microbiologia e Biologia Molecular, Centro de Ciências Biológicas e
Saúde, Universidade Regional do Cariri, Crato, CE, Brazil

^cPhytochemical Research Laboratory, Department of Industrial Pharmacy, Federal
University of Santa Maria, Santa Maria, Brazil

Corresponding author:

Marcos da Silveira Regueira-Neto

mareg1988@gmail.com

Departamento de Genética, CB, Universidade Federal de Pernambuco
Pernambuco, Recife, Brazil

Abstract

Red propolis is a resinous substance produced by honey bees using a plant resin that
is exuded by *Dalbergia ecastaphyllum* (L) Taub. This type of propolis has been
extensively explored in studies that tested the bioactivity against Gram-positive and

Gram-negative bacteria, however the plant resin that is the source of bioactive compounds is underrepresented in those studies. The aim of this study was to investigate the antibacterial activity of red propolis and resin and their association with standard antibiotics to evaluate possible differences of activity. We also submitted red propolis and the resin to a HPLC analysis to confirm the botanical origin. The hydroethanolic extracts of red propolis and *D. ecastaphyllum* resin were analyzed by HPLC-DAD. The extracts were tested against strains of *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Escherichia coli* to obtain MIC. The extracts were also tested against *P. aeruginosa* and *S. aureus* in association with gentamicin and imipenem. The HPLC analysis identified seven compounds with six of them present in both substances. The lowest MIC values obtained in this study were observed against *S. aureus*. In general, MIC values showed to be lower for red propolis against all species tested in comparison to resin. Red propolis and resin showed synergistic effect against all the strains tested when combined with gentamicin. However, when we combined these substances to imipenem we only observed synergistic effect against *P. aeruginosa* strains. Despite the synergistic behavior to be similar for both substances we observed that inhibitory concentrations of drugs were lower when associated with red propolis in comparison to resin. In conclusion, both of the substance tested has antibacterial activity but the results showed that red propolis had a better performance and possibly indicate that honey bees can improve the activity of compounds present in red propolis. When we compared the quantitative values we observed that the inhibitory concentrations of drugs were lower when associated with red propolis.

Keywords: Red propolis; Resin; *Dalbergia ecastaphyllum*; HPLC; Antibacterial activity

50 **Abbreviations:** A, antibiotics; BHI, Brain Heart Infusion; DER, Dalbergia
51 ecastaphyllum resin; DMSO, dimethyl sulfoxide; EC06, *Escherichia coli* 06; ECATCC,
52 *Escherichia coli* ATCC; LOD, limit of detection; LOQ, limit of quantification; MIC,
53 minimal inhibitory concentration; PA03, *Pseudomonas aeruginosa* 03; PA24,
54 *Pseudomonas aeruginosa* 24; RP, red propolis; SA10, *Staphylococcus aureus* 10;
55 SAATCC, *Staphylococcus aureus* ATCC; SD, standard deviation.

56

1. Introduction

The genus *Dalbergia* (Fabaceae) consists of shrubs, lianas and trees which comprises around 250 species in total (Hartvig et al., 2015). This pantropical genus is distributed in the North, Central and South America and West Africa (zipcodezoo, 2017). Despite *Dalbergia ecastaphyllum* (L) Taub to be a non-mangrove plant, this species grows in association with mangrove in Brazil and its distribution comprises all Brazil's coastal region (Diop et al., 2001).

Many insect's species from the families Cerambycidae (Coleoptera), Curculionidae (Coleoptera), Pyralidae (Lepidoptera), Oecophoridae (Lepidoptera), Cossidae (Lepidoptera), are known for cause a variety of damages to trees causing many losses to the wood industry (Nair, 2007). In response to that insect attack trees have some mechanisms to avoid infestation and the entry of fungi. In tropical leguminous trees that produces resin there are pocket secretory structures. Those resin pockets are filled with resin secreted by resin-producing epithelial cells. The exudation of the resin, in some situations, is caused by injuries made by an agent attempting to enter the tissue. The resin pressure enables the trees to seal off injured areas, thereby inhibiting the entry of microorganisms (Langenheim, 2003).

The plant resin exuded by *D. ecastaphyllum* is used by honey bees *Apis mellifera* in the Northeast of Brazil for the production of red propolis. The red colored resin from *D. ecastaphyllum* is collected, chewed and salivary enzymes are added and then the partially digested material is mixed with bee's wax (Burdock, 1998). That resinous mixture called propolis is used by the bees to avoid intruders in the hive by protecting the entrance and sealing holes. Propolis is used also to prevent contamination inside the hive because of its antiseptic effect (Righi et al., 2010).

Since the old times propolis has been used by humans around the world in the treatment of a range of diseases (Toreti et al., 2013). Propolis from different origins have specific physiochemical characteristics and in Brazil it was reported until now 13 different types of propolis (Park et al., 2000; Dausch et al., 2007). The thirteenth type of Brazilian propolis, the red propolis, can be found in the northeast region of Brazil (Dausch et al., 2007; Lopez et al., 2014). Red propolis samples from several Brazilian states (Alagoas, Paraíba, Pernambuco and Sergipe) were tested against Gram-negative and Gram-positive bacteria (Cabral et al., 2009; Righi et al., 2010; Lopez et al., 2015; Regueira Neto et al., 2017). The antibacterial activity of this type of propolis has been attributed to flavonoids, specially isoflavonoids and prenylated benzophenones (Trusheva et al., 2006).

Antibacterial resistance has become a big problem in public health (Biedenbach et al., 2016). In a study Lautenbach et al. (2010) reported that in the last decade the resistance of *Pseudomonas aeruginosa* to imipenem increased from 13% to 20%. In Addition to that, resistance to aminoglycosides has been observed in Gram-negative bacteria and one of the possible solutions to overcome this problem is the combination of drugs or drugs and natural products to reach a synergistic effect (Gad, Mohamed, and Ashour 2011). Previous studies has combined different types of propolis with antimicrobial and antifungal drugs and the authors observed synergistic effect between them (Pippi et al. 2015; Wojtyczka et al. 2013) . However, there are no reports of synergistic study using the plant resin of *Dalbergia ecastaphyllum*.

Red propolis gets all attention regard to application in medical studies, however the Resin that is the source of bioactive components is mostly explored when it comes to confirm the botanical origins of propolis through chemical characterization (Silva et al.,

2007; Piccinelli et al., 2011; Lopez et al 2014). Antibacterial activity studies remain scarce for the resin of *Dalbergia ecastaphyllum* and previous studies just tested the resin against Gram-positive bacteria (Bueno-Silva et al. 2017).

The process in which the resin is submitted when it is chewed by honey bees still unknown, but researchers have pointed out the chewing process and the mixing with bee's saliva as an important step in propolis production (Ghisalberti, 1979; Marcucci, 1995). In addition to this, we also do not know how that process can affect the compounds present in propolis. Therefore, the aim of this study was to investigate the antibacterial activity of the resin and red propolis with and without association with standard antibiotics to evaluate possible differences of activity. We also performed a chemical characterization of the resin and red propolis to confirm the botanical origin.

2. Material and Methods

2.1 Propolis and resin samples

Red propolis (RP) samples were collected in an apiary located at Japaratinga, state of Alagoas and resin (DER) samples were collected from *Dalbergia ecastaphyllum* trees located at Tamandaré, state of Pernambuco. The raw samples of red propolis and resin were stored at -20 °C and then they were dissolved in hydroethanolic solution (ethanol 54%) for 72 h. Afterward, the extract was filtered and concentrated using a rotary vacuum evaporator (model Q-344B-Quimis, Brazil). The concentrated solution was frozen and then lyophilized to obtain a fine powder. For the microbiological assays, the dry extract of RP and DER were solubilized in dimethyl sulfoxide (DMSO) and then DMSO-extract solutions were diluted in sterile water to reach the concentration of 1024 µg/mL.

2.2 Chemical, apparatus and general procedures

All chemicals were of analytical grade. Acetonitrile, phosphoric acid, chlorogenic acid, caffeic acid, *p*-coumaric acid and ellagic acid were purchased from Merck (Darmstadt, Germany). Quercetin, apigenin and luteolin were acquired from Sigma Chemical Co. (St. Louis, MO, USA). High performance liquid chromatography (HPLC-DAD) was performed with a Shimadzu Prominence Auto Sampler (SIL-20A) HPLC system (Shimadzu, Kyoto, Japan), equipped with Shimadzu LC-20AT reciprocating pumps connected to a DGU 20A5 degasser with a CBM 20A integrator, SPD-M20A diode array detector and LC solution 1.22 SP1 software.

2.3 HPLC-DAD analysis

Propolis and Resin at a concentration of 15 mg/mL was injected by means of a model SIL-20A Shimadzu Auto sampler. Separations were carried out using Phenomenex C₁₈ column (4.6 mm x 250 mm x 5 µm particle size). The mobile phase was water with 1% phosphoric acid (v/v) (solvent A) and HPLC grade acetonitrile (solvent B) at a flow rate of 0.6 mL/min and injection volume 40 µL. The composition gradient was: 5% solvent B reaching 15% at 10 min; 30% solvent B at 25 min, 65% solvent B at 40 min and 98% solvent B at 45 min, followed by 50 min at isocratic elution until 60 min. At 80 min the gradient reached the initial conditions again, following the method described by Carvalho et al. (2016) with slight modifications. The sample and mobile phase were filtered through 0.45 µm membrane filter (Millipore) and then degassed by ultrasonic bath prior to use. Stock solutions of standards references were prepared in the acetonitrile: water (1:1, v/v) at a concentration range of 0.030 – 0.500 mg/mL. Quantifications were carried out by integration of the peaks using the external standard method, at 254 nm for ellagic acid; 327 nm for caffeic acid, *p*-coumaric acid and chlorogenic acids; and 366 for quercetin, apigenin and luteolin. The chromatography peaks were confirmed by comparing its retention time with those of reference standards and by DAD spectra (200 to 600 nm). Calibration curve for chlorogenic acid: $Y = 12457x + 1045.9$ ($r = 0.9996$); caffeic acid: $Y = 13509x + 1173.2$ ($r = 0.9998$); apigenin: $Y = 10865x + 1473.7$ ($r = 0.9999$); ellagic acid: $Y = 12758x + 1064.8$ ($r = 0.9993$); quercetin: $Y = 11470x + 1357.8$ ($r = 0.9997$); *p*-coumaric acid: $Y = 13541x + 1269.5$ ($r = 0.9999$) and luteolin: $Y = 10582x + 1346.9$ ($r = 0.9997$). All chromatography operations were carried out at ambient temperature and in triplicate.

2.4 Limit of detection (LOD) and limit of quantification (LOQ)

LOD and LOQ were calculated based on the standard deviation of the responses and the slope using three independent analytical curves, as defined by Boligon et al. (2015). LOD and LOQ were calculated as 3.3 and $10 \sigma/S$, respectively, where σ is the standard deviation of the response and S is the slope of the calibration curve.

2.5 Bacterial strains

The bacterial strains used in this study were the clinical isolates of *Escherichia coli* 06 (EC06), *Pseudomonas aeruginosa* 03 (PA03), *P. aeruginosa* 24 (PA24) and *Staphylococcus aureus* 10 (SA10) and standard strains of *E. coli* ATCC 25922 (ECATCC) and *S. aureus* ATCC 6538 (SAATCC). The microorganisms EC06, SA10, PA03 and PA24 were obtained from clinical isolates (Table 1). The bacterial strains were maintained and activated, prior to the assay overnight at 37 °C on Nutrient Agar (Difco Laboratories).

Table 1 - Bacterial source and resistance profile of clinical isolates.

Bacteria	Source	Resistance profile
<i>Escherichia coli</i> 06	Urine culture	Cf, Cef, Ca, Cro
<i>Pseudomonas aeruginosa</i> 03	Urine culture	Cpm,Ctz,Imi,Cip,Ptz,Lev,Mer,Ami
<i>Pseudomonas aeruginosa</i> 24	Nasal secretion	Cpm,Ctz,Imi,Cip,Ptz,Lev,Mer,Ami
<i>Staphylococcus aureus</i> 10	Rectal swab	Ca, Cef, Cf, Oxa, Pen, Amp, Amox, Mox, Cip, Lev, Asb, Amc, Eri, Cla, Azi, Clin

Amp - Ampicillin; Asb - Ampicillin + Sulbactam; Ami - Amikacin; Amox - Amoxicillin; Amc - Amoxicillin + Ac. clavulanic; Azi - Azithromycin; Ca - Cefadroxil; Cf - Cephalotin; Cef - Cephalexin; Cla - Clarithromycin; Cro - Ceftriaxone; Ctz - ceftazidime; Cip - Ciprofloxacin; Cpm=Cfepime; Clin - Clindamycin; Eri – Eritromicin; Oxa - oxacillin; Imi

– Imipenem; Lev - levofloxacin; Mer - meropenem; Mox - Moxifloxacin; Pen - Penicillin; Ptz - Piperacillin + Tazobactam.

2.6 Drugs

Gentamicin and Imipenem were obtained from Sigma Chemical Co. All drugs were dissolved in sterile water.

2.7 Minimal inhibitory concentration

The minimal inhibitory concentration (MIC) of red propolis and resin were determined in a microdilution assay using 100 μ L of each suspended bacterial strain inoculum in saline solution which corresponds to 0.5 of McFarland scale, followed by the addition of 900 μ L brain heart infusion (BHI) in 1,5 mL microtubes. The BHI-inoculum solutions were transferred to a 96-well microtiter plates and serial dilutions of each extract were performed with concentrations ranging from 512 to 8 μ g/mL (1:1). The plates were submitted to an incubation for 24 h at 37 °C and the bacterial growth was assessed by the use of resazurin. The MIC was defined according to CLSI (2008) in which is the lowest concentration where no growth can be observed. The antibacterial assays were performed in triplicates and results were expressed as an average of replicates.

2.8 Combined effect of red propolis and resin with standard antibiotics

Red propolis and resin hydroethanolic extract were combined with Imipenem and Gentamicin to assess whether these substances can decrease the MIC of standard antibiotics. The increase of the antibiotic activity of the standard drugs was tested using a sub-inhibitory concentration of the extracts of samples included in this study (MIC/8). For the control, 150 μ L of each bacterial strain in saline solution (0.5 in McFarland scale), were added to a 1,5 mL micro tubes together with 1350 μ L of BHI broth. For

the tests, 150 μ L of each bacterial strain in saline solution (0.5 in McFarland scale), were added together with the red propolis and resin extracts (MIC/8) and completed with BHI until reach 1,5 mL. The previous solutions were then transferred to a 96-well microtiter plate and serial dilutions (1:1) were performed with 100 μ L of the antimicrobial drugs. The plates were incubated at 37 °C for 24 h and the bacterial growth was assessed with resazurin. The plates were incubated at 37° C for 24 h, and bacterial growth was assessed by the use of resazurin. MIC was defined with the concentrations of antibiotics between 2500 and 1,22 μ g/mL. The MIC of controls were assessed using the antibiotics alone.

2.9 Statistical analysis

2.9.1 Microbiological results

We performed the assays in triplicates and results were expressed as average of replicates. The results are expressed as the geometric mean. Two-Way ANOVA was applied as Statistical hypothesis analysis followed by Bonferroni post hoc using GraphPad Prism 6.0 software (2008).

2.9.2 HPLC-DAD

Differences between groups of HPLC were assessed by an analysis of variance model and Tukey's test. The level of significance for the analyses was set to $p < 0.05$. These analyses were performed by using the free software R version 3.1.1. (R Core Team, 2014).

3. Results

3.1 Chemical characterization of red propolis and plant resin

3.1.1 Red propolis

The chemical compounds of the red propolis is shown on the HPLC profile in Fig. 1. Two major peaks were observed in the profile (5 and 6) they were identified as quercetin and luteolin, respectively. The other compounds present in the red propolis were chlorogenic acid, caffeic acid, ellagic acid, p-coumaric acid and apigenin.




Fig. 1. Representative high performance liquid chromatography profile of red propolis hydroethanolic extract. Chlorogenic acid (peak 1), caffeic acid (peak 2), ellagic acid (peak 3), quercetin (peak 5), luteolin (peak 6) and apigenin (peak 7).

3.1.2 Resin

The HPLC fingerprint of the hydroethanolic extract of the resin of *Dalbergia ecastaphyllum* showed the presence of one major peak (5) identified as quercetin. The others were identified as chlorogenic acid, caffeic acid, ellagic acid, p-coumaric acid, luteolin and apigenin (Fig. 2 and Table 2).




Fig. 2. Representative high performance liquid chromatography profile of resin hydroethanolic extract. Chlorogenic acid (peak 1), caffeic acid (peak 2), ellagic acid (peak 3), *p*-coumaric acid (peak 4), quercetin (peak 5), luteolin (peak 6) and apigenin (peak 7).

Table 2 – Components of the hydroethanolic extract of red propolis and *D. ecastaphyllum* resin.

Compounds	<i>RP</i>	<i>DER</i>	LOD	LOQ
	mg/g	mg/g	µg/mL	µg/mL
Chlorogenic	0.36 ± 0.01 a	0.86 ± 0.02 a	0.015	0.049
Caffeic acid	0.69 ± 0.03 b	3.97 ± 0.04 b	0.008	0.026
Ellagic acid	1.17 ± 0.02 c	1.15 ± 0.01 c	0.026	0.085
<i>p</i> -Coumaric acid	-	0.23 ± 0.01 d	0.013	0.043
Quercetin	5.73 ± 0.04 d	5.84 ± 0.03 e	0.024	0.079
Luteolin	5.78 ± 0.03 d	2.67 ± 0.01 f	0.016	0.052
Apigenin	0.64 ± 0.01 b	3.94 ± 0.02 b	0.011	0.034

Results are expressed as mean ± standard deviations (SD) of three determinations.

Averages followed by different letters differ by Tukey test at $p < 0.05$

3.2 Microbiological assays

3.2.1 Minimal inhibitory concentration

The MIC values for red propolis (Table 3) ranged from 384 µg/mL to ≥ 1024 µg/mL against *E. coli*. The MIC values observed against strains of *S. aureus* ranged from 53

µg/mL to 512 µg/mL. However, for the *P. aeruginosa* used in this study the MIC values were all the same, 512 µg/mL.

The plant resin showed MIC values (Table 3) ranging from 682 µg/mL to ≥ 1024 µg/mL against two strains of *E. coli* and *P. aeruginosa*. MIC against *S. aureus* ranged from 85 µg/mL to 1024 µg/mL.

Table 3 – MIC values of the red propolis and plant resin against Gram-positive and Gram-negative bacterial strains

Bacterial strains	MIC (µg/mL)	
	Red propolis	Resin
EC06	≥ 1024	≥ 1024
ECATCC	384	682
PA03	512	682
PA24	512	≥ 1024
SA10	53	85.3
SAATCC	512	≥ 1024

3.2.2 Combined effect of red propolis and *Dalbergia ecastaphyllum* resin with standard antibiotics

The red propolis and *Dalbergia ecastaphyllum* resin showed similar results when they were associated to antibiotics (Fig. 3). RP and DER showed synergistic activity when combined to imipenem and gentamicin against both strains of *P. aeruginosa* (PA03 e PA24). The RP and DER also showed synergistic effect against *S. aureus* (SA10 and

SAATCC) when combined to gentamicin, however no effect was observed when the samples were combined to imipenem and tested against SA10 and SAATCC. The values obtained for these tests showed that RP reached lower MICs against all strains used in this study when compared to the values obtained with the DER (Table 4).




Fig. 3 – Association of red propolis and *D. ecastaphyllum* resin with standard antibiotics. The histograms show the results of the antibiotics activity of RD and DER combined with standard drugs against *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

Table 4 – Values of the bacterial growth inhibition reached with the association of the RP and DER with standard drugs

RP x PA03			RP x PA24		RP x SA10		RP x SAATCC	
Antibiotics	RP+A	Control	RP+A	Control	RP+A	Control	RP+A	Control
Imipenem	0.5 µg/mL	5.0 µg/mL	1 µg/mL	3.2 µg/mL	0.5 µg/mL	0.5 µg/mL	2 µg/mL	1.5 µg/mL
Gentamicin	787 µg/mL	992 µg/mL	3.9 µg/mL	9.7 µg/mL	2.5 µg/mL	12 µg/mL	24 µg/mL	30 µg/mL
DER x PA03			DER x PA24		DER x SA10		DER x SAATCC	
Antibiotics	DER+A	Control	DER+A	Control	DER+A	Control	DER+A	Control
Imipenem	1 µg/mL	5 µg/mL	0.5 µg/mL	3.17 µg/mL	0.5 µg/mL	0.5 µg/mL	3.17 µg/mL	1.58 µg/mL
Gentamicin	2500 µg/mL	3149 µg/mL	39 µg/mL	78 µg/mL	62 µg/mL	124 µg/mL	248 µg/mL	312 µg/mL

Results are expressed as mean ± standard deviations (SD) of three determinations.

A= antibiotics; RP= red propolis; DER= *Dalbergia ecastaphyllum* resin; PA03: *Pseudomonas aeruginosa* 03; PA24: *P. aeruginosa* 24; SA10: *Staphylococcus aureus* 10; SAATCC: *S. aureus* ATCC.

4. Discussion

Right after the discovery of red propolis in the Northeastern region of Brazil the first publications started to appear and it was determined by chromatographic methods the botanical origin of the Brazilian red propolis. Silva et al. (2007) compared HPLC profiles of resin samples from 20 species of plant to samples of red propolis and only one plant showed a similar profile to that found for red propolis, and the plant was identified as *Dalbergia ecastaphyllum*. A similar study was also conducted by Dougsch et al. (2007), in addition to HPLC analysis they also observed bees collecting red resin from plants that they later confirmed that was *D. ecastaphyllum*. In these previous studies the chemical profile of red propolis was exactly the same as those for *D. ecastaphyllum* (Dougsch et al., 2007; Silva et al., 2007).

In our study we detected seven compounds: chlorogenic acid, caffeic acid, ellagic acid, quercetin, luteolin and apigenin were found in samples from both red propolis and *D. ecastaphyllum* resin. However, p-Coumaric acid was only detected in samples from DER. This phenolic acid, which is not present in our sample collected in Alagoas, along with it caffeic acid, quercetin and luteolin were previously reported in other samples of red propolis from Alagoas and Pernambuco (Silva et al., 2007; Daugsch et al., 2007; Cabral et al., 2009; Regueira Neto et al., 2017). Chlorogenic acid, ellagic acid and apigenin were also reported in red propolis from Pernambuco (Regueira Neto et al., 2017). Quercetin and luteolin were also found in *D. ecastaphyllum* resin from previous studies using samples from Alagoas (Dougsch et al., 2007; Silva et al., 2007). Neuroprotective, anti-cancer, anti-inflammatory, antioxidante, antimicrobial and anti-leishmania are among the bioactivites reported for the compounds identified in our

study (Ural et al., 2015; Bak et al., 2016; Fonseca-Silva et al., 2015; Kasala et al., 2016; Tsang et al., 2016; Pei et al., 2016).

Once the amount of substances per gram of red propolis analyzed in this study was compared with the values we found in a previous study (Regueira Neto et al 2017), we could observe that the amount of chlorogenic acid, caffeic acid, ellagic acid, p-coumaric acid, quercetin, luteolin and apigenin were higher in samples collected in the state of Pernambuco. This result does not surprise us because the red propolis sample used in this study was collected in the rainy season and as we observe in the previous study (Regueira Neto et al., 2017), samples of red propolis collected in the rainy season tend to bear a lower amount of the substances.

The hydroethanolic extract of red propolis from the Brazilian states of Alagoas, Pernambuco, Paraíba and Sergipe has been tested against Gram-positive and Gram-negative bacteria (Alencar et al., 2007; Bueno-Silva et al., 2013; Lopez et al., 2015). However, reports about the antibacterial activity of the plant resin produced by *Dalbergia ecastaphyllum* remains scarce. In our study the lowest MIC was observed for RP (53 µg/mL) against SA10 strain followed by the MIC for DER (85 µg/mL) for the same *S. aureus* strain. When we compared the MIC values between RP and DER for all the bacterial strains we observed that the values were lower for RP (Table 2). In the one-year period study analyzing the antibacterial activity of red propolis and *D. ecastaphyllum* resin against *Streptococcus mutans*, *S. sobrinus*, *Staphylococcus aureus* and *Actinomyces naeslundii* performed by Bueno-Silva et al 2016, the authors also showed that the MIC values for hydroethanolic extract of red propolis were lower than the MIC observed for *D. ecastaphyllum* (collected in March, July and September) resin against *Staphylococcus aureus* and *Actinomyces naeslundii*. However, for the

most of samples collected in other months any difference was not observed between red propolis and resin (Bueno-Silva et al., 2017).

Drug resistance is a major concern in hospitals over the world (Biedenbach et al., 2016), accordingly many studies have been carried out testing antibacterial drugs association with natural products. The synergistic behavior between antimicrobial drugs and propolis from different types and geographical regions have been performed against *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Salmonella* and *Candida* strains and the researches successfully obtained synergistic effect with those association (Orsi et al., 2012; Wojtyczka et al., 2013; Pippi et al., 2015; Regueira Neto et al., 2017). In our present study, when we combined the hydroethanolic extract of red propolis with gentamicin we could observe synergistic effect against all strains used in this study. However, when we combined the same red propolis extract with imipenem we only had synergistic effect against *P. aeruginosa* strains. In a previous work, we found similar results when we combined red propolis collected in the state of Pernambuco during the dry season (Regueira Neto et al., 2017). Here we have the first report of the synergistic behavior between *Dalbergia ecastaphyllum* resin and the antibacterial drugs gentamicin and imipenem. The association between the ethanolic extract of DER and the antibiotic drugs we observed synergistic effect against all strains of *S. aureus* and *P. aeruginosa*. However, when we combined the DER extract with imipenem we only had synergistic effect against *P. aeruginosa* strains. The DER-drugs results are similar to those found for RP-drugs, but when we compared the quantitative values we observed that inhibitory concentrations of drugs were lower when associated with RP (Table 4).

One thing that caught our attention in these results is the fact that RP had better results than DER. It might be due to modifications that the resin is submitted during propolis production by honey bees. As we mentioned above, after collecting, the resin is chewed and salivary enzymes are added to the mixture. The hypopharyngeal gland of honey bees produces digestive enzymes that possibly play a role in propolis production. Polyphenols act as a substrate for various enzymes and are subjected to be metabolized by glucosidase (Vauzour et al., 2012). Some fungi β -glucosidases enzymes are known for hydrolyzing plant fungitoxic glycosides to less toxic or less soluble aglyca (Schmidt et al. 2011).

5 Conclusions

It was possible through HPLC analysis to identify six compounds in common between red propolis and *Dalbergia ecastaphyllum* resin with p-coumaric acid only present in the plant resin. The MIC assay showed that both red propolis and *D. ecastaphyllum* resin are more effective against the Gram-positive bacteria *Staphylococcus aureus*. In addition to this the study also showed that red propolis had lower MICs for all bacteria species included in this study when compared to *D. ecastaphyllum* resin. Red propolis and resin showed similar synergistic behavior when combined with gentamicin and imipenem. However, the quantitative results showed that the MICs values for red propolis were also lower in comparison to *D. ecastaphyllum* resin. These results possibly indicate that honey bees can improve the activity of compounds present in red propolis and open doors for further studies to try to elucidate the mechanisms in which the botanical material is processed by honey bees during propolis production and what is the impact of this step in propolis bioactivity.

387 6. Acknowledgements

388 The authors are grateful to Laboratório de Microbiologia e Biologia Molecular from
389 Universidade Federal do Cariri for the technical support in microbiological analysis.
390 The authors also acknowledge to the Phytochemical Research Laboratory from
391 Universidade Federal de Santa Maria for the logistic and technical assistance. This
392 work was supported by Conselho Nacional de Desenvolvimento Científico e
393 Tecnológico (grant numbers 141397/2014-4).

394 Conflict of Interest

395 None.

396

7. References

- Alencar, S.M.; Oldoni, T.L.C.; Castro, M.L.; Cabral, I.S.R.; Costa-Neto, C.M.; Cury, J.A.; Rosalen, P.L.; IKEGAKI, M. Chemical composition and biological activity of a new type of Brazilian propolis: Red própolis. *Journal of Ethnopharmacology*, v.113, n.2, p.278-83, 2007. <https://doi.org/10.1016/j.jep.2007.06.005>
- Bak, J., Kim, H.J., Kim, S.Y., Choi, Y.-S., 2016. Neuroprotective effect of caffeic acid phenethyl ester in 3-nitropropionic acid-induced striatal neurotoxicity. *Korean. J. Physiol. Pharmacol.* 20 (3), 279e286. <http://doi.org/10.4196/kjpp.2016.20.3.279>.
- Biedenbach, D.J., Giao, P.T., Hung Van, P., Su Minh Tuyet, N., Thi Thanh Nga, T., Phuong, D.M., et al., 2016. Antimicrobial-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* from patients with hospital-acquired or ventilator-associated pneumonia in Vietnam. *Clin. Ther.* 38 (9), 2098e2105. <http://doi.org/10.1016/j.clinthera.2016.07.172>
- Boligon, A.A., Piana, M., Kubiça, T.F., Mario, D.N., Dalmolin, T.V., Bonez, P.C., et al., 2015. HPLC analysis and antimicrobial, antimycobacterial and antiviral activities of *Tabernaemontana catharinensis* A. DC. *J. Appl. Biomed.* 13, 7e18. <https://doi.org/10.1016/j.jab.2014.01.004>
- Bueno-Silva, B., Alencar, S.M., Koo, H., Ikegaki, M., Silva, G.V.J., Napimoga, M.H., et al., 2013. Anti-inflammatory and antimicrobial evaluation of Neovestitol and vestitol isolated from Brazilian red propolis. *J. Agric. Food Chem.* 61, 4546e4550. DOI: 10.1021/jf305468f
- Bueno-Silva, Bruno, Alexandre Marsola, Masaharu Ikegaki, Severino M. Alencar, and Pedro L. Rosalen. 2017. "The Effect of Seasons on Brazilian Red Propolis and

- 421 Its Botanical Source: Chemical Composition and Antibacterial Activity.” *Natural*
 422 *Product Research* 31 (11): 1318–24. doi:10.1080/14786419.2016.1239088.
- 423 Burdock, G. A. Review of the Biological Properties and Toxicity of Bee Propolis
 424 (Propolis). *Food and Chemical Toxicology*, v.36. p. 347-363, 1998.
 425 [https://doi.org/10.1016/S0278-6915\(97\)00145-2](https://doi.org/10.1016/S0278-6915(97)00145-2)
- 426 Cabral, I.S.R.; Oldoni, T.L.C.; Prado, A.; Bezerra, R.M.N.; Alencar, S.M. Phenolic
 427 composition, antibacterial and antioxidant activities of Brazilian red propolis.
 428 *Quimica Nova*, v.32, n.6, p.1523-1527, 2009. [http://dx.doi.org/10.1590/S0100-](http://dx.doi.org/10.1590/S0100-40422009000600031)
 429 40422009000600031
- 430 Carvalho, F.B., Boligon, A.A., Athayde, M.L., Rubin, M.A., Ferreira, J., Trevisan, G.,
 431 2016. Inhibitory effect of *Scutia buxifolia* extracts, fractions, and ursolic acid on
 432 Nap, Kp-ATPase activity in vitro in membranes purified from rat hearts. *J.*
 433 *Ethnopharmacol.* 179, 45e54. <https://doi.org/10.1016/j.jep.2015.12.035>
- 434 Daugusch, A.; Moraes, C.S.; Fort, P.; Park, Y.K. Brazilian Red Propolis—Chemical
 435 Composition and Botanical Origin. *eCAM* ;v.5, n.4, p.435–441, 2007. doi:
 436 10.1093/ecam/nem057
- 437 Diop ES, Gordon C, Semesi AK, Soumaré A, Diallo, Guissé A, Diouf M, Ayivor JS.
 438 Mangroves of Africa. In: *Mangrove ecosystems: function and management*. Ed.
 439 Luiz Drude de Lacerda. Berlin; Heideberg; New York; Barcelona; Hong Kong;
 440 London; Milan; Paris; Tokyo: Springer, 2001. 298p
- 441 Fonseca-Silva, F., Canto-Cavalheiro, M.M., Menna-Barreto, R.F.S., AlmeidaAmaral,
 442 E.E., 2015. Effect of apigenin on *Leishmania amazonensis* is associated with
 443 reactive oxygen species production followed by mitochondrial dysfunction. *J.*
 444 *Nat. Prod.* 78 (4), 880e884. <http://doi.org/10.1021/acs.jnatprod.5b00011>
- 445 Gad, Gamal F., Heba A. Mohamed, and Hossam M. Ashour. 2011. “Aminoglycoside

- Resistance Rates, Phenotypes, and Mechanisms of Gram-Negative Bacteria from Infected Patients in Upper Egypt.” Edited by Frank DeLeo. *PLoS ONE* 6 (2). Public Library of Science: e17224. doi:10.1371/journal.pone.0017224.
- Ghisalberti E L (1979) Propolis: a review. *Bee World* 60,59±84.
- GraphPad Software, Inc., 2008, Accessed 5 November 2008. <http://www.graphpad.com/faq/viewfaq.cfm?faq¼136>
- Hartvig I, Czako M, Kjær ED, Nielsen LR, Theilade I (2015) The Use of DNA Barcoding in Identification and Conservation of Rosewood (*Dalbergia* spp.). *PLoS ONE* 10(9): e0138231. doi:10.1371/journal.pone.0138231
- Kasala, E.R., Bodduluru, L.N., Barua, C.C., Gogoi, R., 2016. Antioxidant and antitumor efficacy of Luteolin, a dietary flavone on benzo(a)pyrene-induced experimental lung carcinogenesis. *Biomed. Pharmacother.* 82, 568e577. <http://doi.org/10.1016/j.biopha.2016.05.042>.
- Langenheim JH. Plant resins: chemistry, evolution, ecology and ethnobotany. Portland: Timber Press, Inc, 2003, 612p.
- Lopez, B.G.C.; Lourenço, C.C.; Alves, D.A.; Machado, D.; Lancellotti, M.; Sawaya, A.C.H.F. Antimicrobial and cytotoxic activity of red propolis: an alert for its safe use. *Journal of Applied Microbiology*, v.119, p.677—687, 2015. doi: 10.1111/jam.12874.
- López, B.G.C.; Schmidt, E.M.; Eberlin, M.N.; Sawaya, A.C.H.F. Phytochemical markers of different types of red propolis. *Food Chemistry*, v.146, p. 174–180, 2014. doi: 10.1016/j.foodchem.2013.09.063
- Marcucci, MC. Propolis: Chemical composition, biological properties and therapeutic activity. *Apidologie*, v. 26, p. 83-99, 1995. DOI: 10.1051/apido:19950202

- 470 Nair KSS. Tropical forest insect pests: ecology, impact and management. New York:
471 Cambridge University Press, 2007, 422p.
- 472 Orsi, R.O., Fernandes, A., Bankova, V., Sforcin, J.M., 2012. The effects of Brazilian
473 and Bulgarian propolis in vitro against *Salmonella Typhi* and their synergism
474 with antibiotics acting on the ribosome. *Nat. Prod. Res.* 26 (5), 430e437.
475 <http://doi.org/10.1080/14786419.2010.498776>
- 476 Park, Y.K., Ikegaki, M., Alencar, S.M., Moura, F.F., 2000. Evaluation of Brazilian
477 propolis by both physicochemical methods and biological activity. *Honeybee*
478 *Sci.* 21, 85e90.
- 479 Pei, K., Ou, J., Huang, J., Ou, S., 2016. p-Coumaric acid and its conjugates: dietary
480 sources, pharmacokinetic properties and biological activities. *J. Sci. Food Agric.*
481 96 (9), 2952e2962. <http://doi.org/10.1002/jsfa.7578>
- 482 Piccinelli, A.L., Lotti, C., Campone, L., Cuesta-Rubio, O., Fernandez, M.C., Rastrelli,
483 L., 2011. Cuban and Brazilian red propolis: Botanical origin and comparative
484 analysis by high-performance liquid chromatography_Photodiode Array
485 Detection/Electrospray Ionization Tandem Mass Spectrometry. *J. Agric. Food*
486 *Chem.* 59, 6484e6491 x.doi.org/10.1021/jf201280z.
- 487 Pippi, B., Lana, A.J.D., Moraes, R.C., Güez, C.M., Machado, M., Oliveira, L.F.S., 2015.
488 In vitro evaluation of the acquisition of resistance, antifungal activity and
489 synergism of Brazilian red propolis with antifungal drugs on *Candida* spp. *J.*
490 *Appl. Microbiol.* 118, 839e850. <http://dx.doi.org/10.1111/jam.12746>
- 491 R Core Team, 2014. R: a Language and Environment for Statistical Computing. R
492 Foundation for Statistical Computing, Vienna, Austria. [http://www.R-](http://www.R-project.org/)
493 [project.org/](http://www.R-project.org/).
- 494 Regueira Neto, M.S., S.R. Tintino, A.R.P. da Silva, M.D.S. Costa, A.A. Boligon,

- 495 E.F.F. Matias, V. de Queiroz Balbino, I.R.A. Menezes, and H.D. Melo Coutinho.
 496 2017. "Seasonal Variation of Brazilian Red Propolis: Antibacterial Activity,
 497 Synergistic Effect and Phytochemical Screening." *Food and Chemical*
 498 *Toxicology* 107. doi:10.1016/j.fct.2017.03.052.
- 499 Righi, A.A.; Alves, T.R.; Negri, G.; Marques, L.M.; Breyer, H.; Salatino, A. Brazilian red
 500 propolis: unreported substances, antioxidant and antimicrobial activities.
 501 Journal of the Science of the Food and Agriculture, v.91, p.2363–2370, 2011.
 502 DOI: 10.1002/jsfa.4468
- 503 Schmidt, Sabine, Sandra Rainieri, Simone Witte, Ulrich Matern, and Stefan Martens.
 504 2011. "Identification of a *Saccharomyces Cerevisiae* Glucosidase That
 505 Hydrolyzes Flavonoid Glucosides." *Applied and Environmental Microbiology* 77
 506 (5). American Society for Microbiology (ASM): 1751–57.
 507 doi:10.1128/AEM.01125-10.
- 508 Schmidt, Sabine, Sandra Rainieri, Simone Witte, Ulrich Matern, and Stefan Martens.
 509 2011. "Identification of a *Saccharomyces Cerevisiae* Glucosidase That
 510 Hydrolyzes Flavonoid Glucosides." *Applied and Environmental Microbiology* 77
 511 (5). American Society for Microbiology (ASM): 1751–57.
 512 doi:10.1128/AEM.01125-10.
- 513 Silva, B.B., Rosalen, P.L., Cury, J.A., Ikegaki, M., Souza, V.C., Esteves, A., et al.,
 514 2007. Chemical composition and Botanical origin of red propolis, a new type of
 515 Brazilian propolis. *eCAM* 1e4. <http://dx.doi.org/10.1093/ecam/nem059>.
- 516 Toreti, V.C.; Sato H.H.; Pastore G.M.; Park, Y.K. Recent Progress of Propolis for Its
 517 Biological and Chemical Compositions and Its Botanical Origin. Evidence-
 518 Based Complementary and Alternative Medicine. v. 2013, Article ID 697390, p.
 519 13, 2013. doi: 10.1155/2013/697390

- Trusheva, B.; Popova, M.; Bankova, V.; Simova, S.; Marcucci, M.C.; Miorin, P.L. et al. Bioactive Constituents of Brazilian Red Propolis. *eCAM*, v. 3, n.2, p. 249–254, 2006. doi: 10.1093/ecam/nel006
- Tsang, M.S.M., Jiao, D., Chan, B.C.L., Hon, K.-L., Leung, P.C., Lau, C.B.S., et al., 2016. Anti-inflammatory activities of pentaherbs formula, berberine, gallic acid and chlorogenic acid in atopic dermatitis-like skin inflammation. *Molecules* 21 (4), 519. <http://doi.org/10.3390/molecules21040519>.
- Ural, M.S., Yonar, M.E., Misir, S., Yonar, S., 2015. Protective effect of ellagic acid on oxidative stress and antioxidant status in *Cyprinus carpio* during malathion exposure. *Cell. Mol. Biol. (Noisy-le-grand)* 61 (5), 58e63.
- Vauzour D, Vafeidou K, Spencer JPE. Polyphenols. In: *Phytnutrients*. Ed. Andrew Salter, Ed. Helen Wiseman, Ed. Gregory Tucker. Chichester: Blackwell Publishing Ltd.2012. 312p
- Wojtyczka, R.D., Dziedzic, A., Idzik, D., Kępa, M., Kubina, R., Kabała-Dzik, A., et al., 2013. Susceptibility of *Staphylococcus aureus* clinical isolates to propolis extract alone or in combination with antimicrobial drugs. *Molecules* 18, 9623e9640. <http://dx.doi.org/10.3390/molecules18089623>.
- ZipcodeZoo (2017). http://zipcodezoo.com/index.php/Dalbergia_ecastaphyllum. Accessed 31 May

3.3 ARTIGO 3 - ANTITRYPANOSOMAL, ANTILEISHMANIAL AND CYTOTOXIC ACTIVITIES OF BRAZILIAN RED PROPOLIS AND PLANT RESIN OF *DALBERGIA ECASTOPHYLLUM* (L) TAUB.

ARTICLE IN PRESS


Food and Chemical Toxicology xxx (xxxx) xxx–xxx



Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox



Antitrypanosomal, antileishmanial and cytotoxic activities of Brazilian red propolis and plant resin of *Dalbergia ecastaphyllum* (L) Taub

Marcos da Silveira Regueira-Neto^{a,*}, Saulo Relison Tintino^b, Miriam Rolón^c, Cathia Coronel^c, Maria C. Vega^c, Valdir de Queiroz Balbino^a, Henrique Douglas de Melo Coutinho^b

^a Laboratório de Bioinformática e Biologia Evolutiva, Departamento de Genética, Centro de Biociências, UFPE, Brazil

^b Laboratório de Microbiologia e Biologia Molecular, Centro de Ciências Biológicas e Saúde, Universidade Regional do Cariri, Brazil

^c Centro para el Desarrollo de la Investigación Científica (CEDIC), Fundación Moisés Bertoní/Laboratorios Díaz Gill, Asunción, Paraguay

ARTICLE INFO

Keywords:
Dalbergia ecastaphyllum
Cytotoxic
Leishmania
Red propolis
Trypanosoma

ABSTRACT

The treatment for leishmaniasis and Chagas disease can be hard and painful, such that many patients give up on the treatment. In order to find an alternative path for the treatment of these diseases, researchers are using natural products to fight these parasites. The aim of this study was to evaluate the antiprotozoan and cytotoxic activities of red propolis samples collected from different Brazilian states and seasons whilst searching for possible activity differences. We also compared the red propolis results with the ones obtained for the plant resin extract collected from *Dalbergia ecastaphyllum* trees. The hydroethanolic red propolis extracts from Pernambuco and Alagoas, and the *D. ecastaphyllum* resin were evaluated regarding their antileishmanial, antitrypanosomal and cytotoxic activity. All extracts showed antiprotozoan and cytotoxic activity. RP-PER showed to be more cytotoxic against protozoan parasites and fibroblast cells. All propolis extracts showed a higher cytotoxic activity when compared to resin extracts. The propolis sample collected in Pernambuco during the rainy season killed the parasites with lower concentrations than the sample collected in the dry season. The IC₅₀ observed against the parasites could be used without high fibroblast cell damage.

1. Introduction

Leishmaniasis and American Trypanosomiasis are diseases caused by protozoan parasites and are considered a life-threatening illness and a public health problem in Latin America (WHO, 2017, 2018). Leishmaniasis is a group of complex diseases caused by more than 20 *Leishmania* species transmitted by sand flies. The most common form of the disease is the cutaneous leishmaniasis (CL), followed by two other forms of leishmaniasis: mucocutaneous (ML) and visceral (VL) (WHO, 2018). CL and ML can be caused by *Leishmania braziliensis* and VL can be caused by *L. infantum* (Bomfim et al., 2017; Ponte-Sucre et al., 2017). American Trypanosomiasis also known as Chagas disease is a vector-borne disease caused by the protozoan parasite *Trypanosoma cruzi*. Chagas disease is transmitted to humans by the faeces or urine from triatomine bugs known as 'kissing bugs'. Chagas disease is characterised by a skin lesion or a swelling of the eye lids, cardiac disorders and oesophageal or colonic enlargement (WHO, 2017).

Treatments available for these diseases are made using first line drug choices. For the treatment of CL and ML, meglumine antimoniate (Glucantime[®], Sanofi aventis) is the first line choice in Ecuador,

followed by amphotericin B and pentamidine. For VL treatment the oral drug miltefosine is used (Paladin, Canadá) (Ayres et al., 2007; Hashiguchi et al., 2017). Benznidazole and nifurtimox are used in the treatment for Chagas Disease. However, those drugs are only effective against the acute phase of the infection (Chatelain, 2017). Despite drug availability, the treatment may be abandoned by patients due to the painfulness of the drug injection, strong adverse reactions, high cost, complicated drug administration, and drug toxicity (Hashiguchi et al., 2017; WHO, 2017). These problems are aggravated by the development of parasitic drug resistance. Researchers facing these problems are trying to find an alternative path for treating these infections. A variety of studies are trying to prove the efficacy of the use of natural plant or animal products for the treatment of leishmaniasis and Chagas disease. Those studies have shown that natural products are a good source of bioactive compounds which might optimise the biological activity of drugs and minimise adverse reactions. A large amount of chemical compounds such as alkaloids, steroids, terpenes, coumarins and flavonoids from plant and animal origins have been tested against different *Leishmania* and *Trypanosoma* species (Cheuka et al., 2016; Oryan, 2015; Pereira et al., 2008).

* Corresponding author. Departamento de Genética, CB, Universidade Federal de Pernambuco, Pernambuco, Recife, Brazil.

E-mail address: mareg1988@gmail.com (M.d.S. Regueira-Neto).

<https://doi.org/10.1016/j.fct.2018.04.029>

Received 24 January 2018; Received in revised form 10 April 2018; Accepted 13 April 2018
0278-6915/ © 2018 Elsevier Ltd. All rights reserved.

Propolis is a resinous substance produced by *Apis mellifera* honey bees with the purpose of protecting the hive, sealing holes, preventing contamination of the hive's internal environment by fungi and bacteria and covering intruders who die inside the hive in order to avoid their decomposition (Righi et al., 2011; Salatino et al., 2005). Honey bees use plant materials such as plant resins, pollens and bud excretions to produce propolis where the physiochemical characteristics of the different propolis types are a reflection of the plant species from each region (da Silva et al., 2015; Dausch et al., 2008). Propolis in Brazil is divided into 13 groups based on their physiochemical characteristics (Yongkun et al., 2000; Dausch et al., 2008). The thirteenth type of Brazilian propolis, red propolis, discovered by 2007 in the Northeast of Brazil, has demonstrated since then a variety of biological activities, e.g. antioxidant (Alencar et al., 2007; Righi et al., 2011), antimicrobial (Bispo Junior et al., 2012; Regueira et al., 2017), anti-cancerous (Awale et al., 2008; Frozza et al., 2017), anti-inflammatory (Bueno-Silva et al., 2013; Cavendish et al., 2015), cytotoxic (Alencar et al., 2007), wound repairing (Batista et al., 2012), antinociceptive (Cavendish et al., 2015) and antiprotazoal (Nascimento et al., 2016; Omar et al., 2016).

In the last 20 years numerous studies on the *in vitro* bioactivity of propolis have been performed against *Leishmania* and *Trypanosoma* species. Propolis from diverse geographical origins, e.g. South America, Europe and Africa, and types, e.g. brown, green and red, have already demonstrated activity against the *Leishmania* species: *L. amazonensis*, *L. braziliensis*, *L. infantum* and *L. major*, and the *Trypanosoma* species: *T. cruzi*, *T. brucei* and *T. evansi* (Higashi and de Castro, 1994; Ayres et al., 2007; Machado, Leon, and De Castro, 2007; Omar et al., 2016). Ayres et al. (2007) compared the effect of green and red propolis against *Leishmania* promastigote and amastigote forms where they observed that the red propolis was the most effective against *Leishmania* and least cytotoxic against macrophages with the red propolis also enhancing its production. From Nigerian red propolis, 10 compounds were isolated and a moderate to high activity was observed against *Trypanosoma brucei* (Omar et al., 2016).

The geographical location where the propolis is produced has an important influence on the propolis' physiochemical characteristics. Different places on different continents and countries have their very own plant species, climate and soil diversity, where these factors strongly affect propolis characteristics (Sampaio et al., 2016; Teixeira et al., 2010). The chemical compounds, antibacterial and antifungal activities of a variety of propolis types were previously explored in seasonality effect studies with some of them showing seasonal influence over propolis biological activities (Bankova et al., 1998; Isla et al., 2012; Mendonça et al., 2015; Regueira et al., 2017). However, no seasonal red propolis effect against protozoan parasites has been reported until now.

For a drug or a natural product to be used as a treatment against microbial infections it is important that they are not cytotoxic to healthy human cells. A variety of propolis types, e.g. brown, green, yellow and red, from various regions in the world were proven to be cytotoxic against a range of cancer cells (Machado et al., 2016). However, when it comes to the *in vitro* cytotoxic activity evaluation against healthy cells, some studies have shown that propolis from various geographical places and types may in some cases present cytotoxic or protective activities when applied to fibroblast cultures (Gjertsen et al., 2011; Tyska-Czochara et al., 2014; Zare Jahromi et al., 2014). Those studies are important for the development of new drugs or cosmetics, e.g. sunscreen and anti-aging products (Alshaher et al., 2004; Ebadi and Fazeli, 2017).

The present study aimed to evaluate the leishmanicide, trypanocide and cytotoxic activities of red propolis collected from different Brazilian states and seasons to evaluate any possible activity differences. We also compared the results obtained with the red propolis with the ones obtained with the plant resin extract collected from *Dalbergia ecastaphyllum* trees, recognized as the botanical source of the Brazilian red propolis.

2. Material and methods

2.1. Propolis and resin samples

Red propolis samples were collected in the Brazilian states of Pernambuco in the municipality of Tamandaré (RP-PED and RP-PER) and Alagoas in the city of Japaratinga (RP-AL). The Pernambuco's samples were collected during two seasons: rainy (between April and August) (RP-PER) and dry (between December and March) (RP-PED). Those periods are historically known to have the highest and the lowest precipitation in the state of Pernambuco (APAC, 2016). Plant resin collection from *Dalbergia ecastaphyllum* trees was performed in mangroves near the apiary in the state of Pernambuco. The raw red propolis and resin samples were stored at -20°C and these were then dissolved in hydroethanolic solution (ethanol 54%) for 72 h. Afterward, the extract was filtered and concentrated using a rotary vacuum evaporator (model Q-344B-Quimis, Brazil). The concentrated solution was frozen and then lyophilised to obtain a fine powder.

2.2. Antiparasitic activity

2.2.1. Cell lines

The Chagas clone *Trypanosoma cruzi* CL-B5, was used as described by Le-Senne et al. (2002). Parasites were stably transfected with the *Escherichia coli* β -galactosidase gene (*lacZ*). Epimastigote forms were grown at 28°C in liver infusion tryptose broth (Difco, Detroit, MI) with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA), penicillin (Ern, S.A., Barcelona, Spain) and streptomycin (Reig Jofre' S.A., Barcelona, Spain), then harvested during the exponential growth phase (Roldos et al., 2008). The duration of the test was of 24 h. *Leishmania Braziliensis* Vianna and *L. infantum* were obtained from the Instituto de Investigaciones en Ciencias de la Salud, Asunción, Paraguay–IICS. Strain maintenance, cultivation form and promastigote form isolations were performed according to Roldos et al. (2008). The *L. braziliensis* Vianna (MHOM/BR/75/M2903) and *L. infantum* (MCAN/ES/92/BCN83) strains were used in the promastigote inhibition assays, where they were grown at 22°C in Schneider's *Drosophila melanogaster* medium supplemented with 20% FBS. For the cytotoxic assays, the fibroblast cell line NCTC929 was used and grown in Minimal Essential Medium (Sigma, St. Louis, MO). The culture medium was supplemented with heat-inactivated FBS (10%), penicillin G (100 U/mL) and streptomycin (100 mg/mL). Cultures were kept at 37°C in a humid atmosphere with 5% CO_2 . The viability of the strains was evaluated according to Roldos et al. (2008), through the use of Resazurin as a colorimetric method.

2.2.2. Chemicals and drugs

Resazurin sodium salt (Sigma-Aldrich, St. Louis, MO) was stored at 4°C protected from light. Resazurin solution was prepared by adding 1% phosphate buffer, pH 7, filtered and sterilised prior to use. Chlorophenol red- β -D-galactopyranoside (CPRG; Roche, Indianapolis, IN) was dissolved in 0.9% Triton X-100 (pH 7.4). Penicillin G (Ern, S.A., Barcelona, Spain), streptomycin (Reig Jofre' S.A., Barcelona, Spain) and dimethylsulphate were also used. The liver infusion tryptose broth (LIT) (Difco, Detroit, MI) culture medium was used.

2.2.3. *In vitro* epimastigote susceptibility assay by CPRG assay

The assay was performed according to Vega et al. (2005) using 96-well microplates with cultures which had not reached the stationary phase. Epimastigote forms of the *Trypanosoma cruzi* parasite were seeded ($1 \times 10^5/\text{mL}$) in 200 μL of LIT medium. The plates were then incubated with the red propolis and resin samples (15.62–1000 $\mu\text{g}/\text{mL}$) at 28°C for 72 h. 50 μL of CPRG solution was added to reach a final concentration of 200 mM. The plates were incubated at 37°C for an additional 6 h and the β -galactosidase activity was then measured at an absorbance of 595 nm. Each experiment was performed three-times and independently, each concentration was tested in triplicate in each

experiment. The efficacy of each compound was estimated by calculating the anti-epimastigote and the result was expressed in percentage inhibition.

2.2.4. *In vitro* leishmanicidal assay

L. braziliensis Vianna and *L. infantum* promastigotes were grown to a concentration of 106 cells/mL and then transferred to the test. The red propolis and resin samples were dissolved in Dimethyl sulfoxide (DMSO) used at an atoxic concentration to achieve the concentrations to be tested where the solution was then transferred to microplates. The compound activity was evaluated after 72 h by direct cell counting after serial dilutions and compared with an untreated control.

2.2.5. Cytotoxic assays

NCTC 929 fibroblasts were added to a 96-well microplate at a final concentration of 104 cells/well. The cells were grown at 37 °C in an atmosphere of 5% CO₂. The medium was removed and the samples were added until reaching 200 µL. A 24 h culture was performed. After this incubation, 20 µL of a 2 µM Resazurin solution was added to each well. The plates were incubated for 3 h and the resazurin reduction was measured at 490 and 595 nm and compared to a blank control.

2.2.6. Statistical analysis

The statistical analysis of IC₅₀ values are expressed as mean ± S.D., using the software Probit TSK version 1.5 (SPSSInc., Chicago, IL).

3. Results

3.1. Leishmanicidal activity of the red propolis and the *D. ecastaphyllum* resin extracts

The *in vitro* antileishmanial activity of the hydroethanolic extracts from the Brazilian red propolis from Pernambuco and Alagoas and the plant resin collected from *D. ecastaphyllum* trees were performed against *Leishmania braziliensis* and *L. infantum* promastigote forms. After 72 h of extract incubation with the parasites we observed that the lowest IC₅₀ belongs to RP-PER, both against *L. braziliensis* and *L. infantum* (Table 1). The RP-PED had the second lowest IC₅₀ against *L. braziliensis*, however its IC₅₀ against *L. infantum* was a little higher. The red propolis extract from Alagoas had an IC₅₀ similar to those observed for RP-PED. The resin showed one of the highest IC₅₀ for both treated species when compared to the propolis extract. All aforementioned results are shown in Table 1. An interesting observation is that the RP-PED extract was the only one which the highest concentration used to treat *Leishmania* could kill 100% of the parasites. These results are followed by the ones observed for the RP-AL and DER against *L. infantum* promastigote forms.

3.2. Trypanocide activity of the red propolis and the *D. ecastaphyllum* plant resin extracts

In the antitrypanosomal test, the RP-PER extract showed the lowest IC₅₀ against *Trypanosoma cruzi* epimastigote forms (Table 2). The RP-PER IC₅₀ result is followed by RP-PED, RP-AL and DER. The highest RP-PER concentration tested (1000 µg/mL) killed almost 100% of the parasites. However, the other extracts maintained the epimastigote death percentage around 80% for the highest concentration tested. The RP-PED, RP-AL and DER extracts also showed similar death percentages (around 80%) for the extracts concentrations 1000, 500, 250 and 125 µg/mL.

3.3. Cytotoxic effect of the Brazilian red propolis and the *D. ecastaphyllum* plant resin extracts

As we observed in the previous experiments, the RP-PER also showed the lowest IC₅₀ when compared to the IC₅₀ values of the other

extracts. The RP-PER 1000, 500, 250 and 125 µg/mL concentration values presented exactly or almost 100% fibroblast cell death. However, the other extracts, at the previously mentioned concentrations, displayed a fibroblast death percentage near 70%. These results can be observed in Table 2.

RP-PER – Red propolis from Pernambuco rainy season; RP-PED – Red propolis from Pernambuco Dry Season; RP-AL – Red propolis from Alagoas; DER- *Dalbergia ecastaphyllum* resin; %AP – Percentual of killed promastigotes forms; ± SD – Standard Deviation; IC_{50Lb} – Concentration in which 50% of *L. braziliensis* parasites are killed; IC_{50Li} – Concentration in which 50% of *L. infantum* parasites are killed.

RP-PER – Red propolis from Pernambuco rainy season; RP-PED – Red propolis from Pernambuco Dry Season; RP-AL – Red propolis from Alagoas; DER- *Dalbergia ecastaphyllum* resin; %AE – Percentual of killed epimastigotes forms; ± SD – Standard Deviation; %C – Percentual of killed fibroblasts NCTC 929; IC_{50Tc} – Concentration in which 50% of *T. cruzi* parasites are killed; IC_{50F} – Concentration in which 50% of fibroblasts cells are killed.

4. Discussion

4.1. Antileishmanial activity of the red propolis and *Dalbergia ecastaphyllum* resin

The propolis *in vitro* antileishmanial activity has been reported for propolis samples from different geographical origins, e.g. Ecuador (Cuesta-Rubio et al., 2017), Portugal (Falcão et al., 2014), Cuba (Monzote et al., 2012), Bolivia (Nina et al., 2016), Bulgaria (Machado et al., 2007), Turkey (Duran et al., 2011) and Brazil (Ayres et al., 2007), as well as from a variety of types, e.g. green (Ayres et al., 2007), brown (Monzote et al., 2012), yellow (Monzote et al., 2012) and red (Nascimento et al., 2016). Our study analysed the leishmanicidal activity of three different red propolis samples from Pernambuco and Alagoas against *Leishmania braziliensis* and *L. infantum*. The red propolis sample from Pernambuco RP-PER displayed the lowest IC₅₀ against *L. braziliensis* and *L. infantum*. These results show that the red propolis from Pernambuco can be very cytotoxic against *Leishmania* promastigote forms. Ayres et al. (2007) in a study using red propolis samples from Alagoas observed an 84.5% *L. amazonensis* inhibition using a red propolis extract solution of 6 µg/mL. Those results differ from our results from Alagoas in which we found an IC₅₀ of 55.79 µg/mL for *L. braziliensis* and 109.49 µg/mL against *L. infantum*. Similar to our results are those found by Nascimento et al., (2016) where they reported the use of nanoparticles loaded with red propolis from Alagoas against *L. braziliensis* promastigote forms. When we compared the leishmanicidal activity of the three red propolis samples used in our study against both *Leishmania* species we observed that *L. braziliensis* promastigote forms were more susceptible to all red propolis extracts than *L. infantum* parasites. The red propolis samples used in this study were previously analysed by our group to identify the chemical composition of the red propolis samples (Regueira et al., 2017). In this study we identified nine compounds: apigenin, caffeic acid, chlorogenic acid, ellagic acid, luteolin, p-coumaric acid, quercetin, rutin and vitexin. It has been reported in the scientific literature that flavonoids such as quercetin, luteolin and rutin have high leishmanicidal activity (Nascimento et al., 2016). Other studies say that chalcones present in the red propolis can inhibit *Leishmania* parasite growth by affecting the cytoplasmic membrane and the mitochondrial complex (Chen et al., 2001; Torres-Santos et al., 2009).

In this study we report for the first time the antileishmanial activity of the plant resin used by honey bees for red propolis production. We had the chance to compare the biological activity of the red propolis and the plant resin collected from *Dalbergia ecastaphyllum* against *L. braziliensis* and *L. infantum* in this study. According to the results displayed in Table 1 the red propolis samples from Alagoas and Pernambuco showed a better performance compared to the *Dalbergia*

Table 1

Antileishmanial activities of the hydroethanolic extracts of red propolis and *Dalbergia ecastaphyllum* plant resin.

Sample	Conc. µg/mL	%AP ± SD (<i>L. braziliensis</i>)	Conc. µg/mL	%AP ± SD (<i>L. infantum</i>)
RP-PER	1000	100.00 ± 0.21	1000	100.00 ± 0.24
	500	100.00 ± 0.32	500	84.77 ± 0.92
	250	99.12 ± 0.21	250	95.27 ± 0.81
	125	97.17 ± 0.16	125	92.80 ± 0.71
	62.5	85.87 ± 0.29	62.5	87.18 ± 2.05
	31.25	48.20 ± 0.09	31.25	43.51 ± 1.78
	15.62	–	15.62	–
IC ₅₀ µL: 35.22			IC ₅₀ µL: 37.45	
RP-PED	1000	68.11 ± 3.75	1000	62.41 ± 0.56
	500	66.92 ± 2.80	500	54.17 ± 1.82
	250	65.59 ± 0.55	250	54.56 ± 2.19
	125	64.82 ± 0.32	125	50.31 ± 0.57
	62.5	60.94 ± 0.12	62.5	45.58 ± 0.14
	31.25	57.95 ± 0.45	31.25	0.00 ± 0.55
	15.62	1.51 ± 0.92	15.62	0.00 ± 2.22
IC ₅₀ µL: 42.29			IC ₅₀ µL: 200.66	
RP-AL	1000	69.43 ± 0.85	1000	97.57 ± 6.23
	500	66.03 ± 4.90	500	79.26 ± 1.86
	250	66.03 ± 0.21	250	67.09 ± 0.85
	125	65.89 ± 0.06	125	62.22 ± 0.10
	62.5	63.75 ± 0.14	62.5	62.24 ± 1.28
	31.25	48.11 ± 0.01	31.25	10.54 ± 2.05
	15.62	19.17 ± 0.64	15.62	0.00 ± 0.03
IC ₅₀ µL: 55.79			IC ₅₀ µL: 109.49	
DER	1000	79.72 ± 4.08	1000	91.86 ± 1.10
	500	67.10 ± 0.06	500	94.20 ± 0.66
	250	66.08 ± 3.32	250	74.05 ± 1.07
	125	64.32 ± 1.33	125	64.30 ± 0.98
	62.5	62.17 ± 1.46	62.5	0.00 ± 0.91
	31.25	31.33 ± 1.63	31.25	0.00 ± 1.20
	15.62	0.00 ± 4.31	15.62	0.00 ± 0.66
IC ₅₀ µL: 90.46			IC ₅₀ µL: 134.56	

ecastaphyllum samples. In a study using *D. oliveri* and *D. cultrate* timber, Takahashi et al. (2004) obtained the MLC (minimum lethal concentration) and the MIC (minimal inhibitory concentration) of *Dalbergia* timber extracts against *Leishmania major* promastigote forms. They observed that *D. oliveri* obtained a MLC and MIC of 400 and 200 µg/mL, respectively whilst *D. cultrate* obtained 50 and 25 µg/mL, respectively. A hypothesis that could explain the difference between the red propolis and the plant resin activity against *Leishmania* parasites could be the fact that the plant material composition used in the propolis production process might be enhanced by honey bees during the chewing stage.

4.2. Red propolis and *Dalbergia ecastaphyllum* resin trypanocidal activity

In the last decades a variety of studies investigated the use of natural products for the treatment of Chagas disease. In this study we also evaluated the *in vitro* antitrypanosomal activity of red propolis and the resin exuded by *Dalbergia ecastaphyllum* trees. As we observed with *Leishmania* promastigotes, the RP-PER showed the lowest IC₅₀ against *Trypanosoma cruzi* epimastigote forms. This result was followed by the RP-PED, RP-AL and DER extracts. Both of the Pernambuco's red propolis extracts had a lower IC₅₀ than Alagoas'. As we also observed against *Leishmania* parasites, the three red propolis extracts had a better effect compared with the plant resin extract. In a study comparing the antitrypanosomal activity of three different types of Brazilian propolis, green, brown and red, against *T. cruzi*, Dantas Silva et al., (2017) observed that Brazilian red propolis samples displayed the highest activity compared to other types of propolis. Also against *T. cruzi*, Salomão et al. (2008) observed that Brazilian red propolis was cytotoxic against

trypomastigote forms and they reported that the red propolis extract was the most active among the tested extracts. The Nigerian red propolis, which is very similar to Brazilian propolis, showed to be more effective against *Trypanosoma brucei* as a crude extract than the isolated compounds (Omar et al., 2016). As it is widely reported for a range of red propolis activities, the propolis trypanocidal activity is also due to the presence of flavonoids in their chemical composition. The mean mechanisms by which propolis may kill *Trypanosoma* parasites involves mitochondrial and plasma membrane alterations. In *T. cruzi* epimastigote forms mitochondrial swelling, altered vacuoles and myelin figure formations were observed. Such changes compromise the lipid biosynthesis of *T. cruzi* epimastigotes, consequently affecting their plasma membrane (Dantas et al., 2006; Menna-Barreto et al., 2009).

4.3. Red propolis and *D. ecastaphyllum* resin cytotoxic activity

Propolis use by humans as medicine has been reported since 300 B.C. (Toreti et al., 2013). The development of techniques over the centuries has made human propolis use to be applied for the most diverse purposes. Currently, numerous biological activities have been attributed to propolis, e.g. antioxidant, anti-inflammatory, antibacterial, anti-fungal, anticancer, wound repair, antinociceptive, and cytotoxic (Alencar et al., 2007; Batista et al., 2012; Lima Cavendish et al., 2015; da Silva Frozza et al., 2013; Machado et al., 2016; Righi et al., 2011). In an attempt to guarantee the safe use of propolis derivatives or even raw propolis, researches are testing propolis from diverse geographical origins to evaluate the cytotoxic potential of those samples (Jacob et al., 2015; Murase et al., 2013). In this study we

Table 2

Trypanocidal and cytotoxic activities of the hydroethanolic extracts of red propolis and *Dalbergia ecastaphyllum* plant resin.

Sample	Conc. µg/mL	%AE ± SD (T. cruzi)	Conc. µg/mL	%C ± SD (Fibroblast)
RP-PER	1000	99.77 ± 1.63	1000	100.00 ± 0.35
	500	81.95 ± 0.21	500	100.00 ± 0.90
	250	87.78 ± 0.51	250	99.62 ± 0.79
	125	77.83 ± 0.49	125	97.06 ± 0.94
	62.5	76.70 ± 0.57	62.5	90.63 ± 0.26
	31.25	63.74 ± 0.07	31.25	9.30 ± 1.92
	15.62	–	15.62	–
IC ₅₀ TC: < 31		IC ₅₀ F: 48.09		
RP-PED	1000	80.86 ± 1.20	1000	71.31 ± 0.08
	500	77.30 ± 0.00	500	66.95 ± 0.08
	250	77.15 ± 1.27	250	68.98 ± 0.48
	125	75.19 ± 0.52	125	51.94 ± 0.42
	62.5	68.76 ± 0.98	62.5	33.53 ± 0.42
	31.25	40.56 ± 0.72	31.25	4.63 ± 1.48
	15.62	25.13 ± 0.81	15.62	0.00 ± 6.29
IC ₅₀ TC: 54.86		IC ₅₀ F: 142.26		
RP-AL	1000	79.79 ± 1.20	1000	63.27 ± 0.35
	500	77.46 ± 0.49	500	62.76 ± 0.78
	250	76.28 ± 0.81	250	60.20 ± 0.68
	125	76.82 ± 0.47	125	55.24 ± 0.14
	62.5	60.54 ± 1.01	62.5	37.87 ± 2.62
	31.25	32.16 ± 0.07	31.25	0.01 ± 2.12
	15.62	5.75 ± 1.98	15.62	1.92 ± 2.97
IC ₅₀ TC: 59.84		IC ₅₀ F: 127.31		
DER	1000	81.25 ± 0.95	1000	60.21 ± 0.71
	500	80.56 ± 0.49	500	61.58 ± 0.01
	250	77.89 ± 0.42	250	58.35 ± 0.42
	125	74.38 ± 0.49	125	24.64 ± 2.33
	62.5	42.79 ± 0.35	62.5	1.84 ± 2.12
	31.25	20.27 ± 1.63	31.25	0.00 ± 0.92
	15.62	–	15.62	0.00 ± 0.07
IC ₅₀ TC: 88.86		IC ₅₀ F: 228.02		

analysed the red propolis and the *D. ecastaphyllum* plant resin cytotoxic activity against mouse fibroblasts. The lowest IC₅₀ was observed for RP-PER with 48.09 µg/mL while the other extracts obtained IC₅₀ values three to five-fold higher. If we take a look at the extract concentrations which killed close to 0% of the fibroblasts, these being 31.25 µg/mL for RP-PER, RP-PED and RP-AL, and 62.5 µg/mL for DER, and compare it with percentage values of *L. braziliensis*, *L. infantum* and *T. cruzi* which were killed at these same concentrations, we observe that in most of cases the extracts killed almost 50% of the *L. braziliensis* and *T. cruzi* parasites. The aforementioned observation shows that the red propolis extracts from Pernambuco, Alagoas and the plant resin can probably be used against *L. braziliensis* and *T. cruzi* parasites without causing significant damage to healthy cells. Previous studies analysed the propolis cytotoxic potential against gingival and pulp fibroblasts cells and the authors observed that propolis solutions were safe whilst also decreasing apoptosis, increasing metabolic activity and proliferation of periodontal ligament cells (Alshaher et al., 2004; Gjertsen et al., 2011; Sonmez et al., 2005). However, it was also observed that green propolis at concentrations of 31.25 µg/mL or more might be cytotoxic to mouse fibroblasts (Funari et al., 2007).

4.4. Seasonal effect on red propolis antiprotozoal and cytotoxic activity

The geographical location where the propolis is produced plays an important role in determining the chemical composition of each type, where the plant, soil, climate and seasonality diversity influence the chemical composition of propolis (Sampaio et al., 2016; Teixeira et al., 2010). In this study we analysed the impact of seasonality on antileishmanial, antitrypanosomal and the cytotoxic activity of the red propolis collected from Pernambuco, Brazil during the dry and rainy seasons. In our study we observed that the RP-PER showed a more efficient antiprotozoan and cytotoxic activity than the RP-PED. The IC₅₀ obtained against *Leishmania infantum* and mouse fibroblasts were five-fold and three-fold higher when compared to the results obtained with RP-PER, respectively. Regarding their activity against *L. braziliensis* and *Trypanosoma cruzi* there were slight differences, however the RP-PED still obtained a higher IC₅₀ compared to RP-PER. These results demonstrate that the red propolis collected during the rainy season is more efficient against the parasites than the samples collected in the dry season. We observed the opposite when we tested the same samples combined with standard drugs against two bacteria species – *Pseudomonas aeruginosa* and *Staphylococcus aureus* – in a previous study. The red propolis collected in the dry season when combined to drugs had a more efficient synergistic activity than the samples from the rainy season (Regueira et al., 2017). On the other hand, Mendonça et al. (2015) in study on the seasonality of the red propolis from Sergipe, Brazil observed a positive correlation between yield and the pluviosity. Thus we can see here that seasonality influence on propolis bioactivity and how the extracts act against microorganisms is complex. Different red propolis samples collected in specific periods might have an enhanced bioactivity against specific targets, which is the case of the red propolis from Pernambuco, Brazil where the sample collected during the dry season had a better activity against bacteria while the sample collected during the rainy season performed better against protozoan parasites. To properly address this question, other factors which influence propolis activity need to be explored.

5. Conclusions

The evaluation of the *in vitro* cytotoxic activity of red propolis samples from Pernambuco and Alagoas against *Leishmania* and *Trypanosoma* parasites showed that all the extracts possessed high cytotoxic activity against the parasites. However, the RP-PER presented the lowest IC₅₀ against all tested species when compared to the others. Between the *Leishmania* species included in this study, *L. braziliensis* was the most susceptible to the action of the extracts. Propolis samples, in general, showed a better performance against the parasites when compared to the *Dalbergia ecastaphyllum* resin extract. According to this, honey bees may possibly modulate the chemical compounds present in the plant resin when they mix the plant material with their saliva and wax during the production of red propolis. To prove this, further studies are necessary. The concentration of extracts needed to kill at least 50% of fibroblasts cells are higher than the concentrations needed to kill the parasites, which makes the red propolis, despite its high toxicity, safe to be used at specific concentrations. We also observed the effect of seasonality on red propolis samples from Pernambuco, in which the red propolis collected during the rainy season showed to be more effective than the one collected in the dry season.

Conflicts of interest

The authors have no competing interests to declare.

Acknowledgements

The authors are grateful to Centro para el Desarrollo de la Investigación Científica (CEDIC) for the technical support in

antiprotazoal and cytotoxic analysis. This work was sponsored by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (141397/2014-4).

Transparency document

Transparency document related to this article can be found online at <http://dx.doi.org/10.1016/j.fct.2018.04.029>.

References

- Alencar, S.M., Oldoni, T.L.C., Castro, M.L., Cabral, I.S.R., Costa-Neto, C.M., Cury, J.A., Rosalen, P.L., Ikegaki, M., 2007. Chemical composition and biological activity of a new type of Brazilian propolis: red propolis. *J. Ethnopharmacol.* 113, 278–283. <https://doi.org/10.1016/j.jep.2007.06.005>.
- Alshaher, A., Wallace, J., Agarwal, S., Bretz, W., Baugh, D., 2004. Effect of propolis on human fibroblasts from the pulp and periodontal ligament. *J. Endod.* 30, 359–361. <https://doi.org/10.1097/00004770-200405000-00012>.
- Agência Pernambucana de Águas e Clima, 2016. Climatologia da Precipitação Mensal. <http://www.apac.pe.gov.br/meteorologia/>, Accessed date: 18 December 2016.
- Awale, S., Li, F., Onozuka, H., Esumi, H., Tezuka, Y., Kadota, S., 2008. Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. *Bioorg. Med. Chem.* 16, 181–189. <https://doi.org/10.1016/j.bmc.2007.10.004>.
- Ayres, D.C., Marcucci, M.C., Giorgio, S., 2007. Effects of Brazilian propolis on Leishmania amazonensis. *Mem. Inst. Oswaldo Cruz* 102, 215–220. <https://doi.org/10.1590/S0074-02762007005000020>.
- Bankova, V., Boudourova-Krasteva, G., Popov, S., Sforcin, J.M., Cunha Funari, S.R., 1998. Seasonal variations of the chemical composition of Brazilian propolis. *Apidologie* 29, 361–367. <https://doi.org/10.1051/apido:19980406>.
- Batista, L.L.V., Campesato, E.A., Assis, M.L.B. de, Barbosa, A.P.F., Grillo, L.A.M., Dornelas, C.B., 2012. Comparative study of topical green and red propolis in the repair of wounds induced in rats. *Rev. Col. Bras. Cir.* 39, 515–520.
- Bispo Junior, W., Oliveira Miranda, E., Alvino, V., Araújo, B., Wanderlei Silva, D., Porfírio, Z., 2012. Atividade antimicrobiana de frações da própolis vermelha de Alagoas, Brasil. *Antimicrobial activity of fractions of red propolis from Alagoas, Brazil* 33, pp. 3–10. <https://doi.org/10.5433/1679-0367.2012v33n1p03>.
- Bomfim, L.G.S., Magalhães, L.S., Santos-Filho, M.A.A., Peres, N.T.A., Corrêa, C.B., Tanajura, D.M., Silva, A.M., Lipscomb, M.W., Borges, V.M., Jesus, A.R., Almeida, R.P., de Moura, T.R., 2017. Leishmania infantum induces the release of sTREM-1 in visceral leishmaniasis. *Front. Microbiol.* 8 (2265). <https://doi.org/10.3389/fmicb.2017.02265>.
- Bueno-Silva, B., Alencar, S.M., Koo, H., Ikegaki, M., Silva, G.V.J., Napimoga, M.H., Rosalen, P.L., 2013. Anti-inflammatory and antimicrobial evaluation of neovestitol and vestitol isolated from Brazilian red propolis. *J. Agric. Food Chem.* 61, 4546–4550. <https://doi.org/10.1021/jf305468f>.
- Chatelain, E., 2017. Chagas disease research and development: is there light at the end of the tunnel? *Comput. Struct. Biotechnol. J.* 15, 98–103. <https://doi.org/10.1016/j.csbj.2016.12.002>.
- Chen, M., Zhai, L., Christensen, S.B., Theander, T.G., Kharazmi, A., 2001. Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones 45. pp. 2023–2029. <https://doi.org/10.1128/AAC.45.7.2023-2029.2001>.
- Cheuka, P., Mayoka, G., Mutai, P., Chibale, K., 2016. The role of natural products in drug discovery and development against neglected tropical diseases. *Molecules* 22 (58). <https://doi.org/10.3390/molecules22010058>.
- Cuesta-Rubio, O., Campo Fernández, M., Márquez Hernández, I., Jaramillo, C.G.J., González, V.H., Montes De Oca Porto, R., Marrero Delange, D., Monzote Fidalgo, L., Piccinelli, A.L., Campone, L., Rastrelli, L., 2017. Chemical profile and anti-leishmanial activity of three Ecuadorian propolis samples from Quito, Guayaquil and Cotacachi regions. *Fitoquímica* 120, 177–183. <https://doi.org/10.1016/j.fytote.2017.06.016>.
- da Silva, R.O., Andrade, V.M., Bullé Rêgo, E.S., Azevedo Dória, G.A., Santos Lima, B. Dos, da Silva, F.A., de Souza Araújo, A.A., de Albuquerque Júnior, R.L.C., Cordeiro Cardoso, J., Zanardo Gomes, M., 2015. Acute and sub-acute oral toxicity of Brazilian red propolis in rats. *J. Ethnopharmacol.* 170, 66–71. <https://doi.org/10.1016/j.jep.2015.05.009>.
- da Silva Frozza, C.O., Garcia, C.S.C., Gambato, G., de Souza, M.D.O., Salvador, M., Moura, S., Padilha, F.F., Seixas, F.K., Collares, T., Borsuk, S., Dellagostin, O.A., Henriques, J.A.P., Roesch-Ely, M., 2013. Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis. *Food Chem. Toxicol.* 52, 137–142. <https://doi.org/10.1016/j.fct.2012.11.013>.
- Dantas, A.P., Salomão, K., Barbosa, H.S., De Castro, S.L., 2006. The effect of Bulgarian propolis against Trypanosoma cruzi and during its interaction with host cells. *Mem. Inst. Oswaldo Cruz* 101, 207–211.
- Dantas Silva, R.P., Machado, B.A.S., Barreto, G. de A., Costa, S.S., Andrade, L.N., Amaral, R.G., Carvalho, A.A., Padilha, F.F., Barbosa, J.D.V., Umsza-Guez, M.A., 2017. Antioxidant, antimicrobial, antiparasitic, and cytotoxic properties of various Brazilian propolis extracts. *PLoS One* 12, e0172585. <https://doi.org/10.1371/journal.pone.0172585>.
- Daugusch, A., Moraes, C.S., Fort, P., Park, Y.K., 2008. Brazilian red propolis—chemical composition and botanical origin. *Evid. Based. Complement. Alternat. Med* 5, 435–441. <https://doi.org/10.1093/ecam/nem057>.
- Duran, N., Muz, M., Culha, G., Duran, G., Ozer, B., 2011. GC-MS analysis and antileishmanial activities of two Turkish propolis types. *Parasitol. Res.* 108, 95–105. <https://doi.org/10.1007/s00436-010-2039-z>.
- Ebadi, P., Fazeli, M., 2017. Anti-photoaging potential of propolis extract in UVB-irradiated human dermal fibroblasts through increasing the expression of FOXO3A and NGF genes. *Biomed. Pharmacother.* 95, 47–54. <https://doi.org/10.1016/j.biopha.2017.08.019>.
- Falcão, S.L., Vale, N., Cos, P., Gomes, P., Freire, C., Maes, L., Vilas-Boas, M., 2014. Vitro evaluation of Portuguese propolis and floral sources for antiprotazoal, antibacterial and antifungal activity. *Phyther. Res.* 28, 437–443. <https://doi.org/10.1002/ptr.5013>.
- Frozza, C.O. da S., Santos, D.A., Rufatto, L.C., Minetto, L., Scariot, F.J., Echeverrigaray, S., Pich, C.T., Moura, S., Padilha, F.F., Borsuk, S., Savegnago, L., Collares, T., Seixas, F.K., Dellagostin, O., Roesch-Ely, M., Henriques, J.A.P., 2017. Antitumor activity of Brazilian red propolis fractions against Hep-2 cancer cell line. *Biomed. Pharmacother.* 91, 951–963. <https://doi.org/10.1016/j.biopha.2017.05.027>.
- Funari, C.S., de Oliveira Ferro, V., Mather, M.B., 2007. Analysis of propolis from Baccharis dracunculifolia DC. (Compositae) and its effects on mouse fibroblasts. *J. Ethnopharmacol.* 111, 206–212. <https://doi.org/10.1016/j.jep.2006.11.032>.
- Gjertsen, A.W., Stothz, K.A., Neiva, K.G., Pileggi, R., 2011. Effect of propolis on proliferation and apoptosis of periodontal ligament fibroblasts. *Oral Surgery. Oral Med. Oral Pathol. Oral Radiol. Endodontol.* 112, 843–848. <https://doi.org/10.1016/j.tripleo.2011.08.004>.
- Hashiguchi, Y., Velez, L.N., Villegas, N.V., Mimori, T., Gomez, E.A.L., Kato, H., 2017. Leishmaniasis in Ecuador: comprehensive review and current status. *Acta Trop.* 166, 299–315. <https://doi.org/10.1016/j.actatropica.2016.11.039>.
- Higashi, K.O., de Castro, S.L., 1994. Propolis extracts are effective against Trypanosoma cruzi and have an impact on its interaction with host cells. *J. Ethnopharmacol.* 43, 149–155.
- Isla, M.L., Dantur, Y., Salas, A., Danert, C., Zampini, C., Arias, M., Ordóñez, R., Maldonado, L., Bedascarrasbure, E., Nieva Moreno, M.I., 2012. Effect of seasonality on chemical composition and antibacterial and anticandida activities of Argentine propolis. *Design of a topical formulation*. *Nat. Prod. Commun* 7, 1315–1318.
- Jacob, A., Parolia, A., Pau, A., Davamani Amalraj, F., 2015. The effects of Malaysian propolis and Brazilian red propolis on connective tissue fibroblasts in the wound healing process. *BMC Complement. Alternat. Med.* 15 (294). <https://doi.org/10.1186/s12906-015-0814-1>.
- Le-Senne, A., Muelas-Serrano, S., Fernández-Portillo, C., Escario, J.A., Gómez-Barrio, A., 2002. Biological characterization of a beta-galactosidase expressing clone of Trypanosoma cruzi CL strain. *Mem. Inst. Oswaldo Cruz* 97, 1101–1105. <https://doi.org/10.1590/S0074-02762002000800006>.
- Lima Cavendish, R., de Souza Santos, J., Belo Neto, R., Oliveira Paixão, A., Valéria Oliveira, J., Divino de Araújo, E., Berretta e Silva, A.A., Maria Thomazzi, S., Cordeiro Cardoso, J., Zanardo Gomes, M., 2015. Antinociceptive and anti-inflammatory effects of Brazilian red propolis extract and formononetin in rodents. *J. Ethnopharmacol.* 173, 127–133. <https://doi.org/10.1016/j.jep.2015.07.022>.
- Machado, C.S., Mokochinski, J.B., de Lira, T.O., de Oliveira, F. de C.E., Cardoso, M.V., Ferreira, R.G., Saway, A.C.H.F., Ferreira, A.G., Pessoa, C., Cuesta-Rubio, O., Monteiro, M.C., de Campos, M.S., Torres, Y.R., 2016. Comparative study of chemical composition and biological activity of yellow, Green, Brown, and red Brazilian propolis. *Evid. Based. Complement. Alternat. Med* 2016 (6057650). <https://doi.org/10.1155/2016/6057650>.
- Machado, G.M. de C., Leon, L.L., De Castro, S.L., 2007. Activity of Brazilian and Bulgarian propolis against different species of Leishmania. *Mem. Inst. Oswaldo Cruz* 102, 73–77.
- Mendonça, L.S. de, Mendonça, F.M.R. de, Araújo, Y.L.F.M. de, Araújo, E.D. de, Ramalho, S.A., Narain, N., Jain, S., Orellana, S.C., Padilha, F.F., Cardoso, J.C., Mendonça, L.S. de, Mendonça, F.M.R. de, Araújo, Y.L.F.M. de, Araújo, E.D. de, Ramalho, S.A., Narain, N., Jain, S., Orellana, S.C., Padilha, F.F., Cardoso, J.C., 2015. Chemical markers and antifungal activity of red propolis from Sergipe, Brazil. *Food Sci. Technol* 35, 291–298. <https://doi.org/10.1590/1678-457X.6554>.
- Menna-Barreto, R.F.S., Salomão, K., Dantas, A.P., Santa-Rita, R.M., Soares, M.J., Barbosa, H.S., de Castro, S.L., 2009. Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study. *Micron* 40, 157–168. <https://doi.org/10.1016/j.micron.2008.08.003>.
- Monzote, L., Cuesta-Rubio, O., Campo Fernandez, M., Márquez Hernandez, I., Fraga, J., Pérez, K., Kerstens, M., Maes, L., Cos, P., 2012. In vitro antimicrobial assessment of Cuban propolis extracts. *Mem. Inst. Oswaldo Cruz* 107, 978–984. <https://doi.org/10.1590/S0074-02762012000800003>.
- Murase, H., Shimazawa, M., Kakino, M., Ichihara, K., Tsuruma, K., Hara, H., 2013. The effects of Brazilian Green propolis against excessive light-induced cell damage in retina and fibroblast cells. Evidence-based complement. *Altern. Med* 2013, 1–11. <https://doi.org/10.1155/2013/238279>.
- Nascimento, T.G., da Silva, P.F., Azevedo, L.F., da Rocha, L.G., de Moraes Porto, I.C.C., Lima e Moura, T.F.A., Basilio-Júnior, I.D., Grillo, L.A.M., Dornelas, C.B., Fonseca, E.J. da S., de Jesus Oliveira, E., Zhang, A.T., Watson, D.G., 2016. Polymeric nanoparticles of Brazilian red propolis extract: preparation, characterization, antioxidant and leishmanicidal activity. *Nanoscale Res. Lett.* 11 (301). <https://doi.org/10.1186/s11671-016-1517-3>.
- Nina, N., Lima, B., Feresin, G.E., Giménez, A., Salamanca Capusiri, E., Schmeda-Hirschmann, G., 2016. Antibacterial and leishmanicidal activity of Bolivian propolis. *Lett. Appl. Microbiol.* 62, 290–296. <https://doi.org/10.1111/lam.12543>.
- Omar, R.M.K., Igoli, J., Gray, A.I., Ebloma, G.U., Clements, C., Fearnley, J., Edrada Ebel, R.A., Zhang, T., De Koning, H.P., Watson, D.G., 2016. Chemical characterisation of Nigerian red propolis and its biological activity against Trypanosoma Brucei. *Phytochem. Anal.* 27, 107–115. <https://doi.org/10.1002/pca.2605>.

ARTICLE IN PRESS

M.d.S. Regueira-Neto et al.

Food and Chemical Toxicology xxx (xxxx) xxx–xxx

- Oryan, A., 2015. Plant-derived compounds in treatment of leishmaniasis. *Iran. J. Vet. Res.* 16, 1–19.
- Pereira, R., Silva, D., Maria De Carvalho, C., Holanda, X., Santos De Arruda Barbosa, V., Pereira De Oliveira, D., Lima, N.A., Cláudia, A., Da Câmara, J., Da, A., Medeiros, C., Helena, M., Constantino, S., 2008. Brazilian Archives of Biology and Technology effect of medicinal plants on the parasitemia of *Trypanosoma cruzi* and on the bio-distribution of sodium pertechnetate ($Na\ 99m\ TcO\ 4$). *Braz. Arch. Biol. Technol.* 51, 209–214.
- Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M.P., López-Vélez, R., García-Hernández, R., Pountain, A.W., Mwenechanya, R., Papadopolou, B., 2017. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. *PLoS Neglected Trop. Dis.* 11, e0006052. <https://doi.org/10.1371/journal.pntd.0006052>.
- Regueira, M.S., Tintino, S.R., da Silva, A.R.P., Costa, M. do S., Boligon, A.A., Matias, E.F.F., de Queiroz Balbino, V., Menezes, I.R.A., Melo Coutinho, H.D., 2017. Seasonal variation of Brazilian red propolis: antibacterial activity, synergistic effect and phytochemical screening. *Food Chem. Toxicol.* 107, 572–580. <https://doi.org/10.1016/j.fct.2017.03.052>.
- Righi, A.A., Alves, T.R., Negri, G., Marques, L.M., Breyer, H., Salatino, A., 2011. Brazilian red propolis: unreported substances, antioxidant and antimicrobial activities. *J. Sci. Food Agric.* 91, 2363–2370. <https://doi.org/10.1002/jsfa.4468>.
- Roldos, V., Nakayama, H., Rolón, M., Montero-Torres, A., Trucco, F., Torres, S., Vega, C., Marrero-Ponce, Y., Huguaburu, V., Yaluff, G., Gómez-Barrio, A., Sanabria, L., Ferreira, M.E., Rojas de Arias, A., Pandolfi, E., 2008. Activity of a hydroxybenzyl bryophyte constituent against *Leishmania* spp. and *Trypanosoma cruzi*: in silico, in vitro and in vivo activity studies. *Eur. J. Med. Chem.* 43, 1797–1807. <https://doi.org/10.1016/J.EJMECH.2007.11.007>.
- Salatino, A., Teixeira, E.W., Negri, G., Message, D., 2005. Origin and chemical variation of Brazilian propolis. *Evid. Based. Complement. Alternat. Med.* 2, 33–38. <https://doi.org/10.1093/ecam/neh060>.
- Salomão, K., Pereira, P.R.S., Campos, L.C., Borba, C.M., Cabello, P.H., Marcucci, M.C., de Castro, S.L., 2008. Brazilian propolis: correlation between chemical composition and antimicrobial activity. *Evidence-based complement. Alternative Med.* 5, 317–324. <https://doi.org/10.1093/ecam/nem058>.
- Sampaio, B.L., Edrada-Ebel, R., Da Costa, F.B., 2016. Effect of the environment on the secondary metabolic profile of *Tithonia diversifolia*: a model for environmental metabolomics of plants. *Sci. Rep.* 6 (29265). <https://doi.org/10.1038/srep29265>.
- Sonmez, S., Kirilmaz, L., Yucesoy, M., Yücel, B., Yilmaz, B., 2005. The effect of bee propolis on oral pathogens and human gingival fibroblasts. *J. Ethnopharmacol.* 102, 371–376. <https://doi.org/10.1016/j.jep.2005.06.035>.
- Takahashi, M., Fuchino, H., Satake, M., Agatsuma, Y., Sekita, S., 2004. In vitro screening of leishmanicidal activity in Myanmar timber extracts. *Biol. Pharm. Bull.* 27, 921–925.
- Teixeira, E.W., Message, D., Negri, G., Salatino, A., Stringheta, P.C., 2010. Seasonal variation, chemical composition and antioxidant activity of Brazilian propolis samples. *Evid. Based. Complement. Alternat. Med.* 7, 307–315. <https://doi.org/10.1093/ecam/nem177>.
- Toreti, V.C., Sato, H.H., Pastore, G.M., Park, Y.K., 2013. Recent progress of propolis for its biological and chemical compositions and its botanical origin. *Evidence-based complement. Alternative Med.* 2013, 1–13. <https://doi.org/10.1155/2013/697390>.
- Torres-Santos, E.C., Sampaio-Santos, M.I., Buckner, F.S., Yokoyama, K., Gelb, M., Urbina, J.A., Rossi-Bergmann, B., 2009. Altered sterol profile induced in *Leishmania amazonensis* by a natural dihydroxymethoxylated chalcone. *J. Antimicrob. Chemother.* 63, 469–472. <https://doi.org/10.1093/jac/dkn546>.
- Tyszká-Czochara, M., Paško, P., Reczyński, W., Szłósarczyk, M., Bystrowska, B., Opoka, W., 2014. Zinc and propolis reduces cytotoxicity and proliferation in skin fibroblast cell culture: total polyphenol content and antioxidant capacity of propolis. *Biol. Trace Elem. Res.* 160, 123–131. <https://doi.org/10.1007/s12011-014-0019-3>.
- Vega, C., Rolón, M., Martínez-Fernández, A.R., Escario, J.A., Gómez-Barrio, A., 2005. A new pharmacological screening assay with *Trypanosoma cruzi* epimastigotes expressing β -galactosidase. *Parasitol. Res.* 95, 296–298. <https://doi.org/10.1007/s00436-005-1300-3>.
- World Health Organization, 2017. Chagas Disease (American Trypanosomiasis). <http://www.who.int/mediacentre/factsheets/fs340/en/>, Accessed date: 20 February 2017.
- World Health Organization, 2018. Leishmaniasis. <http://www.who.int/mediacentre/factsheets/fs375/en/>, Accessed date: 15 April 2018.
- Yongkun, P., Ikegaki, M., Alencar, S.M. de, Moura, F.F. de, 2000. Evaluation of Brazilian propolis by both physicochemical methods and biological activity. *Honeybee Sci.* 21, 85–90.
- Zare Jahromi, M., Ranjbarian, P., Shiravi, S., 2014. Cytotoxicity evaluation of Iranian propolis and calcium hydroxide on dental pulp fibroblasts. *J. Dent. Res. Dent. Clin. Dent. Prospects* 8, 130–133. <https://doi.org/10.5681/joddd.2014.024>.

4 CONCLUSÕES

1. Nove compostos químicos foram identificados nos extratos da própolis vermelha e da resina de *Dalbergia ecastaphyllum*. As diferenças de concentração deles nos extratos hidroetanólicos podem estar associados a fatores geográficos e sazonais;
2. Todos os extratos de própolis vermelha coletados em Pernambuco e Alagoas, incluindo a resina de *D. ecastaphyllum*, apresentaram atividades antibacteriana, antitripanosoma, atileishmania e citotóxica. Essas atividades são atribuídas à presença de flavonóides na composição;
3. A estação em que a própolis é coletada tem uma influência significativa na atividade biológica desses compostos;
4. Em todos os testes realizados, os extratos hidroetanólicos da própolis vermelha apresentaram uma maior eficácia frente aos micro-organismos em relação à resina vegetal e essa diferença pode estar relacionada à potencialização da ação dos compostos da resina durante à produção da própolis;
5. A própolis vermelha pernambucana é similar do ponto de vista de atividade biológica e composição química à própolis vermelha de Alagoas.

REFERÊNCIAS

- AGÊNCIA PERNAMBUCANA DE ÁGUAS E CLIMA. **Climatologia da Precipitação Mensal**. Disponível em <http://www.apac.pe.gov.br/meteorologia/>. Acesso em: 18 Dez. 2016.
- ALENCAR, S. M.; OLDONI, T. L. C.; CASTRO, M. L.; CABRAL, I. S. R.; COSTA-NETO, C. M.; CURY, J. A.; ROSALEN, P. L.; IKEGAKI, M. Chemical composition and biological activity of a new type of Brazilian propolis: Red propolis. **Journal of Ethnopharmacology**, v. 113, n. 2, p. 278–283, 5 set. 2007. Disponível em: <<http://www.sciencedirect.com/science/article/pii/S037887410700284X?via%3Dihub>>. Acesso em: 3 dez. 2017.
- ALSHAHER, A.; WALLACE, J.; AGARWAL, S.; BRETZ, W.; BAUGH, D. Effect of Propolis on Human Fibroblasts from the Pulp and Periodontal Ligament. **Journal of Endodontics**, v. 30, n. 5, p. 359–361, maio 2004. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/15107650>>. Acesso em: 4 jan. 2018.
- AMIN, M. U.; KHURRAM, M.; KHATTAK, B.; KHAN, J. Antibiotic additive and synergistic action of rutin, morin and quercetin against methicillin resistant *Staphylococcus aureus*. **BMC complementary and alternative medicine**, v. 15, p. 59, 12 mar. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25879586>>. Acesso em: 20 dez. 2016.
- ARIAS, M. C.; SHEPPARD, W. S. Phylogenetic relationships of honey bees (Hymenoptera:Apinae:Apini) inferred from nuclear and mitochondrial DNA sequence data. **Mol. Phylogenetic Evolution**. v. 37, p. 25–35, 2005.
- AWALE, S.; LI, F.; ONOZUKA, H.; ESUMI, H. TEZUKA, Y.; KADOTA, S. Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. **Bioorganic and Medical Chemistry**, v.16, p.181–189, 2008.
- AYRES, D. C.; MARCUCCI, M. C.; GIORGIO, S. Effects of Brazilian propolis on *Leishmania amazonensis*. **Memórias do Instituto Oswaldo Cruz**, v. 102, n. 2, p. 215–220, mar. 2007. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762007000200015&lng=en&nrm=iso&tlng=en>. Acesso em: 31 dez. 2016.
- BAK, J.; KIM, H. J.; KIM, S. Y.; CHOI, Y.-S. Neuroprotective effect of caffeic acid phenethyl ester in 3-nitropropionic acid-induced striatal neurotoxicity. **The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology**, v. 20, n. 3, p. 279–86, maio 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27162482>>. Acesso em: 15 set. 2016.
- BANKOVA, V. Chemical diversity of propolis and the problem of standardization. **Journal of Ethnopharmacology**, v. 100, p. 114–117, 2005.
- BANKOVA, V.; BOUDOUROVA-KRASTOVA, G.; POPOV, S.; SFORCIN, J. M.;

CUNHA FUNARI, S. R. Seasonal variations of the chemical composition of Brazilian propolis. **Apidologie**, v. 29, n. 4, p. 361–367, 1998. Disponível em: <<http://www.apidologie.org/10.1051/apido:19980406>>. Acesso em: 27 dez. 2017.

BANKOVA, V.; CHRISTOV, R.; DELGADO, T.A. Lignans and other constituents of propolis from the Canary Islands. **Phytochemistry**, v.49, p.1411–1415, 1998.

BANKOVA, V.; CHRISTOV, R.; STOEV, G.; POPOV, S. Determination of phenolics from propolis by gas chromatography. **Journal of Chromatography**, v. 607, p. 150 – 153, 1992.

BANKOVA, V.S.; CASTRO, S.L.; MARCUCCI, M.C. Propolis: recent advances in chemistry and plant origin. **Apidologie**, v. 31, n.1, p.3–15, 2000.

BANSKOTA, A.H.; TEZUKA, Y.; PRASAIN, J.K.; MATSUSHIGE, K.; SAIKI, I.; KADOTA, S.H. Chemical constituents of Brazilian propolis and their cytotoxic activities, **Journal of Natural Products**, v.61, p. 896–900, 1998.

BARTH, O.M.; LUZ, C.F.P. Palynological analysis of Brazilian red propolis samples. **Journal of Apicultural Research and Bee World**, v.48, n.3, p.181-188, 2009.

BATISTA, L. L. V.; CAMPESATTO, E. A.; ASSIS, M. L. B. de; BARBOSA, A. P. F.; GRILLO, L. A. M.; DORNELAS, C. B. Comparative study of topical green and red propolis in the repair of wounds induced in rats. **Revista do Colegio Brasileiro de Cirurgioes**, v. 39, n. 6, p. 515–20, dez. 2012. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/23348649>>. Acesso em: 26 dez. 2017.

BIEDENBACH, D. J.; GIAO, P. T.; HUNG VAN, P.; SU MINH TUYET, N.; THI THANH NGA, T.; PHUONG, D. M.; VU TRUNG, N.; BADAL, R. E. Antimicrobial-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii* From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam. **Clinical Therapeutics**, v. 38, n. 9, p. 2098–2105, set. 2016. Disponível em: <<http://linkinghub.elsevier.com/retrieve/pii/S0149291816306154>>. Acesso em: 20 dez. 2016.

BILIKOVA, K.; KRAKOVA, T.K.; YAMAGUCHI, K.; YAMAGUCHI, Y. Major royal jelly proteins as markers of authenticity and quality of honey. **Arh Hig Rada Toksikol**; v.66, p.259-267, 2015.

BISPO JUNIOR, W.; OLIVEIRA MIRANDA, E.; ALVINO, V.; ARAUJO, B.; WANDERLEI SILVA, D.; PORFIRIO, Z. Atividade antimicrobiana de frações da própolis vermelha de Alagoas, Brasil Antimicrobial activity of fractions of red propolis from Alagoas, Brazil. v. 33, n. 1, p. 3–10, 2012. Disponível em: <<http://www.uel.br/revistas/uel/index.php/seminabio/article/viewFile/4589/11065>>. Acesso em: 26 dez. 2017.

BOLIGON, A. A.; PIANA, M.; KUBIÇA, T. F.; MARIO, D. N.; DALMOLIN, T. V.; BONEZ, P. C.; WEIBLEN, R.; LOVATO, L.; ALVES, S. H.; CAMPOS, M. M. A.; ATHAYDE, M. L. HPLC analysis and antimicrobial, antimycobacterial and antiviral activities of *Tabernaemontana catharinensis* A. DC. **Journal of Applied**

Biomedicine, v. 13, n. 1, p. 7–18, 1 fev. 2015. Disponível em: <<http://www.sciencedirect.com/science/article/pii/S1214021X14000301>>. Acesso em: 3 dez. 2017.

BOMFIM, L. G. S.; MAGALHÃES, L. S.; SANTOS-FILHO, M. A. A.; PERES, N. T. A.; CORRÊA, C. B.; TANAJURA, D. M.; SILVA, A. M.; LIPSCOMB, M. W.; BORGES, V. M.; JESUS, A. R.; ALMEIDA, R. P.; DE MOURA, T. R. Leishmania infantum Induces the Release of sTREM-1 in Visceral Leishmaniasis. **Frontiers in Microbiology**, v. 8, p. 2265, 16 nov. 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/29201022>>. Acesso em: 22 dez. 2017.

BRAZILIAN HEALTH SURVEILLANCE AGENCY (ANVISA). **Technical chamber of Phytotherapy Meidcines. CATEF**. <http://www.anvisa.gov.br/medicamentos/catef/propolis.htm>. Acesso em: 19 Nov. 2016.

BUENO-SILVA, B.; ALENCAR, S. M.; KOO, H.; IKEGAKI, M.; SILVA, G. V. J.; NAPIMOGA, M. H.; ROSALEN, P. L. Anti-Inflammatory and Antimicrobial Evaluation of Neovestitol and Vestitol Isolated from Brazilian Red Propolis. **Journal of Agricultural and Food Chemistry**, v. 61, n. 19, p. 4546–4550, 15 maio 2013. Disponível em: <<http://pubs.acs.org/doi/10.1021/jf305468f>>. Acesso em: 3 dez. 2017.

BUENO-SILVA, B.; MARSOLA, A.; IKEGAKI, M.; ALENCAR, S. M.; ROSALEN, P. L. The effect of seasons on Brazilian red propolis and its botanical source: chemical composition and antibacterial activity. **Natural Product Research**, v. 31, n. 11, p. 1318–1324, 3 jun. 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27701899>>. Acesso em: 3 dez. 2017.

BURDOCK, G. A. Review of the biological properties and toxicity of bee propolis (propolis). **Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association**, v. 36, n. 4, p. 347–63, abr. 1998. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/9651052>>. Acesso em: 30 ago. 2018.

BURDOCK, G. A. Review of the Biological Properties and Toxicity of Bee Propolis (Propolis). **Food and Chemical Toxicology**, v.36. p. 347-363, 1998.

CABRAL, I. S. R.; OLDONI, T. L. C.; PRADO, A.; BEZERRA, R. M. N.; ALENCAR, S. M. de; IKEGAKI, M.; ROSALEN, P. L. Composição fenólica, atividade antibacteriana e antioxidante da própolis vermelha brasileira. **Química Nova**, v. 32, n. 6, p. 1523–1527, 2009. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422009000600031&lng=pt&nrm=iso&tlng=pt>. Acesso em: 26 dez. 2017.

CARVALHO, A. M. A Synopsis of the Genus Dalbergia (Fabaceae: Dalbergieae) in Brazil. **Brittonia**, v. 49, n. 1, p. 87, jan. 1997.

CARVALHO, F. B.; BOLIGON, A. A.; ATHAYDE, M. L.; RUBIN, M. A.; FERREIRA, J.; TREVISAN, G. Inhibitory effect of Scutia buxifolia extracts, fractions, and ursolic acid on Na⁺, K⁺-ATPase activity in vitro in membranes purified from rat hearts.

Journal of Ethnopharmacology, v. 179, p. 45–54, 17 fev. 2016. Disponível em: <<http://www.sciencedirect.com/science/article/pii/S0378874115302865?via%3Dihub>>. Acesso em: 3 dez. 2017.

CAVENDISH, R.L.; DE SOUZA SANTOS, J.; BELO NETO, R.; OLIVEIRA PAIXÃO, A.; VALÉRIA OLIVEIRA, J.; DIVINO DE ARAUJO, E.; BERRETTA E SILVA, A. A.; MARIA THOMAZZI, S.; CORDEIRO CARDOSO, J.; ZANARDO GOMES, M. Antinociceptive and anti-inflammatory effects of Brazilian red propolis extract and formononetin in rodents. **Journal of Ethnopharmacology**, v. 173, p. 127–133, 15 set. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26192808>>. Acesso em: 26 dez. 2017.

CHATELAIN, E. Chagas disease research and development: Is there light at the end of the tunnel? **Computational and Structural Biotechnology Journal**, v. 15, p. 98–103, 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/28066534>>. Acesso em: 16 jan. 2017.

CHEN, M.; ZHAI, L.; CHRISTENSEN, S. B.; THEANDER, T. G.; KHARAZMI, A. Inhibition of Fumarate Reductase in *Leishmania major* and *L. donovani* by Chalcones. v. 45, n. 7, p. 2023–2029, 2001. Disponível em: <<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90595/pdf/ac002023.pdf>>. Acesso em: 11 jan. 2018.

CHEUKA, P.; MAYOKA, G.; MUTAI, P.; CHIBALE, K. The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases. **Molecules**, v. 22, n. 1, p. 58, 31 dez. 2016. Disponível em: <<http://www.mdpi.com/1420-3049/22/1/58>>. Acesso em: 17 jan. 2017.

CLINICAL AND LABORATORY STANDARDS INSTITUTE. **Performance standards for antimicrobial susceptibility testing**; eighteenth informational supplement. CLSI document M100-18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.

CONCEIÇÃO-SILVA, Fátima.; ALVES, Carlos Roberto. **Leishmanioses do Continente Americano**. São Paulo: Ed. Fiocruz, 2014.

CRANE, E. **Beekeeping: Science, Practice and World Resources**., London, UK, Butterworth Heinemann, 1988.

CUESTA-RUBIO, O.; CAMPO FERNÁNDEZ, M.; MÁRQUEZ HERNÁNDEZ, I.; JARAMILLO, C. G. J.; GONZÁLEZ, V. H.; MONTES DE OCA PORTO, R.; MARRERO DELANGE, D.; MONZOTE FIDALGO, L.; PICCINELLI, A. L.; CAMPONE, L.; RASTRELLI, L. Chemical profile and anti-leishmanial activity of three Ecuadorian propolis samples from Quito, Guayaquil and Cotacachi regions. **Fitoterapia**, v. 120, p. 177–183, 1 jul. 2017. Disponível em: <<http://www.sciencedirect.com/science/article/pii/S0367326X17305452?via%3Dihub>>. Acesso em: 4 dez. 2017.

CUESTA-RUBIO, O.; FRONTANA-URIBE B.A.; RAMÍREZ-APAN, T.; CÁRDENAS, J. Polyisoprenylated benzophenones in Cuban propolis; biological activity of nemorosone. **Zeitschrift fur Naturforschung C**, v. 57, n. 3-4, p. 372–378, 2002.

CUSHNIE, T.P.T.; LAMB, A.J. Recent advances in understanding the antibacterial properties of flavonoids. **International Journal of Antimicrobial Agents**, v.38, p. 99– 107, 2011.

DA SILVA FROZZA, C. O.; GARCIA, C. S. C.; GAMBATO, G.; DE SOUZA, M. D. O.; SALVADOR, M.; MOURA, S.; PADILHA, F. F.; SEIXAS, F. K.; COLLARES, T.; BORSUK, S.; DELLAGOSTIN, O. A.; HENRIQUES, J. A. P.; ROESCH-ELY, M. Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis. **Food and Chemical Toxicology**, v. 52, p. 137–142, fev. 2013. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/23174518>>. Acesso em: 26 dez. 2017.

DA SILVA, R. O.; ANDRADE, V. M.; BULLÉ RÊGO, E. S.; AZEVEDO DÓRIA, G. A.; SANTOS LIMA, B. Dos; DA SILVA, F. A.; DE SOUZA ARAÚJO, A. A.; DE ALBUQUERQUE JÚNIOR, R. L. C.; CORDEIRO CARDOSO, J.; ZANARDO GOMES, M. Acute and sub-acute oral toxicity of Brazilian red propolis in rats. **Journal of ethnopharmacology**, v. 170, p. 66–71, 21 jul. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25978955>>. Acesso em: 21 nov. 2016.

DANTAS SILVA, R. P.; MACHADO, B. A. S.; BARRETO, G. de A.; COSTA, S. S.; ANDRADE, L. N.; AMARAL, R. G.; CARVALHO, A. A.; PADILHA, F. F.; BARBOSA, J. D. V.; UMSZA-GUEZ, M. A. Antioxidant, antimicrobial, antiparasitic, and cytotoxic properties of various Brazilian propolis extracts. **PLOS ONE**, v. 12, n. 3, p. e0172585, 30 mar. 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/28358806>>. Acesso em: 7 dez. 2017.

DANTAS, A. P.; SALOMÃO, K.; BARBOSA, H. S.; DE CASTRO, S. L. The effect of Bulgarian propolis against *Trypanosoma cruzi* and during its interaction with host cells. **Memorias do Instituto Oswaldo Cruz**, v. 101, n. 2, p. 207–11, mar. 2006. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/16830714>>. Acesso em: 2 jan. 2017.

DAUGSCH, A.; MORAES, C. S.; FORT, P.; PARK, Y. K. Brazilian red propolis--chemical composition and botanical origin. **Evidence-based complementary and alternative medicine : eCAM**, v. 5, n. 4, p. 435–41, dez. 2008. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/18955226>>. Acesso em: 24 dez. 2017.

DENISOW, B.; DENISOW-PIETRZYK, M. Biological and therapeutic properties of bee pollen: a review. **Journal of the Science of Food and Agriculture**, 2016.
DIOP, E. S.; GORDON, C.; SEMESI, A. K.; SOUMARÉ, A.; DIALLO, N.; GUISSÉ, A.; DIOUF, M.; AYIVOR, J. S. Mangroves of Africa. In: **Mangrove Ecosystems**. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. p. 63–121.

DO NASCIMENTO, T. G.; DA SILVA, P. F.; AZEVEDO, L. F.; DA ROCHA, L. G.; DE MORAES PORTO, I. C. C.; LIMA E MOURA, T. F. A.; BASÍLIO-JÚNIOR, I. D.; GRILLO, L. A. M.; DORNELAS, C. B.; FONSECA, E. J. da S.; DE JESUS OLIVEIRA, E.; ZHANG, A. T.; WATSON, D. G. Polymeric Nanoparticles of Brazilian Red Propolis Extract: Preparation, Characterization, Antioxidant and Leishmanicidal Activity. **Nanoscale Research Letters**, v. 11, n. 1, p. 301, 17 dez. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27316742>>. Acesso em: 5 dez. 2017.

DURAN, N.; MUZ, M.; CULHA, G.; DURAN, G.; OZER, B. GC-MS analysis and antileishmanial activities of two Turkish propolis types. **Parasitology Research**, v. 108, n. 1, p. 95–105, 15 jan. 2011. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/20842509>>. Acesso em: 6 dez. 2017.

EBADI, P.; FAZELI, M. Anti-photoaging potential of propolis extract in UVB-irradiated human dermal fibroblasts through increasing the expression of FOXO3A and NGF genes. **Biomedicine & Pharmacotherapy**, v. 95, p. 47–54, nov. 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/28826096>>. Acesso em: 4 jan. 2018.

ENGEL, M. S. The taxonomy of recent and fossil honey bees (Hymenoptera: Apidae; Apis). **Journal of Hymenoptera Research**, v.8, p. 165–196, 1999.

EUMKEB, G.; CHUKRATHOK, S. Synergistic activity and mechanism of action of ceftazidime and apigenin combination against ceftazidime-resistant *Enterobacter cloacae*. **Phytomedicine**, v. 20, n. 3, p. 262–269, 2013.

FALCÃO, S. I.; VALE, N.; COS, P.; GOMES, P.; FREIRE, C.; MAES, L.; VILAS-BOAS, M. In Vitro Evaluation of Portuguese Propolis and Floral Sources for Antiprotozoal, Antibacterial and Antifungal Activity. **Phytotherapy Research**, v. 28, n. 3, p. 437–443, mar. 2014. Disponível em: <<http://doi.wiley.com/10.1002/ptr.5013>>. Acesso em: 2 jan. 2017.

FERNANDES JÚNIOR, A.; BALESTRIN, E. C.; BETONI, J. E. C.; ORSI, R. de O.; CUNHA, M. de L. R. de S. d; MONTELLI, A. C. Propolis: anti-Staphylococcus aureus activity and synergism with antimicrobial drugs. **Memórias do Instituto Oswaldo Cruz**, v. 100, n. 5, p. 563–566, ago. 2005. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762005000500018&lng=en&nrm=iso&tlng=en>. Acesso em: 9 dez. 2015.

FERNANDES-SILVA, C.C.; SALATINO, A.; SALATINO, M.L.F. Chemical Profiling of Six Samples Of Brazilian Propolis. **Quimica Nova**, v. 36, n. 2, p. 237-240, 2013.

FONSECA-SILVA, F.; CANTO-CAVALHEIRO, M. M.; MENNA-BARRETO, R. F. S.; ALMEIDA-AMARAL, E. E. Effect of Apigenin on Leishmania amazonensis Is Associated with Reactive Oxygen Species Production Followed by Mitochondrial Dysfunction. **Journal of natural products**, v. 78, n. 4, p. 880–4, 24 abr. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25768915>>. Acesso em: 14 set. 2016.

FREIRES, I. A.; DE ALENCAR, S. M.; ROSALEN, P. L. A pharmacological perspective on the use of Brazilian Red Propolis and its isolated compounds against human diseases. **European journal of medicinal chemistry**, v. 110, p. 267–79, 3 mar. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26840367>>. Acesso em: 23 mar. 2016.

FROZZA, C. O. da S.; SANTOS, D. A.; RUFATTO, L. C.; MINETTO, L.; SCARIOT, F. J.; ECHEVERRIGARAY, S.; PICH, C. T.; MOURA, S.; PADILHA, F. F.; BORSUK, S.; SAVEGNAGO, L.; COLLARES, T.; SEIXAS, F. K.; DELLAGOSTIN, O.; ROESCH-ELY, M.; HENRIQUES, J. A. P. Antitumor activity of Brazilian red propolis fractions

against Hep-2 cancer cell line. **Biomedicine & Pharmacotherapy**, v. 91, p. 951–963, jul. 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/28514834>>. Acesso em: 26 dez. 2017.

FROZZA, C. O. S.; GARCIA, C. S. C.; GAMBATO, G.; DE SOUZA, M. D. O.; SALVADOR, M.; MOURA, S.; PADILHA, F. F.; SEIXAS, F. K.; COLLARES, T.; BORSUK, S.; DELLAGOSTIN, O. A.; HENRIQUES, J. A. P.; ROESCH-ELY, M. Chemical characterization, antioxidant and cytotoxic activities of Brazilian red propolis. **Food and Chemical Toxicology**, v. 52, p. 137–142, fev. 2013. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/23174518>>. Acesso em: 28 dez. 2017.

GAD, G. F.; MOHAMED, H. A.; ASHOUR, H. M. Aminoglycoside Resistance Rates, Phenotypes, and Mechanisms of Gram-Negative Bacteria from Infected Patients in Upper Egypt. **PLoS ONE**, v. 6, n. 2, p. e17224, 17 fev. 2011. Disponível em: <<http://dx.plos.org/10.1371/journal.pone.0017224>>. Acesso em: 12 dez. 2017.

GHISALBERTI, E. L. Propolis: A Review. **Bee World**, v. 60, n. 2, p. 59–84, 31 jan. 1979. Disponível em: <<https://www.tandfonline.com/doi/full/10.1080/0005772X.1979.11097738>>. Acesso em: 31 ago. 2018.

GJERTSEN, A. W.; STOTHZ, K. A.; NEIVA, K. G.; PILEGGI, R. Effect of propolis on proliferation and apoptosis of periodontal ligament fibroblasts. **Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology**, v. 112, n. 6, p. 843–848, dez. 2011. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/22099860>>. Acesso em: 4 jan. 2018.

GRAPHPAD Software, Inc. Disponível em: <http://www.graphpad.com/faq/viewfaq.cfm?faq=1362>. Acesso em: 5 Nov. 2008.

GRÖBLACHER, B.; KUNERT, O.; BUCAR, F. Compounds of *Alpinia katsumadai* as potential efflux inhibitors in *Mycobacterium smegmatis*. **Bioorganic & Medicinal Chemistry**, v. 20, n. 8, p. 2701–2706, 2012.

GUO, X.-F.; YANG, Z.-R.; WANG, J.; LEI, X.-F.; LV, X.-G.; DONG, W.-G. Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma. **Molecular Medicine Reports**, v. 11, n. 4, p. 2562–2568, abr. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25434307>>. Acesso em: 31 ago. 2018.

HAN, F.; WALLBERG, A.; WEBSTER, M.T. From where did the Western honeybee (*Apis mellifera*) originate? **Ecology and Evolution**, v. 2, p. 1949–1957, 2012.

HARTVIG, I.; CZAKO, M.; KJÆR, E. D.; NIELSEN, L. R.; THEILADE, I. The Use of DNA Barcoding in Identification and Conservation of Rosewood (*Dalbergia* spp.). **PLOS ONE**, v. 10, n. 9, p. e0138231, 16 set. 2015. Disponível em: <<http://dx.plos.org/10.1371/journal.pone.0138231>>. Acesso em: 20 jan. 2018.

HASHIGUCHI, Y.; VELEZ, L. N.; VILLEGAS, N. V.; MIMORI, T.; GOMEZ, E. A. L.; KATO, H. Leishmaniasis in Ecuador: Comprehensive review and current status.

Acta Tropica, v. 166, p. 299–315, fev. 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27919688>>. Acesso em: 22 dez. 2017.

HASSAN, S. T. S.; BERCHOVÁ, K.; MAJEROVÁ, M.; POKORNÁ, M.; ŠVAJDLENKA, E. *In vitro* synergistic effect of *Hibiscus sabdariffa* aqueous extract in combination with standard antibiotics against *Helicobacter pylori* clinical isolates. **Pharmaceutical Biology**, v. 54, n. 9, p. 1736–1740, 5 set. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26731378>>. Acesso em: 31 ago. 2018.

HIGASHI, K. O.; DE CASTRO, S. L. Propolis extracts are effective against *Trypanosoma cruzi* and have an impact on its interaction with host cells. **Journal of ethnopharmacology**, v. 43, n. 2, p. 149–55, 8 jul. 1994. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/7967655>>. Acesso em: 7 dez. 2017.

ISHIDA, C; NEGRI, G.; SALATINO, A.; BANDEIRA, M.F.C.L. new type of Brazilian propolis: Prenylated benzophenones in propolis from Amazon and effects against cariogenic bacteria. **Food Chemistry**, v.125, p. 966–972, 2011.

ISLA, M. I.; DANTUR, Y.; SALAS, A.; DANERT, C.; ZAMPINI, C.; ARIAS, M.; ORDÓÑEZ, R.; MALDONADO, L.; BEDASCARRASBURE, E.; NIEVA MORENO, M. I. Effect of seasonality on chemical composition and antibacterial and anticandida activities of Argentine propolis. Design of a topical formulation. **Natural product communications**, v. 7, n. 10, p. 1315–8, out. 2012. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/23156997>>. Acesso em: 27 dez. 2017.

IZUTA, H.; NARAHARA, Y.; SHIMAZAWA, M.; MISHIMA, S.; KONDO, S.; HARA, H. 1,1-diphenyl-2-picrylhydrazyl radical scavenging activity of bee products and their constituents determined by ESR. **Biological & pharmaceutical bulletin**, v. 32, n. 12, p. 1947–51, dez. 2009. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/19952409>>. Acesso em: 31 ago. 2018.

JACOB, A.; PAROLIA, A.; PAU, A.; DAVAMANI AMALRAJ, F. The effects of Malaysian propolis and Brazilian red propolis on connective tissue fibroblasts in the wound healing process. **BMC Complementary and Alternative Medicine**, v. 15, n. 1, p. 294, 25 dez. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26303848>>. Acesso em: 4 jan. 2018.

JAIN, S. A.; MARCHIORO, ; G. M.; COSTA, ; A. C.; ; E. D. ARAUJO. Extraction and amplification of DNA from Brazilian Red propolis. **Scientia Plena**, v. 10, n. 03, p. 5, 2014.

JORGE, R.; FURTADO, N. A. J. C.; SOUSA, J. P. B.; FIHO, A. A. da S.; GREGORIO JR., L. E.; MARTINS, C. H. G.; SOARES, A. E. E.; BASTOS, J. K.; CUNHA, W. R.; SILVA, M. L. A. Brazilian Propolis: Seasonal Variation of the Prenylated p-Coumaric Acids and Antimicrobial Activity. **Pharmaceutical Biology**, v. 46, n. 12, p. 889–893, 2008. Disponível em: <<http://www.producao.usp.br/handle/BDPI/20067>>. Acesso em: 27 dez. 2017.

JORGE, R.; FURTADO, N.A.J.C.; SOUSA, J.P.B.; SILVA FILHO, A.A.; GREGÓRIO JUNIOR, L.E.; MARTINS, C.H.G. Brazilian Propolis: Seasonal Variation of the

Prenylated *p*-Coumaric Acids and Antimicrobial Activity. *Pharmaceutical Biology*, v.46, n.12, p.889–893, 2008.

KASALA, E. R.; BODDULURU, L. N.; BARUA, C. C.; GOGOI, R. Antioxidant and antitumor efficacy of Luteolin, a dietary flavone on benzo(a)pyrene-induced experimental lung carcinogenesis. **Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie**, v. 82, p. 568–77, ago. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27470398>>. Acesso em: 16 set. 2016.

KATAYAMA, M.; AOKI, M.; KAWANA, S. Case of anaphylaxis caused by ingestion of royal jelly. **Journal of Dermatology**, v. 35, p. 222–224, 2008.

KUETE, V. Potential of Cameroonian Plants and Derived Products against Microbial Infections: A Review. **Planta Medica**, v. 76, n. 14, p. 1479–1491, 8 out. 2010. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/20533165>>. Acesso em: 31 ago. 2018.

LANGENHEIM, J.H. Plant resins: chemistry, evolution, ecology and ethnobotany. **Annals of Botany**, v. 93, n. 6, p. 784–785, 1 jun. 2004. Disponível em: <<https://academic.oup.com/aob/article-lookup/doi/10.1093/aob/mch103>>. Acesso em: 1 set. 2018.

LE-SENNE, A.; MUELAS-SERRANO, S.; FERNÁNDEZ-PORTILLO, C.; ESCARIO, J. A.; GÓMEZ-BARRIO, A. Biological characterization of a beta-galactosidase expressing clone of *Trypanosoma cruzi* CL strain. **Memórias do Instituto Oswaldo Cruz**, v. 97, n. 8, p. 1101–1105, dez. 2002. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762002000800006&lng=en&tlng=en>. Acesso em: 18 jan. 2018.

LI, F.; AWALE, S.; TEZUKA, Y.; KADOTA, S. Cytotoxic constituents from Brazilian red propolis and their structure–activity relationship. **Bioorganic & Medicinal Chemistry**, v. 16, n. 10, p. 5434–5440, 15 maio 2008. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/18440233>>. Acesso em: 3 jan. 2018.

LIMA CAVENDISH, R.; DE SOUZA SANTOS, J.; BELO NETO, R.; OLIVEIRA PAIXÃO, A.; VALÉRIA OLIVEIRA, J.; DIVINO DE ARAUJO, E.; BERRETTA E SILVA, A. A.; MARIA THOMAZZI, S.; CORDEIRO CARDOSO, J.; ZANARDO GOMES, M. Antinociceptive and anti-inflammatory effects of Brazilian red propolis extract and formononetin in rodents. **Journal of Ethnopharmacology**, v. 173, p. 127–133, 15 set. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26192808>>. Acesso em: 26 dez. 2017.

LOPEZ, B. G.-C.; DE LOURENÇO, C. C.; ALVES, D. A.; MACHADO, D.; LANCELLOTTI, M.; SAWAYA, A. C. H. F. Antimicrobial and cytotoxic activity of red propolis: an alert for its safe use. **Journal of Applied Microbiology**, v. 119, n. 3, p. 677–687, set. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26086953>>. Acesso em: 28 dez. 2017.

LÓPEZ, B. G.-C.; SCHMIDT, E. M.; EBERLIN, M. N.; SAWAYA, A. C. H. F. Phytochemical markers of different types of red propolis. **Food Chemistry**, v. 146, p.

174–180, 1 mar. 2014. Disponível em:
<<http://www.ncbi.nlm.nih.gov/pubmed/24176329>>. Acesso em: 21 jan. 2018.

LOTTI, C.; CAMPO FERNANDEZ, M.; PICCINELLI, A. L.; CUESTA-RUBIO, O.; MÁRQUEZ HERNÁNDEZ, I.; RASTRELLI, L. Chemical Constituents of Red Mexican Propolis. **Journal of Agricultural and Food Chemistry**, v. 58, n. 4, p. 2209–2213, 24 fev. 2010. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/20121106>>. Acesso em: 11 abr. 2018.

MACHADO, C. S.; MOKOCHINSKI, J. B.; DE LIRA, T. O.; DE OLIVEIRA, F. de C. E.; CARDOSO, M. V.; FERREIRA, R. G.; SAWAYA, A. C. H. F.; FERREIRA, A. G.; PESSOA, C.; CUESTA-RUBIO, O.; MONTEIRO, M. C.; DE CAMPOS, M. S.; TORRES, Y. R. Comparative Study of Chemical Composition and Biological Activity of Yellow, Green, Brown, and Red Brazilian Propolis. **Evidence-based complementary and alternative medicine : eCAM**, v. 2016, p. 6057650, 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27525023>>. Acesso em: 1 set. 2016.

MACHADO, G. M. de C.; LEON, L. L.; DE CASTRO, S. L. Activity of Brazilian and Bulgarian propolis against different species of Leishmania. **Memorias do Instituto Oswaldo Cruz**, v. 102, n. 1, p. 73–7, fev. 2007. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/17294003>>. Acesso em: 6 dez. 2017.

MANDAL, S.; DEBMANDAL, M.; PAL, N. K.; SAHA, K. Synergistic anti–Staphylococcus aureus activity of amoxicillin in combination with Emblica officinalis and Nymphae odorata extracts. **Asian Pacific Journal of Tropical Medicine**, v. 3, n. 9, p. 711–714, 1 set. 2010. Disponível em: <<https://www.sciencedirect.com/science/article/pii/S199576451060171X>>. Acesso em: 31 ago. 2018.

MARCUCCI, M. C. Propolis: chemical composition, biological properties and therapeutic activity. **Apidologie**, v. 26, n. 2, p. 83–99, 1995. Disponível em: <<http://www.apidologie.org/10.1051/apido:19950202>>. Acesso em: 3 dez. 2017.

MARCUCCI, M.C.; RODRIGUEZ, J.; FERRERES, F.; BANKOVA, V.; GROTO, R.; POPOV, S. Chemical composition of Brazilian propolis from São Paulo state, Z. **Naturforsch**, v.3, 117–119, 1998.

MARKIEWICZ-ŻUKOWSKA, R.; BORAWSKA, M.H.; FIEDOROWICZ, A.; NALIWAJKO, S.K.; SAWICKA, D.; CAR, H. Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line. **Complementary and Alternative Medicine**, v.13, p.50, 2013.

MATIAS, E. F. F.; SANTOS, F. A. V.; SILVA, J. M. F. L.; SOUZA, C. E. S.; TINTINO, S. R.; GUEDES, G. M. M.; MEDEIROS, C. R.; BRAGA, M. F. B. M.; ALMEIDA, T. S.; COSTA, J. G. M.; MENEZES, I. R. A.; COUTINHO, H. D. M. Screening the in vitro modulation of antibiotic activity of the extracts and fractions of Ocimum gratissimum L. **African Journal of Microbiology Research**, v. 6, n. 9, p. 1902–1907, 9 mar. 2012. Disponível em:

<[http://www.academicjournals.org/ajmr/abstracts/abstract/2012/9Mar/Matias et al.htm](http://www.academicjournals.org/ajmr/abstracts/abstract/2012/9Mar/Matias%20et%20al.htm)>. Acesso em: 31 ago. 2018.

MAYWORM, M.A.S.; LIMA, C.A.; TOMBA, A.C.B.; FERNANDES-SILVA, C.C.; SALATINO, M.L.F.; SALATINO, A. Does Propolis Contain Tannins? **Evidence-Based Complementary and Alternative Medicine**, 2014.

MENDONÇA, I. C. G.; PORTO, I. C. C. de M.; DO NASCIMENTO, T. G.; DE SOUZA, N. S.; OLIVEIRA, J. M. dos S.; ARRUDA, R. E. dos S.; MOUSINHO, K. C.; DOS SANTOS, A. F.; BASÍLIO-JÚNIOR, I. D.; PAROLIA, A.; BARRETO, F. S. Brazilian red propolis: phytochemical screening, antioxidant activity and effect against cancer cells. **BMC Complementary and Alternative Medicine**, v. 15, n. 1, p. 357, 14 dez. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26467757>>. Acesso em: 28 dez. 2017.

MENDONÇA, L. S. de; MENDONÇA, F. M. R. de; ARAÚJO, Y. L. F. M. de; ARAÚJO, E. D. de; RAMALHO, S. A.; NARAIN, N.; JAIN, S.; ORELLANA, S. C.; PADILHA, F. F.; CARDOSO, J. C.; MENDONÇA, L. S. de; MENDONÇA, F. M. R. de; ARAÚJO, Y. L. F. M. de; ARAÚJO, E. D. de; RAMALHO, S. A.; NARAIN, N.; JAIN, S.; ORELLANA, S. C.; PADILHA, F. F.; CARDOSO, J. C. Chemical markers and antifungal activity of red propolis from Sergipe, Brazil. **Food Science and Technology (Campinas)**, v. 35, n. 2, p. 291–298, jun. 2015. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612015000200291&lng=en&nrm=iso&tlng=en>. Acesso em: 27 dez. 2017.

MENNA-BARRETO, R. F. S.; SALOMÃO, K.; DANTAS, A. P.; SANTA-RITA, R. M.; SOARES, M. J.; BARBOSA, H. S.; DE CASTRO, S. L. Different cell death pathways induced by drugs in Trypanosoma cruzi: An ultrastructural study. **Micron**, v. 40, n. 2, p. 157–168, 2009.

MONZOTE, L.; CUESTA-RUBIO, O.; CAMPO FERNANDEZ, M.; MÁRQUEZ HERNANDEZ, I.; FRAGA, J.; PÉREZ, K.; KERSTENS, M.; MAES, L.; COS, P. In vitro antimicrobial assessment of Cuban propolis extracts. **Memórias do Instituto Oswaldo Cruz**, v. 107, n. 8, p. 978–984, dez. 2012. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000800003&lng=en&nrm=iso&tlng=en>. Acesso em: 2 jan. 2017.

MUN, S.-H.; JOUNG, D.-K.; KIM, Y.-S.; KANG, O.-H.; KIM, S.-B.; SEO, Y.-S.; KIM, Y.-C.; LEE, D.-S.; SHIN, D.-W.; KWEON, K.-T.; KWON, D.-Y. Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. **Phytomedicine**, v. 20, n. 8, p. 714–718, 2013.

MURASE, H.; SHIMAZAWA, M.; KAKINO, M.; ICHIHARA, K.; TSURUMA, K.; HARA, H. The Effects of Brazilian Green Propolis against Excessive Light-Induced Cell Damage in Retina and Fibroblast Cells. **Evidence-Based Complementary and Alternative Medicine**, v. 2013, p. 1–11, 2013. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/24416064>>. Acesso em: 4 jan. 2018.

NAIR, K. S. S. **Tropical forest insect pests ecology, impact, and management**. [s.l.] Cambridge University Press, 2007.

NINA, N.; LIMA, B.; FERESIN, G. E.; GIMÉNEZ, A.; SALAMANCA CAPUSIRI, E.; SCHMEDA-HIRSCHMANN, G. Antibacterial and leishmanicidal activity of Bolivian propolis. **Letters in Applied Microbiology**, v. 62, n. 3, p. 290–296, mar. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26743801>>. Acesso em: 31 dez. 2016.

OLDONI, T. L. C.; CABRAL, I. S. R.; D'ARCE, M. A. B. R.; ROSALEN, P. L.; IKEGAKI, M.; NASCIMENTO, A. M.; ALENCAR, S. M. Isolation and analysis of bioactive isoflavonoids and chalcone from a new type of Brazilian propolis. **Separation and Purification Technology**, v. 77, n. 2, p. 208–213, 20 fev. 2011. Disponível em: <<https://www.sciencedirect.com/science/article/pii/S1383586610005058>>. Acesso em: 31 ago. 2018.

OMAR, R. M. K.; IGOLI, J.; GRAY, A. I.; EBILOMA, G. U.; CLEMENTS, C.; FEARNLEY, J.; EDRADA EBEL, R. A.; ZHANG, T.; DE KONING, H. P.; WATSON, D. G. Chemical characterisation of Nigerian red propolis and its biological activity against *Trypanosoma Brucei*. **Phytochemical analysis : PCA**, v. 27, n. 2, p. 107–115, mar. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26662866>>. Acesso em: 5 maio. 2016.

ORSI, R. de O.; SFORCIN, J. M.; FUNARI, S. R. C.; FERNANDES JUNIOR, A.; BANKOVA, V. Synergistic effect of propolis and antibiotics on the *Salmonella Typhi*. **Brazilian Journal of Microbiology**, v. 37, n. 2, p. 108–112, jun. 2006. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822006000200002&lng=en&nrm=iso&tlng=en>. Acesso em: 20 dez. 2016.

ORSI, R. O.; FERNANDES, A.; BANKOVA, V.; SFORCIN, J. M. The effects of Brazilian and Bulgarian propolis in vitro against *Salmonella Typhi* and their synergism with antibiotics acting on the ribosome. **Natural product research**, v. 26, n. 5, p. 430–7, jan. 2012. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/21660841>>. Acesso em: 9 dez. 2015.

ORSOLIC, N.; CAR, N.; LISICIC, D.; BENKOVIC, V.; KNEZEVIC, A.H.; DIKIC, D.; PETRIK, J. Synergism Between Propolis and Hyperthermal Intraperitoneal Chemotherapy with Cisplatin on Ehrlich Ascites Tumor in Mice. **Journal of Pharmaceutical Sciences**, v.102, p.4395–4405, 2013.

ORYAN, A. Plant-derived compounds in treatment of leishmaniasis. **Iranian journal of veterinary research**, v. 16, n. 1, p. 1–19, 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27175144>>. Acesso em: 22 dez. 2017.

ÖZÇELİK, B.; ORHAN, D.; ÖZGEN, S.; ERGUN, F. Antimicrobial Activity of Flavonoids against Extended-Spectrum β -Lactamase (ES β L)-Producing *Klebsiella pneumoniae*. **Tropical Journal of Pharmaceutical Research**. [s.l.: s.n.]. Disponível em: <<http://www.tjpr.org>>. Acesso em: 31 ago. 2018.

PARK, Y. K.; IKEGAKI, M.; ALENCAR, S. M. de; MOURA, F. F. de. Evaluation of Brazilian propolis by both physicochemical methods and biological activity. **Honeybee Science**, v. 21, n. 2, p. 85–90, 2000. Disponível em:

<<https://www.cabdirect.org/cabdirect/abstract/20000508894>>. Acesso em: 19 abr. 2018.

PARK, Y.K.; ALENCAR, S.M.; AGUIAR, C.L. Botanical origin and chemical composition of Brazilian propolis. **Journal of Agriculture and Food Chemistry**, v.50, p.2502–2506, 2002b.

PARK, Y.K.; ALENCAR, S.M.; SCAMPARINI, A.R.P.; AGUIAR, C.L. Propolis produced in South Brazil, Argentine and Uruguay: phytochemical evidence for the plant origin. **Ciência Rural**, Santa Maria, v.32, n.6, p.997-1003, 2002a.

PEI, K.; OU, J.; HUANG, J.; OU, S. p-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activities. **Journal of the science of food and agriculture**, v. 96, n. 9, p. 2952–62, jul. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26692250>>. Acesso em: 16 set. 2016.

PEREIRA, R.; SILVA, D.; MARIA DE CARVALHO, C.; HOLANDA, X.; SANTOS DE ARRUDA BARBOSA, V.; PEREIRA DE OLIVEIRA, D.; LIMA, N. A.; CLÁUDIA, A.; DA CÂMARA, J.; DA, A.; MEDEIROS, C.; HELENA, M.; CONSTANTINO, S. BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY Effect of Medicinal Plants on the Parasitemia of Trypanosoma Cruzi and on the Biodistribution of Sodium Pertechetate (Na 99m TcO 4). **Braz. arch. biol. technol.** v, v. 51, n. 51, p. 209–214, 2008. Disponível em: <<http://www.scielo.br/pdf/babt/v51nspe/v51nspea34.pdf>>. Acesso em: 23 dez. 2017.

PICCINELLI, A. L.; CAMPO FERNANDEZ, M.; CUESTA-RUBIO, O.; MÁRQUEZ HERNÁNDEZ, I.; DE SIMONE, F.; RASTRELLI, L. Isoflavonoids Isolated from Cuban Propolis. **Journal of Agricultural and Food Chemistry**, v. 53, n. 23, p. 9010–9016, 16 nov. 2005. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/16277396>>. Acesso em: 31 ago. 2018.

PICCINELLI, A. L.; LOTTI, C.; CAMPONE, L.; CUESTA-RUBIO, O.; CAMPO FERNANDEZ, M.; RASTRELLI, L. Cuban and Brazilian Red Propolis: Botanical Origin and Comparative Analysis by High-Performance Liquid Chromatography–Photodiode Array Detection/Electrospray Ionization Tandem Mass Spectrometry. **Journal of Agricultural and Food Chemistry**, v. 59, n. 12, p. 6484–6491, 22 jun. 2011. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/21598949>>. Acesso em: 31 ago. 2018.

PINHEIRO, K. S.; RIBEIRO, D. R.; ALVES, A. V. F.; PEREIRA-FILHO, R. N.; OLIVEIRA, C. R. de; LIMA, S. O.; REIS, F. P.; CARDOSO, J. C.; ALBUQUERQUE-JÚNIOR, R. L. C. de. Modulatory activity of brazilian red propolis on chemically induced dermal carcinogenesis. **Acta Cirurgica Brasileira**, v. 29, n. 2, p. 111–117, fev. 2014. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/24604315>>. Acesso em: 31 ago. 2018.

PIPPI, B.; LANA, A. J. D.; MORAES, R. C.; GÜEZ, C. M.; MACHADO, M.; DE OLIVEIRA, L. F. S.; LINO VON POSER, G.; FUENTEFRIA, A. M. In vitro evaluation of the acquisition of resistance, antifungal activity and synergism of Brazilian red propolis with antifungal drugs on Candida spp. **Journal of applied microbiology**, v.

118, n. 4, p. 839–50, abr. 2015. Disponível em:
<<http://www.ncbi.nlm.nih.gov/pubmed/25565139>>. Acesso em: 9 dez. 2015.

PONTE-SUCRE, A.; GAMARRO, F.; DUJARDIN, J.-C.; BARRETT, M. P.; LÓPEZ-VÉLEZ, R.; GARCÍA-HERNÁNDEZ, R.; POUNTAIN, A. W.; MWENECHANYA, R.; PAPADOPOULOU, B. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. **PLOS Neglected Tropical Diseases**, v. 11, n. 12, p. e0006052, 14 dez. 2017. Disponível em: <<http://dx.plos.org/10.1371/journal.pntd.0006052>>. Acesso em: 18 dez. 2017.

PREMRATANACHAI, P.; CHANCHAO, C. Review of the anticancer activities of bee products. **Asian Pacific Journal of Tropical Biomedicine**, v. 4, n.5, p. 337-344, 2014.

PYRZYNSKA, K.; BIESAGA, M. Analysis of phenolic acids and flavonoids in honey. **Trends in Analytical Chemistry**, v. 28, n. 7, p. 893-902, 2009.

R CORE TEAM. R: A language and environment for statistical computing. **R Foundation for Statistical Computing**, Vienna, Austria. Disponível em: <http://www.R-project.org/>. Acesso em: 28 Ago. 2016.

REGUEIRA NETO, M. S.; TINTINO, S. R.; DA SILVA, A. R. P.; COSTA, M. do S.; BOLIGON, A. A.; MATIAS, E. F. F.; DE QUEIROZ BALBINO, V.; MENEZES, I. R. A.; MELO COUTINHO, H. D. Seasonal variation of Brazilian red propolis: Antibacterial activity, synergistic effect and phytochemical screening. **Food and Chemical Toxicology**, v. 107, n. Pt B, p. 572–580, set. 2017. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/28359875>>. Acesso em: 12 dez. 2017.

RIGHI, A. A.; ALVES, T. R.; NEGRI, G.; MARQUES, L. M.; BREYER, H.; SALATINO, A. Brazilian red propolis: unreported substances, antioxidant and antimicrobial activities. **Journal of the Science of Food and Agriculture**, v. 91, n. 13, p. 2363–2370, out. 2011. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/21590778>>. Acesso em: 23 dez. 2017.

ROLDOS, V.; NAKAYAMA, H.; ROLÓN, M.; MONTERO-TORRES, A.; TRUCCO, F.; TORRES, S.; VEGA, C.; MARRERO-PONCE, Y.; HEGUABURU, V.; YALUFF, G.; GÓMEZ-BARRIO, A.; SANABRIA, L.; FERREIRA, M. E.; ROJAS DE ARIAS, A.; PANDOLFI, E. Activity of a hydroxybibenzyl bryophyte constituent against *Leishmania* spp. and *Trypanosoma cruzi*: In silico, in vitro and in vivo activity studies. **European Journal of Medicinal Chemistry**, v. 43, n. 9, p. 1797–1807, 1 set. 2008. Disponível em: <<http://www.sciencedirect.com/science/article/pii/S0223523407004400?via%3Dihub>>. Acesso em: 5 jan. 2018.

RUBINK, W. L.; LUEVANO-MARTINEZ, P.; SUGDEN, E.A.; WILSON, W.T.; COLLINS, A.M. Subtropical *Apis mellifera* (Hymenoptera: Apidae) Swarming Dynamics and Africanization Rates in Northeastern Mexico and Southern Texas. **Ecology and Population Biology**, v. 89, n. 2, p. 243-251, 1996.

RUTTNER, F. **Biogeography and taxonomy of honeybees**. Berlin, Springer-Verlag, 1988.

SADDIQ, A.A.; MOHAMED, A.M. Potential role of Saudi red propolis in alleviating lung damage induced by methicillin resistant *Staphylococcus aureus* virulence in rats. **Pakistan Journal of Pharmaceutical Sciences**, v.9, n.4, p. 1197-1207, 2016.

SAHA, S.; SHILPI, J. A.; MONDAL, H.; HOSSAIN, F.; ANISUZZMAN, M.; MAHADHI HASAN, M.; CORDELL, G. A. Ethnomedicinal, phytochemical, and pharmacological profile of the genus *Dalbergia* L. (Fabaceae). **Phytopharmacology**, v. 4, n. 2, p. 291–346, 2013.

SAHA, S.K.; SAHA, S.; AKHTER, S.M.; KHATUN, S.; ISLAM, M.M.; ROY, P. In Vitro Determination of Minimum Inhibitory Concentration of Aqueous Garlic Extract and Imipenem against *Staphylococcus aureus* and *Escherichia coli*. **Mymensingh Medical Journal**, v.25, n.3, p. 477-84, 2016.

SALATINO, A.; TEIXEIRA, E. W.; NEGRI, G.; MESSAGE, D. Origin and Chemical Variation of Brazilian Propolis. **Evidence-based complementary and alternative medicine : eCAM**, v. 2, n. 1, p. 33–38, mar. 2005. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/15841276>>. Acesso em: 23 dez. 2017.

SALOMÃO, K.; PEREIRA, P. R. S.; CAMPOS, L. C.; BORBA, C. M.; CABELLO, P. H.; MARCUCCI, M. C.; DE CASTRO, S. L. Brazilian Propolis: Correlation between Chemical Composition and Antimicrobial Activity. **Evidence-Based Complementary and Alternative Medicine**, v. 5, n. 3, p. 317–324, set. 2008. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/18830454>>. Acesso em: 7 dez. 2017.

SAMPAIO, B. L.; EDRADA-EBEL, R.; DA COSTA, F. B. Effect of the environment on the secondary metabolic profile of *Tithonia diversifolia*: a model for environmental metabolomics of plants. **Scientific Reports**, v. 6, n. 1, p. 29265, 7 set. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27383265>>. Acesso em: 27 dez. 2017.

SCAZZOCCHIO, F.; D'AURIA, F. D.; ALESSANDRINI, D.; PANTANELLA, F. Multifactorial aspects of antimicrobial activity of propolis. **Microbiological research**, v. 161, n. 4, p. 327–33, jan. 2006. Disponível em: <<http://www.sciencedirect.com/science/article/pii/S0944501305001230>>. Acesso em: 10 dez. 2015.

SCHMIDT, S.; RAINIERI, S.; WITTE, S.; MATERN, U.; MARTENS, S. Identification of a *Saccharomyces cerevisiae* glucosidase that hydrolyzes flavonoid glucosides. **Applied and environmental microbiology**, v. 77, n. 5, p. 1751–7, mar. 2011. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/21216897>>. Acesso em: 3 dez. 2017.

SELIM, S.; ALFY, S.; AL-RUWAILI, M.; ABDO, A.; JAOUNI, S. Susceptibility of imipenem-resistant *Pseudomonas aeruginosa* to flavonoid glycosides of date palm (*Phoenix dactylifera* L.) tamar growing in Al Madinah, Saudi Arabia. **AFRICAN JOURNAL OF BIOTECHNOLOGY**, v. 11, n. 2, p. 416–422, 5 jan. 2011. Disponível

em: <[http://www.academicjournals.org/AJb/abstracts/abs2012/5Jan/Selim et al.htm](http://www.academicjournals.org/AJb/abstracts/abs2012/5Jan/Selim%20et%20al.htm)>. Acesso em: 31 ago. 2018.

SFORCIN, J. M.; FERNANDES, A.; LOPES, C. A.; BANKOVA, V.; FUNARI, S. R. Seasonal effect on Brazilian propolis antibacterial activity. **Journal of ethnopharmacology**, v. 73, n. 1–2, p. 243–9, nov. 2000. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/11025162>>. Acesso em: 27 dez. 2017.

SHEPPARD, W. S.; MEIXNER, M. D.; HEPPARDA, W. S. S.; EIXNERA, M. D. M. *Apis mellifera pomonella*, a new honey bee subspecies from Central Asia. **Apidologie**, v. 34, p. 376–375, 2003.

SILICI S.; KUTLUCA, S. Chemical composition and antibacterial activity of propolis collected by three different races of honeybees in the same region. **Journal of Ethnopharmacology**, v.99, n., p. 69–73, 2005.

SILVA, B. B.; ROSALEN, P. L.; CURY, J. A.; IKEGAKI, M.; SOUZA, V. C.; ESTEVES, A.; ALENCAR, S. M. Chemical composition and botanical origin of red propolis, a new type of brazilian propolis. **Evidence-based complementary and alternative medicine : eCAM**, v. 5, n. 3, p. 313–6, set. 2008. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/18830449>>. Acesso em: 21 jan. 2018.

SILVA, F. H. M.; DE ASSIS RIBEIRO DOS SANTOS, F. Pollen morphology of the shrub and arboreal flora of mangroves of Northeastern Brazil. **Wetlands Ecology and Management**, v. 17, n. 5, p. 423–443, 7 out. 2009.

SILVA, R. O.; ANDRADE, V. M.; BULLÉ RÊGO, E. S.; AZEVEDO DÓRIA, G. A.; SANTOS LIMA, B. Dos; DA SILVA, F. A.; DE SOUZA ARAÚJO, A. A.; DE ALBUQUERQUE JÚNIOR, R. L. C.; CORDEIRO CARDOSO, J.; ZANARDO GOMES, M. Acute and sub-acute oral toxicity of Brazilian red propolis in rats. **Journal of ethnopharmacology**, v. 170, p. 66–71, 21 jul. 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25978955>>. Acesso em: 21 nov. 2016.

SONMEZ, S.; KIRILMAZ, L.; YUCESoy, M.; YÜCEL, B.; YILMAZ, B. The effect of bee propolis on oral pathogens and human gingival fibroblasts. **Journal of Ethnopharmacology**, v. 102, n. 3, p. 371–376, 1 dez. 2005. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/16084044>>. Acesso em: 3 jan. 2018.

TAHER, N. M. Synergistic Effect of Propolis Extract and Antibiotics on Multi-resist *Klebsiella pneumoniae* Strain Isolated from Wound. **Journal of Natural Sciences Research**, v. 5, n. 17, p. 98–103, 2015.

TAKAHASHI, M.; FUCHINO, H.; SATAKE, M.; AGATSUMA, Y.; SEKITA, S. In vitro screening of leishmanicidal activity in myanmar timber extracts. **Biological & pharmaceutical bulletin**, v. 27, n. 6, p. 921–5, jun. 2004. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/15187448>>. Acesso em: 14 jan. 2018.

TATEFUJI, T.; IZUMI, N.; OHTA, T.; ARAI, Sh.; IKEDA, M.; KURIMOTO, M. Isolation and identification of compounds from Brazilian propolis which enhance macrophage

spreading and mobility. **Biological and Pharmaceutical Bulletin**, v.19, p.966–970, 1996.

TAZAWA, S.H.; WARASHINA, T.; NORO, T.; MIYASE, T. Studies on the constituents of Brazilian propolis, **Chemical and Pharmaceutical Bulletin**, v.46, p. 1477–1479, 1998.

TEIXEIRA, E. W.; MESSAGE, D.; NEGRI, G.; SALATINO, A.; STRINGHETA, P. C. Seasonal variation, chemical composition and antioxidant activity of Brazilian propolis samples. **Evidence-based complementary and alternative medicine : eCAM**, v. 7, n. 3, p. 307–15, set. 2010. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/18955317>>. Acesso em: 27 dez. 2017.

THOMSON W. Propolis. **Medical Journal of Australia**, v.153, article 654, 1990.

TOMÁS-BARBERÁN, F. A.; GARCÍA-VIGUERA, C.; VIT-OLIVIER, P.; FERRERES, F.; TOMÁS-LORENTE, F. Phytochemical evidence for the botanical origin of tropical propolis from Venezuela. **Phytochemistry**, v. 34, n. 1, p. 191–196, 3 ago. 1993. Disponível em: <<https://www.sciencedirect.com/science/article/abs/pii/S0031942200908045>>. Acesso em: 31 ago. 2018.

TORETI, V. C.; SATO, H. H.; PASTORE, G. M.; PARK, Y. K. Recent Progress of Propolis for Its Biological and Chemical Compositions and Its Botanical Origin. **Evidence-Based Complementary and Alternative Medicine**, v. 2013, p. 1–13, 2013. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/23737843>>. Acesso em: 13 out. 2017.

TORRES-SANTOS, E. C.; SAMPAIO-SANTOS, M. I.; BUCKNER, F. S.; YOKOYAMA, K.; GELB, M.; URBINA, J. A.; ROSSI-BERGMANN, B. Altered sterol profile induced in *Leishmania amazonensis* by a natural dihydroxymethoxylated chalcone. **Journal of Antimicrobial Chemotherapy**, v. 63, n. 3, p. 469–472, 15 jan. 2009. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/19176591>>. Acesso em: 11 jan. 2018.

TROPICOS. *Dalbergia* distribution. Disponível em: <http://www.tropicos.org/Name/40021450?tab=maps>. Acessado em: 11 de abril de 2018.

TRUSHEVA, B.; POPOVA, M.; BANKOVA, V.; SIMOVA, S.; MARCUCCI, M. C.; MIORIN, P. L.; DA ROCHA PASIN, F.; TSVETKOVA, I. Bioactive constituents of brazilian red propolis. **Evidence-based complementary and alternative medicine : eCAM**, v. 3, n. 2, p. 249–54, jun. 2006. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/16786055>>. Acesso em: 3 dez. 2017.

TRUSHEVA, B.; POPOVA, M.; NAYDENSKI, H.; TSVETKOVA, I.; GREGORIO RODRIGUEZ, J.; BANKOVA, V. New polyisoprenylated benzophenones from Venezuelan propolis. **Fitoterapia**, v. 75, n. 7–8, p. 683–689, dez. 2004. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/15567244>>. Acesso em: 31 ago. 2018.

TSANG, M. S. M.; JIAO, D.; CHAN, B. C. L.; HON, K.-L.; LEUNG, P. C.; LAU, C. B. S.; WONG, E. C. W.; CHENG, L.; CHAN, C. K. M.; LAM, C. W. K.; WONG, C. K. Anti-Inflammatory Activities of Pentaherbs Formula, Berberine, Gallic Acid and Chlorogenic Acid in Atopic Dermatitis-Like Skin Inflammation. **Molecules (Basel, Switzerland)**, v. 21, n. 4, p. 519, 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27104513>>. Acesso em: 14 set. 2016.

TYSZKA-CZOCHARA, M.; PAŚKO, P.; RECZYŃSKI, W.; SZLÓARCZYK, M.; BYSTROWSKA, B.; OPOKA, W. Zinc and Propolis Reduces Cytotoxicity and Proliferation in Skin Fibroblast Cell Culture: Total Polyphenol Content and Antioxidant Capacity of Propolis. **Biological Trace Element Research**, v. 160, n. 1, p. 123–131, 10 jul. 2014. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/24913100>>. Acesso em: 28 dez. 2017.

URAL, M. Ş.; YONAR, M. E.; MIŞE YONAR, S. Protective effect of ellagic acid on oxidative stress and antioxidant status in *Cyprinus carpio* during malathion exposure. **Cellular and molecular biology (Noisy-le-Grand, France)**, v. 61, n. 5, p. 58–63, 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/26516111>>. Acesso em: 15 set. 2016.

VALDIVIA, H.O.; SCHOLTE, L.L.S.; OLIVEIRA, G.; GABALDÓN, T.; BARTHOLOMEU, D.C. The Leishmania metaphylome: a comprehensive survey of Leishmania protein phylogenetic relationships. **BMC Genomics**, v. 16, p.:887, 2015.

VAUZOUR, D.; VAFEIADOU, K.; SPENCER, J. P. E. Polyphenols. In: **Phytonutrients**. Oxford, UK: Wiley-Blackwell, 2012. p. 110–145.

VÁZQUEZ, N. M.; FIORILLI, G.; CÁCERES GUIDO, P. A.; MORENO, S. Carnosic acid acts synergistically with gentamicin in killing methicillin-resistant *Staphylococcus aureus* clinical isolates. **Phytomedicine**, v. 23, n. 12, p. 1337–1343, 15 nov. 2016. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/27765353>>. Acesso em: 31 ago. 2018.

VUJIĆ, M.; POLLAK, L. Composition, labelling, and safety of food supplements based on bee products in the legislative framework of the European Union – Croatian experiences. **Arh Hig Rada Toksikol**, v.66, p.243-249, 2015.

WALLBERG, A.; HAN, F.; WELLHAGEN, G.; DAHLE, B.; KAWATA, M.; HADDAD, N.; SIMÕES, Z.L.P.; ALLSOPP, M.H.; KANDEMIR, I.; RUA, P.; PIRK, C.W.; WEBSTER, M.T. A worldwide survey of genome sequence variation provides insight into the evolutionary history of the honeybee *Apis mellifera*. **Nature Genetics**, v. 46, n. 10, p. 1081-1090, 2014.

WIESE, H. **Apicultura**. Guaíba, RS, Agrolivros, 2 Ed., p. 378, 2005.

WINSTON, M.L. The Biology and Management of Africanized Honey Bees. **Annual Review of Entomology**, v. 37, p. 173-193, 1992.

WINSTON, M.L. **The biology of the honey bee**. Cambridge, MA, Harvard University Press, 1987

WOJTYCZKA, R. D.; DZIEDZIC, A.; IDZIK, D.; KEPA, M.; KUBINA, R.; KABAŁA-DZIK, A.; SMOLEŃ-DZIRBA, J.; STOJKO, J.; SAJEWICZ, M.; WĄSIK, T. J. Susceptibility of Staphylococcus Aureus Clinical Isolates to Propolis Extract Alone or in Combination with Antimicrobial Drugs. **Molecules (Basel, Switzerland)**, v. 18, n. 8, p. 9623–40, 12 jan. 2013. Disponível em: <<http://www.mdpi.com/1420-3049/18/8/9623>>. Acesso em: 9 dez. 2015.

WORLD HEALTH ORGANIZATION. Chagas Disease (American Trypanosomiasis). Disponível em: <http://www.who.int/mediacentre/factsheets/fs340/en/>. Acesso em: 20 de fevereiro de 2017b.

WORLD HEALTH ORGANIZATION. Leishmaniasis. Disponível em: <http://www.who.int/leishmaniasis/en/>. Acesso em: 20 de fevereiro de 2017a.

XIE, Y.; YANG, W.; TANG, F.; CHEN, X.; REN, L. Antibacterial activities of flavonoids: structure-activity relationship and mechanism. **Current medicinal chemistry**, v. 22, n. 1, p. 132–49, 2015. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25245513>>. Acesso em: 22 ago. 2016.

ZARE JAHROMI, M.; RANJBARIAN, P.; SHIRAVI, S. Cytotoxicity evaluation of Iranian propolis and calcium hydroxide on dental pulp fibroblasts. **Journal of dental research, dental clinics, dental prospects**, v. 8, n. 3, p. 130–3, 2014. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25346830>>. Acesso em: 4 jan. 2018.

ZHANG, R.; WANG, X.; LÜ, J. [Isolation of a carbapenem-resistant K1 serotype Klebsiella pneumonia strain and the study of resistance mechanism]. **Zhonghua yi xue za zhi**, v. 94, n. 46, p. 3666–70, 16 dez. 2014. Disponível em: <<http://www.ncbi.nlm.nih.gov/pubmed/25622962>>. Acesso em: 24 out. 2016.

ZIPCODEZOO. Disponível em: http://zipcodezoo.com/index.php/Dalbergia_ecastaphyllum. Acesso em: 31 Mai. 2017.

ZULUETA, A.; ESTEVE, M. J.; FRÍGOLA, A. ORAC and TEAC assays comparison to measure the antioxidant capacity of food products. **Food Chemistry**, v. 114, n. 1, p. 310–316, 1 maio 2009. Disponível em: <<https://www.sciencedirect.com/science/article/pii/S0308814608011047>>. Acesso em: 31 ago. 2018.

ANEXO A – NORMAS DA REVISTA FOOD AND CHEMICAL TOXICOLOGY



FOOD AND CHEMICAL TOXICOLOGY

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

• Description	p.1
• Audience	p.2
• Impact Factor	p.2
• Abstracting and Indexing	p.2
• Editorial Board	p.2
• Guide for Authors	p.5



ISSN: 0278-6915

DESCRIPTION

Food and Chemical Toxicology (FCT), an internationally renowned journal, that publishes original research articles and reviews on **toxic effects**, in animals and humans, of natural or synthetic chemicals occurring in the human environment with particular emphasis on **food, drugs, and chemicals, including agricultural and industrial safety, and consumer product safety**. Areas such as safety evaluation of **novel foods and ingredients, biotechnologically-derived products**, and **nanomaterials** are included in the scope of the journal. FCT also encourages submission of papers on **inter-relationships between nutrition and toxicology** and on *in vitro* techniques, particularly those fostering the **3 Rs**.

The principal aim of the journal is to publish high impact, scholarly work and to serve as a multidisciplinary forum for research in toxicology. Papers submitted will be judged on the basis of scientific originality and contribution to the field, quality and subject matter. **Studies should address at least one of the following:** Adverse physiological/biochemical, or pathological changes induced by **specific defined** substances New techniques for assessing potential toxicity, including molecular biology Mechanisms underlying toxic phenomena Toxicological examinations of specific chemicals or consumer products, both those showing adverse effects and those demonstrating safety, that meet current standards of scientific acceptability

Authors must **clearly and briefly identify what novel toxic effect (s) or toxic mechanism (s)** of the chemical are being reported and what their **significance** is in the abstract. Furthermore, sufficient doses should be included in order to provide information on NOAEL/LOAEL values.

Manuscripts describing research involving the following areas will not be considered: materials/substances of only local interest materials/substances for which the chemical composition is not clearly defined only pharmacological properties, or potentially beneficial effects using *in vitro* or *in vivo* systems chemical analyses of toxins in foods without addressing the toxic implication to humans [risk assessment should be included] unrealistic human doses, inappropriate route of exposure, or *in vitro* experiments that do not reflect serum levels in humans

FCT is committed to the highest standards. Only papers that have not been previously published, that fit in the above mentioned scope, and that have been reviewed by experts in the field prior to publication will be accepted. Cover letters must state that the manuscript is new and original and not under consideration for publication elsewhere. Co-authors should be individuals who have contributed substantially to the content of the papers. All authors must declare any potential conflict of interest and all financial support.

Benefits to authors

We provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see the [Guide for Authors](#) for information on article submission. If you require further information or help, please visit our [Support Center](#)

AUDIENCE

Food scientists, toxicologists, chemists and researchers working in the pharmaceutical industry.

IMPACT FACTOR

2017: 3.977 © Clarivate Analytics Journal Citation Reports 2018

ABSTRACTING AND INDEXING

EMBiology
 Analytical Abstracts
 Aqualine Abstracts
 BIOSIS
 Elsevier BIOBASE
 Cambridge Scientific Abstracts
 Chemical Abstracts
 Chemical Hazards in Industry
 Current Contents/BIOMED Database
 Current Contents/Science Citation Index
 Current Contents/SciSearch Database
 EMBASE
 Health and Safety Science Abstracts
 MEDLINE®
 International Packaging Abstracts
 Research Alert
 Toxicology Abstracts
 Scopus

EDITORIAL BOARD

Editor-in-Chief

José L. Domingo, Lab.Toxicology and Environmental Health, School of Medicine, IISPV, Universitat Rovira i Virgili, Sant Llorenç 21, 43201, Reus, Catalonia, Spain

Co-Editors

Michael Aschner, Dept. of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York, NY 10461, USA

Bryan Delaney, Research Fellow – Toxicology, DuPont Pioneer, Global Industry Affairs and Regulatory, 7100 NW 62nd Avenue, Johnston, Iowa, 50131, USA

Siegfried Knasmüller, Inst. of Cancer Research, Environmental Toxicology Group, Medical University Vienna, Inner Medicine I, Borschkegasse 8a, A-1090, Vienna, Austria

Chada Reddy, Dept. of Biomedical Sciences, University of Missouri, E102 Veterinary Medical Building, 1600 Rollins, Columbia, Missouri, 65211, USA

RIFM Guest Editor

Aristides Tsatsakis, Dept. of Forensic Sciences and Toxicology, University of Crete, 71409, Heraklion, Greece

Associate Editors

Silvia Berlanga de Moraes Barros, School of Pharmaceutical Sciences, Universidade de São Paulo, Av. Prof. Lineu Prestes, 580, 05508-000 São Paulo, Brazil

Qasim Chaudhry, DEFRA Central Science Laboratory, The Food and Environment Research Agency, Sand Hutton, York, YO41 1LZ, UK

Roger Clemens, University of Southern California School of Pharmacy, Los Angeles, California, USA

Mark Feeley, Bureau of Chemical Safety, Chemical Hazard Assessment Division, Health Canada, Tunney's Pasture, Ottawa, K1A 0L2, Ontario, Canada

Swaran Jeet Singh Flora, National Institute of Pharmaceutical Education and Research, Shree Bhawani Paper Mill Road - ITI compound, 229010, Raebareilly, India

Guillermina Font, Fac. of Pharmacy, Dept. of Preventive Medicine, Universitat de València, Avda Vicent Andres Estelles s/n, Burjassot, 46100, Valencia, Spain

Milen Georgiev, Inst. of Microbiology, Bulgarian Academy of Sciences, 139 Ruski Boulevard, 4000, Plovdiv, Bulgaria

Salmaan Inayat-Hussain, Group Health, Safety and Environment Division, Head, Global Toxicology, Petrolim Nasional Berhad, Level 45, Tower 1, PETRONAS Twin Towers, KLCC, 50088, Kuala Lumpur, Malaysia

Demetrios Kouretas, Dept. of Biochemistry & Biotechnology, University of Thessaly, Larissa, Greece

Claire L. Kruger, Director of Health Sciences, Spherix Incorporated, 6430 Rockledge Dr., Westmoreland Bldg. #503, Bethesda, MD 20817, USA

Byung-Mu Lee, College of Pharmacy, Div. of Toxicology, Sungkyunkwan University (SKKU), Cheoncheon-dong 300, 440-746, Suwon, Gyeonggi-do, The Republic of Korea

Palma Ann Marone, Toxicology and Pathology Associates, LLC, Pharmacology and Toxicology, Virginia Commonwealth University, School of Medicine

Yeonhwa Park, Dept. of Food Science, University of Massachusetts at Amherst, Amherst, Massachusetts, MA, USA

Ivonne M.C.M. Rietjens, Sectie Toxicologie, Agrotechnologie en voedingswetenschappen (AFSG), Wageningen Universiteit, Postbus 8000, Bodenummer 92, 6700 EA, Wageningen, Netherlands

Saura Sahu, Office of Applied Research and Safety Assessment, FDA, Center for Food Safety and Applied Nutrition, 8301 Muirkirk Road, Laurel, Maryland, 20708, USA

Dieter Schrenk, Dept. of Food Chemistry and Environmental Toxicology, Technische Universität Kaiserslautern, Erwin-Schroedinger-Str. 52, D-67663, Kaiserslautern, Germany

Emeritus Editors

Alan R. Boobis, Experimental Medicine and Toxicology, Div. of Investigative Science, Imperial College London, Hammersmith Campus, Du Cane Road, W12 0NN, London, UK

Joseph F. Borzelleca, President, Toxicology & Pharmacology, Inc., 8718 September Drive, Richmond, Virginia, VA 23229-7319, USA

A. Wallace Hayes, Dept. of Environmental Health, Harvard T.H. Chan School of Public Health, 300 Longwood Ave., Boston, Massachusetts, MA 02115-5747, USA

Hans Verhagen, Centre for Nutrition and Health (PB84), Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Postbus 1, 3720 BA Bilthoven, Netherlands

Founding Editor

The late Leon Golberg

International Editorial Board

Mohamed Abdelmegeed, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH), Bethesda, Maryland, USA

Naveen Arora, Allergen Biology, CSIR Institute of Genomics and Integrative Biology, New Delhi, India

Susan Barlow

Andrew Bartholomaeus, School of Pharmacy, University of Canberra, Canberra, Australia

Nursen Basaran, Pharmaceutical Toxicology Department, Hacettepe University, Sıhhiye, Ankara, Turkey

Maurizio Battino, Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Università Politecnica delle Marche, Ancona, Italy

Albert Braeuning, Dept. Food Safety, Federal Institute for Risk Assessment (BfR) Bundesinstitut für Risikobewertung, Berlin, Germany

Felix Carvalho, Faculty of Pharmacy, Universidade do Porto, Porto, Portugal

Martin Clift, College of Medicine, Swansea University, Swansea, UK

T.F.X. Collins, Chevy Chase, Maryland, USA

Adrian Covaci, Toxicological Center, University of Antwerp, Wilrijk, Belgium

Deven Dandekar, Xenometrics LLC, Stilwell, Kansas, USA

Mukul Das, Food and Chemical Toxicology Group, Indian Institute of Toxicology Research, Lucknow, India

Barry Delclos, National Center for Toxicological Research (U.S. Food & Drug Admin), Jefferson, Arkansas, USA

Daniel Doerge, National Center for Toxicological Research (U.S. Food & Drug Admin), Jefferson, Arkansas, USA

Maria Dusinska, Norwegian Institute for Air Research, Kjeller, Norway

Margherita Ferrante, Department G. F. Ingrassia, Catania University, Catania, Italy

Isabel Ferreira, Campus de Santa Apolónia, Instituto Politécnico de Bragança (IPB), Bragança, Portugal

Metka Filipic, Dept. for Genetic Toxicology and Cancer Biology, National Institute of Biology, Ljubljana, Slovenia
Kirill Golokhvast, Far Eastern Federal University, Vladivostok, Russian Federation
Kamil Kuca, Biomedical Research Center, University Hospital Hradec Králové, Hradec Kralove, Czech Republic
Pamela Magee, School of Biomedical Sciences, Ulster University, Coleraine Co., Londonderry, Northern Ireland, UK
Howard I. Maibach, Dept. of Dermatology, University of California at San Francisco (UCSF), San Francisco, California, USA
Alberto Mantovani, Dept. of Veterinary Public Health & Food Safety, Istituto Superiore di Sanità, Rome, Italy
Andrey Nikiforov, Toxicology Regulatory Services, Charlottesville, Virginia, USA
Andreas Tsakalof, School of Medicine, University of Thessaly, Larissa, Greece
L.G. Valerio, Jr., Silver Spring, Maryland, USA
Paul White, Environmental and Radiation Health Sciences Directorate, Health Canada, Ottawa, Ontario, Canada
Jianbo Xiao, University of Macau, Taipa, Macau, China

GUIDE FOR AUTHORS

Your Paper Your Way

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the Preparation section below.

INTRODUCTION

Food and Chemical Toxicology (FCT), an internationally renowned journal, aspires to publish original research articles and reviews on **toxic effects**, in animals or humans, of natural or synthetic chemicals occurring in the human environment with particular emphasis on **food, drugs, and chemicals, including agricultural and industrial safety, and consumer product safety**. Areas such as safety evaluation of **novel foods and ingredients, biotechnologically-derived products, and nanomaterials** are included in the scope of the journal. FCT also encourages submission of papers on **inter-relationships between nutrition and toxicology** and on *in vitro* techniques, particularly those fostering the **3 Rs**.

The principal aim of the journal is to publish high impact, scholarly work and to serve as a multidisciplinary forum for research in toxicology. Papers submitted will be judged on the basis of scientific originality and contribution to the field, quality and subject matter. Studies should address at least one of the following: Physiological, biochemical, or pathological changes induced by specific substances Techniques for assessing potential toxicity, including molecular biology Mechanisms underlying toxic phenomena Toxicological examinations of specific chemicals or consumer products, both those showing adverse effects and those demonstrating safety, that meet current standards of scientific acceptability

Manuscripts concerning materials/substances of only local interest for which the chemical composition of the material/substance is **not clearly defined** will **not** be considered. Manuscripts addressing only pharmacological properties, or only potentially beneficial effects using in *in vitro* or *in vivo* systems, are not within the scope of the journal.

FCT is committed to the highest standards. Only papers that have not been previously published, that fit in the above mentioned scope, and that have been reviewed by experts in the field prior to publication will be accepted. Cover letters must state that the paper is new and original and not under consideration for publication elsewhere. Papers pending in other journals will not be considered. Co-authors should be individuals who have contributed substantially to the content of the papers.

Types of paper

The Journal's main purpose is the publication of papers reporting and interpreting original unpublished toxicological research, particularly studies promoting an understanding of the mechanisms underlying toxic effects or improvements in methods for predicting adverse effects. Papers reporting the toxicological examination of specific foods, chemicals or consumer products will be published, irrespective of the positive or negative nature of the results, provided the tests and reporting meet current standards of acceptability. In addition, Short Communications will also be considered, as will concise interpretative Reviews of toxicological topics of contemporary significance. Letters to the Editor will be limited to comments on contributions already published in the journal; if a letter is accepted, a response (for simultaneous publication) will be invited from the authors of the original contribution. All Letters to the Editor should be submitted to the Editor in Chief, Jose L. Domingo through the online submission system of the Journal.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address

- Full postal address

All necessary files have been uploaded:

Manuscript:

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print
- Graphical Abstracts / Highlights files* (where applicable)
- Supplemental files* (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

BEFORE YOU BEGIN

Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

Studies in humans and animals

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](#) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms [sex](#) and [gender](#) should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

Conflict of interest

Food and Chemical Toxicology follows the ICMJE recommendations regarding conflict of interest disclosures. All authors are required to report the following information with each submission: All third-party financial support for the work in the submitted manuscript. All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript. All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. Any other interactions with the sponsor of outside of the submitted work should also be reported. Any relevant patents or copyrights (planned, pending, or issued). Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work.

As a general guideline, it is usually better to disclose a relationship than not. This information will be acknowledged at publication in a Transparency Document. Additional information on the ICMJE recommendations can be found at: <http://www.icmje.org>. The form for conflict of interest disclosure

can be downloaded [here](#), or at http://www.icmje.org/doi_disclosure.pdf (if this link does not display properly in your browser, please right-click the link and select "Save Target As..." or "Save Link as..." from the popup menu.)

Submission declaration

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

Each manuscript must also be accompanied by a cover letter outlining the basic findings of the paper and their significance. Furthermore, it is understood that with submission of this article the authors have complied with the institutional policies governing the humane and ethical treatment of the experimental subjects (i.e. animals and human subjects), and that they are willing to share the original data and materials if so requested.

Preprints

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Changes to authorship

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are required to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. Please see <http://www.elsevier.com/funding>.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of [existing agreements](#) are available online.

Open access

This journal offers authors a choice in publishing their research:

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our [universal access programs](#).
- No open access publication fee payable by authors.
- The Author is entitled to post the [accepted manuscript](#) in their institution's repository and make this public after an embargo period (known as green Open Access). The [published journal article](#) cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal can be found below.

Gold open access

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

Creative Commons Attribution (CC BY)

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 2800**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

Elsevier Researcher Academy

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Referees

The Editors require submissions by the authors of the names and addresses of 4 potential reviewers for this submission. The institutional address and e-mail address are required. At least 2 of the referees should be from a different country to the corresponding author's. The Editors reserve the right to use these or other reviewers.

PREPARATION**NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality

figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

Please ensure the text of your paper is double-spaced– this is an essential peer review requirement.

Figures and tables embedded in text

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

REVISED SUBMISSIONS

Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - numbered sections

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

Highlights

Please amend your research highlights so that they consist of 3 to 5 brief bullet points which convey the core findings of your work. Please ensure EACH bullet point does NOT exceed 125 characters (including spaces). An example is given below:

RESEARCH HIGHLIGHTS EXAMPLE:

* Research highlights are a mandatory field of a submitted paper & therefore should not exceed 85 characters including spaces.

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Abbreviations should be used sparingly; they should be defined when first used in the paper but also listed in alphabetical order under *Abbreviations* as a footnote to the title page (see above).

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Nomenclature and units

All measurements should be expressed in metric, preferably SI, units. Test chemicals and enzymes must be clearly identified, IUPAC and CAS names being used, wherever possible with the aid of CAS Registry and EC numbers. Pesticides should be referred to be their ISO names and human and veterinary drugs by their INNs.

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files. A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

Figure captions

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes](#).

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/food-and-chemical-toxicology>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference formatting

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style

Text: All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication;
2. *Two authors:* both authors' names and the year of publication;
3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references can be listed either first alphabetically, then chronologically, or vice versa.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).... Or, as demonstrated (Jones, 1999; Allan, 2000)... Kramer et al. (2010) have recently shown ...'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2018. The art of writing a scientific article. *Heliyon*. 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>.

Reference to a book:

Strunk Jr., W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304.

Reference to a website:

Cancer Research UK, 1975. Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13 March 2003).

Reference to a dataset:

[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. *Mendeley Data*, v1. <https://doi.org/10.17632/xwj98nb39r.1>.

Journal abbreviations source

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to

supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

Data linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

Data in Brief

You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for *Data in Brief* as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the open access data journal, *Data in Brief*. Please note an open access fee of 500 USD is payable for publication in *Data in Brief*. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

MethodsX

You have the option of converting relevant protocols and methods into one or multiple MethodsX articles, a new kind of article that describes the details of customized research methods. Many researchers spend a significant amount of time on developing methods to fit their specific needs or setting, but often without getting credit for this part of their work. MethodsX, an open access journal, now publishes this information in order to make it searchable, peer reviewed, citable and reproducible. Authors are encouraged to submit their MethodsX article as an additional item directly alongside the revised version of their manuscript. If your research article is accepted, your methods article will

automatically be transferred over to MethodsX where it will be editorially reviewed. Please note an open access fee is payable for publication in MethodsX. Full details can be found on the MethodsX website. Please use [this template](#) to prepare your MethodsX article.

Data statement

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

AFTER ACCEPTANCE

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>

ANEXO B – NORMAS DA REVISTA FOOD AND CHEMISTRY.



FOOD CHEMISTRY

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

• Description	p.1
• Audience	p.2
• Impact Factor	p.2
• Abstracting and Indexing	p.2
• Editorial Board	p.3
• Guide for Authors	p.5



ISSN: 0308-8146

DESCRIPTION

The Aims and Scope of *Food Chemistry* are assessed and modified on an annual basis to reflect developments in the field. This means that research topics that have been deemed in scope previously may now fall outside of the scope of the journal as our scientific and technical understanding of the fields evolve and topics become less novel, original or relevant to *Food Chemistry*.

Food Chemistry publishes original research papers dealing with the advancement of the **chemistry** and **biochemistry** of **foods** or the analytical methods/ approach used. All papers should focus on the novelty of the research carried out.

Topics include:

- Chemistry relating to major and minor **components of food**, their nutritional, physiological, sensory, flavour and microbiological aspects;
- **Bioactive constituents** of foods, including antioxidants, phytochemicals, and botanicals. Data must accompany sufficient discussion to demonstrate their relevance to food and/or food chemistry;
- Chemical and biochemical composition and structure changes in molecules induced by processing, distribution and domestic conditions;
- **Effects of processing** on the composition, quality and safety of foods, other bio-based materials, by-products, and processing wastes;
- Chemistry of **food additives**, **contaminants**, and other agro-chemicals, together with their metabolism, toxicology and food fate.

Analytical papers related to the microbiological, sensory, nutritional, physiological, authenticity and origin aspects of food. Papers should be primarily concerned with new or novel methods (especially instrumental or rapid) provided adequate validation is described including sufficient data from real samples to demonstrate robustness. Papers dealing with significant improvements to existing methods, or data from application of existing methods to new foods, or commodities produced in unreported geographical areas, will also be considered.

For Analytical Papers, especially those dedicated to the development and validation of methods, authors are encouraged to follow internationally recognized guidelines, such as EURACHEM - for chemical compounds (<https://www.eurachem.org/index.php/publications/guides/mv>) or FDA - for microbiological data (<https://www.fda.gov/downloads/ScienceResearch/FieldScience/UCM298730.pdf>) and proper statistical methods should be applied. Special attention should be given to linearity, selectivity, determination of LOD/LOQ, repeatability and reproducibility of the analysis. Authors should also pay attention to trueness and, when possible (quantitative methods), determine the uncertainty of measurement. Overall, real samples should be analyzed by the state-of-the-art and the newly developed method for validation purposes.

- Methods for the determination of both major and minor components of food especially nutrients and non-nutrient bioactive compounds (with putative health benefits) will be considered.
- Results of method inter-comparison studies and development of food reference materials for use in the assay of food components;
- Methods concerned with the chemical forms in food, nutrient bioavailability and nutritional status;
- General authentication and origin [e.g. Country of Origin Labelling (COOL), Protected Designation of Origin (PDO), Protected Geographical Indication (PGI), Certificate of Specific Character (CSC)] determination of foods (both geographical and production including commodity substitution, and verification of organic, biological and ecological labelling) USING CHEMICAL MARKERS, providing sufficient data from authentic samples should be included to ensure that interpretations are meaningful.

Food Chemistry will not consider papers that focus on purely clinical or engineering aspects without any contribution to chemistry; pharmaceutical or non-food herbal remedies; traditional or folk medicines; or survey/surveillance data.

Papers on therapeutic application of food compounds/isolates for treatment, cure or prevention of human diseases will not be considered for inclusion in *Food Chemistry*.

AUDIENCE

Food technologists, scientists and chemists

IMPACT FACTOR

2017: 4.946 © Clarivate Analytics Journal Citation Reports 2018

ABSTRACTING AND INDEXING

Global Health
 Publications in Food Microbiology
 Current Contents
 Science Citation Index
 SciSearch
 EMBASE
 Chemical Abstracts
 Nutrition Abstracts
 EMBiology
 CAB Abstracts
 Chemical Engineering Biotechnology Abstracts
 Sociedad Iberoamericana de Informacion Cientifica (SIIC) Data Bases
 Scopus
 BIOSIS
 FSTA (Food Science and Technology Abstracts)

EDITORIAL BOARD

Editor-in-Chief

P. Finglas, Quadram Institute Bioscience, Norwich, England, UK

Editor-in-Chief Emeritus

G.G. Birch, Food and Nutritional Sciences, University of Reading, PO Box 217 Whiteknights, RG6 6AH, Reading, England, UK

Editorial Office

Editors

S.B. Astley, EuroFIR AISBL, Brussels, Belgium

D. Charalampopoulos, University of Reading, Reading, UK

S. Elmore, University of Reading, Reading, England, UK

L. Melton, University of Auckland, Auckland, New Zealand

K. Miyashita, Hokkaido University, Hakodate, Japan

F. Shahidi, Memorial University of Newfoundland, St John's, NL, Newfoundland and Labrador, Canada

J. Van Camp, Universiteit Gent, Gent, Belgium

R.E. Wrolstad, Oregon State University, Corvallis, Oregon, USA

Associate Editors

C. Alasalvar, TÜBİTAK Marmara Research Center, Gebze/Kocaeli, Turkey

E.R. Amante, Universidade Federal de Santa Catarina, Florianópolis, Brazil

I. Castanheira, Instituto Nacional de Saúde Dr Ricardo Jorge (INSA-IP), Lisboa, Portugal

D. Granato, Universidade Estadual de Ponta Grossa, Parana, Brazil

F. Hidalgo, Instituto de la Grasa (IG), Sevilla, Spain

A. Ismail, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

P. Kilmartin, University of Auckland, Auckland Mail Centre, Auckland, New Zealand

R.B. Pegg, University of Georgia, Athens, Georgia, USA

P. Zhou, Jiangnan University, Wuxi, China

Editorial Board Members

R. Aluko, University of Manitoba, Winnipeg, Manitoba, Canada

R. Amarowicz, Polish Academy of Sciences, Olsztyn, Poland

P. Andrade, University of Porto, Porto, Portugal

S.G. Anema, Fonterra, Palmerston North, New Zealand

J.H. Banoub, Fisheries and Oceans Canada, St. John's, Newfoundland and Labrador, Canada

J.C.M. Barreira, Polytechnic Institute of Bragança, Bragança, Portugal

M. Battino, University of Ancona, Ancona, Italy

J.C. Beaulieu, U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), New Orleans, Louisiana, USA

R.G. Berger, Leibniz University Hannover, Hannover, Germany

T. Beta, University of Manitoba, Winnipeg, Manitoba, Canada

M. Betti, University of Alberta, Edmonton, Alberta, Canada

J. Birch, University of Otago, Dunedin, New Zealand

B. Cabanillas, University of Bonn, Bonn, Germany

A. M. Cabral, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil

Y. Chen, Jiangnan University, Wuxi, China

L. Dean, North Carolina State University, Raleigh, North Carolina, USA

A. Escarpa, University of Alcalá, Alcalá de Henares, Madrid, Spain

B. Fedrizzi, University of Auckland, Auckland, New Zealand

M. Gidley, University of Queensland, St Lucia, Queensland, Australia

V. Gökmen, Hacettepe University, Ankara, Turkey

M. Jenner, Devon, UK

O.G. Jones, Purdue University, West Lafayette, Indiana, USA

M. Jung, Woosuk University, Jeonbuk, The Republic of Korea

S. Kelly, University of East Anglia, Norwich, England, UK

J.F. Kennedy, Chembiotech Laboratories, Tenbury Wells, England, UK

J. Lee, U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), Parma, Idaho, USA

M. Lu, University of Nebraska at Lincoln, Lincoln, Nebraska, USA

A. Madadlou, French National Institute for Agricultural Research (INRA), Rennes, France

M. Mathlouthi, Université de Reims Champagne-Ardenne, Reims Cedex, France

S. Porretta, Stazione Sperimentale per L'Industria delle Conserve Alimentari, Parma, Italy

P. Putnik, University of Zagreb, Zagreb, Croatia

P. Rubiolo, Università degli Studi di Torino, Torino, Italy

B. Saad, Universiti Teknologi PETRONAS, Seri Iskandar, Perak Darul Ridzuan, Malaysia

H. Schönfeldt, University of Pretoria, Pretoria, South Africa
J.-H. Shim, Chonnam National University, Gwangju, The Republic of Korea
D. Sun-Waterhouse, South China University of Technology, Guangzhou, China
F. Toldrá, Institute of Agricultural Chemistry and Food Technology, Paterna (Valencia), Spain
R. Tsao, Agriculture and Agri-Food Canada (AAFC), Guelph, Ontario, Canada
A. Tudos, Shell Global Solutions, Amsterdam, Netherlands
J. B. Xiao, University of Macau, Taipa, Macau, China
V. Yaylayan, McGill University, Ste Anne de Bellevue, Quebec, Canada
L. Yu, University of Maryland, College Park, Maryland, USA
L. Yu, University of Maryland, College Park, Maryland, USA
R. Zeleny, European Commission, Geel, Belgium
Y.J. Zhong, Corbion, Kansas, USA

GUIDE FOR AUTHORS

Guide for Authors updated September 2017

INTRODUCTION

The Aims and Scope of Food Chemistry are assessed and modified on an annual basis to reflect developments in the field. This means that research topics which may have been deemed in scope in previous years may now fall outside of the scope of the journal as our scientific and technical understanding of the field evolves and topics become less novel, original or relevant to Food Chemistry.

Ten essential rules to ensure your manuscript is handled promptly

The manuscript fits the Aims and Scope of the journal (<http://www.journals.elsevier.com/food-chemistry>) Manuscript is in accordance with ARTICLE TYPE - GUIDELINES and includes a hypothesis statement (<http://www.elsevier.com/journals/food-chemistry/0308-8146/guide-for-authors#14000>) The text is written in good English. Authors who feel their manuscript might require editing to meet correct scientific English requirements may wish to use an English Language Editing service such as the one available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>). Manuscript text is divided into numbered sections; line and page numbers are added and text is double-spaced. An ethical statement is required for experiments involving humans or animals. Conflict-of-interest statement is included at the end of the manuscript. The number of figures and tables combined does not exceed a total of six; additional tables and figures can be submitted as supplementary material. All relevant sources (i.e. peer-reviewed articles, websites, books etc.) should be included in the Reference list. Cover letter is prepared, introducing your article and explaining the novelty of the research. Highlights identify important outcomes of your work and stand alone (i.e. do not require someone to read the article to understand what they mean). These are presented in 3-5 points, 85 characters each).

Submission checklist

This checklist allows authors to ensure that the manuscript meets the Food Chemistry requirements before submission. Checklist can also be downloaded here [here](#)

1) Study contents:

The Authors should ensure that The manuscript fits within **Aims & Scope** of Food Chemistry. Please note that the Aims and Scope are regularly updated. The research is **novel** and has **not been published previously** - see "Responsible research publication: international standards for authors" from COPE for more information http://publicationethics.org/files/International%20standards_authors_for%20website_11_Nov_2011_0.pdf **Ethical consent** has been obtained in case of work on animals and/or humans. **2) Manuscript preparation:**

The Authors should ensure that The formatting of the manuscript follows the requirements of the Guide for Authors. The language follows the requirements of the Guide for Authors. The number of words and of figures/tables is within limits: • Research article: 7500 words, 6 tables and figures combined

- Review article: 10 000 words, 6 tables and figures combined
 - Short communication: 3000 words, 6 tables and figures combined
- More tables and figures? Submit as **supplementary material**. The **title page** contains title, author names, affiliations and corresponding author telephone. **Email addresses are required for ALL authors. Authors must provide and use a unique, individual e-mail address and not one that is shared with another author registered in the submission system, or a department. Author names - please ensure that names are listed in the order first name/FAMILY NAME (e.g. Marie CURIE) - this will ensure they are listed correctly in indexing services..** The **highlights** are provided (3-5 bullet points, max 85 characters each including spaces). The manuscript contains a **conflict of interest** statement (before references). Continuous **line numbering** is provided throughout the manuscript (including captions and references); **page numbering** is provided. All **sources** (references) are provided in alphabetical order. Figures and tables (6 combined) include clear **legends**. The manuscript contains appropriate **ethical approval** and **informed consent** (if applicable, include statement). Food Chemistry now requires the inclusion of a hypothesis statement in the Introduction, and response

in the Discussion. Please ensure this is included **3) Before submission: Manuscript** file is provided as a Microsoft Word file. A **cover letter** is included. Three or more suggested **reviewers** are provided (including affiliation and professional email address), **at least two of which are from a different country than the Authors and none from the same institution.** **Keywords** are provided.

Now you are ready to submit at <http://ees.elsevier.com/foodchem>

Types of paper

Original research papers; review articles; rapid communications; short communications; letters to the Editor.

1. Research papers - original full-length research papers that have not been published previously, except in a preliminary form, and should not exceed 7,500 words from introduction to conclusion (not including references) (including no more than six tables and figures combined - additional tables and figures can be submitted as supplementary material). Research papers should not contain more than 40 references.

2. Review articles - will be accepted in areas of topical interest, will normally focus on literature published over the previous five years, and should not exceed 10,000 words from introduction to conclusion (not including references) (including allowance for no more than six tables and figures combined). Review articles should not contain more than 120 references. If it is felt absolutely necessary to exceed these numbers (tables, figures, references), please contact the editorial office for advice before submission.

3. Short communications - Short communications of up to 3000 words from introduction to conclusion (not including references), describing work that may be of a preliminary nature but merits publication. These papers should not contain more than 40 references.

4. Viewpoints - Authors may submit viewpoints of no more than 1200 words on any subject covered by the Aims and Scope.

5. Letters to the Editor - Letters are published from time to time on matters of topical interest.

BEFORE YOU BEGIN

Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

Another useful source of guidance is "Responsible research publication: international standards for authors" from COPE (http://publicationethics.org/files/International%20standards_authors_for%20website_11_Nov_2011_0.pdf).

Guidelines in the US and Canada, Europe and Australia specifically state that hypothermia (use of ice slurries) is not an acceptable method for killing fish in the research environment.

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

Preprints

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Conditions of authorship, and changes to authorship

All authors should have made substantial contributions to all of the following: the conception and design of the study, or acquisition of data, or analysis and interpretation of data drafting the article or revising it critically for important intellectual content final approval of the version to be submitted.

If all 3 of these conditions are not met, a person does not qualify as an author, and any contribution made by them should be mentioned in the Acknowledgements section of the manuscript.

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

It is the policy of Food Chemistry that no additions, deletions or changes to authorship of a paper will be permitted after the article is accepted.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of [existing agreements](#) are available online.

Subscription or open access your choice

This journal offers authors a choice in publishing their research:

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our [universal access programs](#).
- No open access publication fee payable by authors.

Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article (subscription or open access), the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

Creative Commons Attribution (CC BY)

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 2800**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

Elsevier Researcher Academy

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Authors must provide and use an email address unique to themselves and not shared with another author registered in the submission system, or a department.

Referees

Authors are required to submit with their articles, the names, complete affiliations (spelled out), country and contact details (including current and valid (preferably business) e-mail address) of three potential reviewers. Email addresses and reviewer names will be checked for validity. **Your potential reviewers should not be from your institute, and at least two should be from countries other than those of the authors.** Authors should not suggest reviewers with whom they have collaborated within the past two years. Your submission will be rejected if these are not supplied. Names provided may be used for other submissions on the same topic. Reviewers must have specific expertise on the subject of your article and/or the techniques employed in your study. Briefly state the appropriate expertise of each reviewer (not simply "has an interest in this topic").

Review Policy

A peer review system involving at least two reviewers is used to ensure high quality of manuscripts accepted for publication. The Managing Editor and Editors have the right to decline formal review of a manuscript when it is deemed that the manuscript is on a topic outside the scope of the Journal; makes no contribution to the advancement of the chemistry of foods is lacking technical or scientific merit; is focused on foods or processes that are of narrow regional scope and significance; is fragmentary and providing marginally incremental results; reports only routine work (lacks novelty) or is poorly written.

PREPARATION

Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

Use of wordprocessing software

General: Manuscripts must be typewritten, double-spaced with 2 cm margins. Each page must be numbered, and lines must be consecutively numbered from the start to the end of the manuscript. Good quality printouts with a font size of 12 or 10 pt are required. The corresponding author should be identified (include a valid E-mail address). Full postal and email addresses must be given for all co-authors. Authors should consult a recent issue of the journal for style if possible. The Editors reserve the right to adjust style to certain standards of uniformity.

Article structure

Follow this order when typing manuscripts: Title, Authors, Affiliations, Abstract, Keywords, Main text (*Introduction, Material and Methods, Results, Conclusion*), Acknowledgements, Appendix, References, Figure Captions. The corresponding author should be identified with an asterisk and footnote. All other footnotes (except for table footnotes) should be identified with superscript Arabic numbers. The title of the paper should unambiguously reflect its contents.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

• **Author names and affiliations.** Please clearly indicate the full given name(s) and family name(s) of each author and check that all names are accurately spelled. Please ensure that names are listed in the order first name/FAMILY NAME (e.g. Marie CURIE) - this will ensure they are listed correctly in indexing services. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• **Corresponding author.** Clearly indicate the one author who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

The abstract should not exceed 150 words.

Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core (most important) findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view [example Highlights](#) on our information site. Do not use abbreviations in the highlights and ensure that highlights can be understood independent of the manuscript.

Subdivision - numbered sections

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Hypotheses

Nearly all scientific papers benefit from inclusion of a statement of hypothesis. Such statements should be clear, concise, and declarative. The statement should describe the one or more key hypotheses that the work described in the manuscript was intended to confirm or refute. Inclusion of a hypothesis statement makes it simple to contrast the hypothesis with the most relevant previous literature and point out what the authors feel is distinct about the current hypothesis (novelty). It also permits the authors to describe why they feel it would be important to prove the hypothesis correct (significance). The hypothesis shall be stated in the introductory section, and the conclusion section shall include your conclusion about whether the hypothesis was confirmed or refuted, as well as describing any new hypotheses generated by the work described. Here is an example of a famous, excellent hypothesis statement; declarative, concise, clear, and testable: **"Equal volumes of gases, at the same temperature and pressure, contain equal numbers of molecules."** Lorenzo Romano Amedeo Carlo Avogadro di Quareqa e di Carreto (Avogadro), 1811

Chemical compounds

You can enrich your article by providing a list of chemical compounds studied in the article. The list of compounds will be used to extract relevant information from the NCBI PubChem Compound database and display it next to the online version of the article on ScienceDirect. You can include up to 10 names of chemical compounds in the article. For each compound, please provide the [PubChem CID](#) of the most relevant record as in the following example: Glutamic acid (PubChem CID:611). Please position the list of compounds immediately below the 'Keywords' section. It is strongly recommended to follow the exact text formatting as in the example below:

Chemical compounds studied in this article

Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 44152164); Benzalkonium chloride (PubChem CID: 15865)

More information.

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI. Temperatures should be given in degrees Celsius. The unit 'billion' is ambiguous and should not be used.

Abbreviations for units should follow the suggestions of the British Standards publication BS 1991. The full stop should not be included in abbreviations, e.g. m (not m.), ppm (not p.p.m.); % and '/' should be used in preference to 'per cent' and 'per'. Where abbreviations are likely to cause ambiguity or might not be understood easily by an international readership, units should be spelled out in full.

Statistics

Appropriate application of statistical analysis should be applied throughout the article.

Artwork

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Size the illustrations close to the desired dimensions of the published version.

A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Figures

Photographs, charts and diagrams are all to be referred to as "Figure(s)" and should be numbered consecutively in the order to which they are referred. All illustrations should be clearly marked with the figure number and the first author's name.

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;

- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

Figure Captions

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

References

Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Example: CTAHR (College of Tropical Agriculture and Human Resources, University of Hawaii). Tea (*Camellia sinensis*) a New Crop for Hawaii, 2007. URL http://www.ctahr.hawaii.edu/oc/freepubs/pdf/tea_04_07.pdf. Accessed 14.02.11.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their

article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes](#).

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/food-chemistry>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

All publications cited in the text should be presented in a list of references following the text of the manuscript. See Types of Paper for reference number limits. In the text refer to the author's name (without initials) and year of publication (e.g. "Steventon, Donald and Gladden (1994) studied the effects..." or "...similar to values reported by others (Anderson, Douglas, Morrison & Weiping, 1990)..."). For 2-6 authors all authors are to be listed at first citation. At subsequent citations use first author et al.. When there are more than 6 authors, first author et al. should be used throughout the text. The list of references should be arranged alphabetically by authors' names and should be as full as possible, listing all authors, the full title of articles and journals, publisher and year. The manuscript should be carefully checked to ensure that the spelling of authors' names and dates are exactly the same in the text as in the reference list.

Reference style

Text: Citations in the text should follow the referencing style used by the American Psychological Association. You are referred to the Publication Manual of the American Psychological Association, Sixth Edition, ISBN 978-1-4338-0561-5, copies of which may be [ordered online](#) or APA Order Dept., P.O.B. 2710, Hyattsville, MD 20784, USA or APA, 3 Henrietta Street, London, WC3E 8LU, UK.

List: references should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J. A. J., & Lupton, R. A. (2010). The art of writing a scientific article. *Journal of Scientific Communications*, 163, 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

Van der Geer, J., Hanraads, J. A. J., & Lupton, R. A. (2018). The art of writing a scientific article. *Heliyon*, 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>.

Reference to a book:

Strunk, W., Jr., & White, E. B. (2000). *The elements of style*. (4th ed.). New York: Longman, (Chapter 4).

Reference to a chapter in an edited book:

Mettam, G. R., & Adams, L. B. (2009). How to prepare an electronic version of your article. In B. S. Jones, & R. Z. Smith (Eds.), *Introduction to the electronic age* (pp. 281–304). New York: E-Publishing Inc.

Reference to a website:

Cancer Research UK. Cancer statistics reports for the UK. (2003). <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> Accessed 13 March 2003.

Reference to a dataset:

[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T. (2015). *Mortality data for Japanese oak wilt disease and surrounding forest compositions*. Mendeley Data, v1. <https://doi.org/10.17632/xwj98nb39r.1>.

Reference to a conference paper or poster presentation:

Engle, E.K., Cash, T.F., & Jarry, J.L. (2009, November). The Body Image Behaviours Inventory-3: Development and validation of the Body Image Compulsive Actions and Body Image Avoidance Scales. Poster session presentation at the meeting of the Association for Behavioural and Cognitive Therapies, New York, NY.

Data visualization

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

Data linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking](#) page.

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals](#) page.

Data in Brief

You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for *Data in Brief* as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to *Data in Brief* where it will be editorially reviewed and published in the open access data journal, *Data in Brief*. Please note an open access fee of 500 USD is payable for publication in *Data in Brief*. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

Data statement

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement](#) page.

Interactive plots

This journal enables you to show an Interactive Plot with your article by simply submitting a data file. [Full instructions](#).

After submission

Click [HERE](#) to see what may happen to your manuscript once it is submitted.

AFTER ACCEPTANCE

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. It is important to ensure that all corrections are sent back to us in one communication. Check carefully before replying. This is your last opportunity to correct errors. Proofreading is solely your responsibility.

Offprints

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>